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ABSTRACT 
The aim of this project was to investigate some aspects of the equine sarcoid of the 
donkey (Equus asinus). The study was undertaken in a large population of animals 
located at The Donkey Sanctuary, Sidford, Devon, in order to assess the feasibility 
of eventual vaccination against the disease. All material was derived from clinical 
cases and no animal experimentation was involved in the investigations. 
The epidemiological studies were based upon information exported from 
the clinical records maintained on The Donkey Sanctuary mainframe computer. Of 
those donkeys developing sarcoids at The Sanctuary, the sex, age, age at which the 
animal entered The Sanctuary and the duration of stay were all shown to be factors 
affecting the likelihood of an individual donkey having sarcoids. In general, the 
disease was most likely to affect young male donkeys within the first four years at 
The Sanctuary and the tumours were most frequently observed in the paragenital 
region. A general linear model was constructed and it was demonstrated that male 
donkeys were, at best 1.1 times and, at worst, 4.5 times more likely to have sarcoids 
than females. The disease model was then used as a management tool for the 
identification of animals at the highest risk of developing sarcoids, in order to 
effect more prompt therapeutic intervention. 
The serological status of donkeys at The Sanctuary was investigated by the 
immunoblot assay of sera from sarcoid-affected and clinically-normal donkeys for 
the presence of antibody to disrupted bovine papillomavirus type 2 (BPV-2) virion 
and to the Ll open reading frame (ORF) encoded fusion protein. Antibody to the 
antigenic targets was demonstrated in 86 per cent of donkeys in the case of the Ll 
fusion protein and 96 per cent of donkeys in the case of disrupted virion; there was 
no correlation between the presence of antibody and clinical status. The antibody 
detected by immunoblot was unable to neutralise the transforming activity of BPV-
2 in vitro. 
Attempts to isolate papillomavirus particles from sarcoids removed from 
donkeys were unsuccessful, although virions were demonstrated in an early sarcoid 
removed from a horse at the University of Glasgow Veterinary SchooL 
The molecular investigations on 18 sarcoid tumours from The Sanctuary 
identified the presence of papillomaviral DNA homologous to BPV-2 DNA under 
stringent conditions, in all samples. Restriction endonuclease analysis of 15 of the 
tumours demonstrated papillomaviral DNA similar to BPV-l and BPV-2. 
Nucleotide base sequence analysis of a cloned papillomaviral element from a 
sarcoid showed that the isolate was 95.6 and 98.0 per cent homologous to BPV-l in 
the Ll and E5 ORFs, respectively. The results of the restriction endonuclease 
analysis were confirmed by the use of consensus primers and the polymerase chain 
reaction, localising an additional KpnI site in four of the BPV-l-like samples to the 
region between the HindIII site and the origin of the viral genome . 
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CHAPTER I 
CHAPTER I 
GENERAL INTRODUCTION 
AND 
REVIEW OF THE LITERATURE 
1.1. HISTORICAL BACKGROUND 
The equine sarcoid was first recognised as a distinct tumour of the equine 
integument by Jackson in 1936. The term "sarcoid", adapted from human pathology 
and meaning sarcoma-like, was proposed in order to denote a specific disease 
entity, whilst allowing the pathologist to abdicate the responsibility of deciding 
whether the lesion was a true neoplasm or a chronic inflammatory process 
(Jackson, 1936). Although the definition has been widely accepted for over 55 
years, various terms have been, and continue to be, used to describe sarcoids, 
including warts, angleberries, fibromas and dermal fibrosarcomas. There are many 
early references to warts in the literature. According to Fenner, Bachmann, Gibbs, 
Murphy, Studdert and White (1987), a stable master of the Caliph of Bagdad 
described equine warts in the ninth century and the clinical descriptions provided 
by Youatt (1866), Fitzwygram (1881) and Robertson (1883) are of lesions that 
would now be termed sarcoids. 
1.2. NEOPLASTIC DISEASE IN THE HORSE 
Sir Rupert Willis, cited by Cotran, Kumar and Robbins (1989), defined a neoplasm 
as "... an abnormal mass of tissue, the growth of which exceeds and is unco-
ordinated with that of normal tissues and persists in the same excessive manner 
f r ce a i Ii which evoked the chanQ"e" _ The same authors (Cotran 
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equine neoplasia, stated that despite the extensive published literature, "tumours in 
horses do not in fact seem to be particularly cornmon, either as medical or as 
surgical cases." However, the large number of papers which report or survey 
neoplastic disease in equidae (Cotchin cited over 100) may indicate that the 
prevalence of equine neoplasia is worthy of more extensive investigation. 
In order to compare neoplastic disease in the different domestic species, 
adjustments which compensate for the vast interspecies life-span variation must be 
applied. Dorn and Priester (1987) applied Life-span Correction Factors based on 
maximum recorded life-span compared to man (Table 1). The results of this 
correction demonstrated that the estimated rate of neoplasia per 100,000 horses 
per year of life-span was approximately 2.5 times that of the rates for cattle, dogs 
and cats combined. In addition, the rate of malignant tumours in the horse was 
second only to that of the dog amongst the domestic species. However, correction 
for life-span does not take into account the influence of husbandry: Cats and dogs 
usually die as geriatric animals, horses may be allowed to survive their natural life-
span but production animals rarely, if ever, survive beyond middle age. 
Table 1. Estimated tumour rates of the domestic species, before and after correction for life-span. 
The correction factors are based on maximum recorded ages expressed as a proportion of an 
arbitrary 100 years for man (After Dorn and Priester, 1987). 
Estimated rate of tumours/l00,OOOjYear 
Adjustment Unadjusted Adjusted 
Species factor Benign Malignant Total Benign Malignant Total 
Cattle 0.30 49.7 177.2 226.9 14.9 53.2 68.1 
Horses 0.46 2148.3 256.3 2404.6 988.2 117.9 1106.1 
Cats 0.28 35.1 257.4 292.5 15.7 72.1 87.8 
Dogs 0.20 643.7 828.3 1472.0 133.7 165.7 299.4 
N eo lastic disease has been reported in every body system of the horse, for 
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(Schumacher, Smith and Morgan, 1988); Cardiovascular (Johnson, Beech and Saik, 
1988); Lymphoid (Neufield, 1973); Ocular (Bistner, 1974); CNS (Bistner, 
Campbell, Shaw, Leininger, and Gholbrial, 1983); Urinary (Brown and Holt, 
1985); Reproductive (Hinrichs and Hunt, 1990); Endocrine (Heinrichs, 
Baumgartner and Capen, 1990); Integumentary (Mullowney, 1985). However, the 
system most frequently affected is the integumentary system. In the survey of 12 
North American Veterinary colleges, by Priester and Mantel (1971) and Priester 
(1973), skin tumours accounted for over 45 per cent of the total number of 
tumours. Ocular and genital lesions, the second and third most frequently affected 
systems, accounted for only 13 per cent and 10 per cent, respectively. This 
predominance of integumentary tumours may therefore bias any general 
conclusions about neoplastic disease in the horse. 
Neoplastic disease includes both benign and malignant tumours, the latter 
more normally associated with the term "cancer". The perception of neoplasia in 
any species is undoubtedly influenced by the malignancy and/or life-threatening 
potential of the tumour, and any broad overview which classifies tumours by 
degree of malignancy may mask the fact that one tumour type in one system 
predominates and thus distorts interpretation of the data. Analysis of the equine 
data reported by Priester (1973), reveals that only 6 per cent of tumours of the 
integumentary system were malignant (the integumentary tumours together 
comprised over 45 per cent of all neoplasms) whilst 78 per cent of ocular and 52 
per cent of genital tumours were malignant. It is evident from this that tumors of 
the skin and, in particular benign lesions, are the most commonly encountered 
manifestations of neoplastic disease in the horse. 
1.3. TuMOURS OF THE EQUINE INTEGUMENT 
With specific reference to the equine integument, Thomsett (1979) stated that 
imnort::lnt ~kin tllmOllTI: nf thl" hnTl:1" lil:tina thp I:~T{'niil n~nil1{"\TTl~ 
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range of tumour types including, the sarcoid, papilloma, squamous cell carcinoma, 
fibroma, melanoma, neurofibroma, keloid, lipoma, haemangioma, 
adenocarcinoma, lymphosarcoma, fibrosarcoma, sarcoma, adenoma, mast cell 
tumour, myxofibroma, sebaceous tumour, osteoma, sweat gland adenoma, adnexal 
carcinoma, basal cell tumour, carcinoma, haemangiopericytoma, histiocytoma, 
lymphangioma and a plasma cell tumour. The abundance of the benign lesions has 
already been mentioned (Priester, 1973) and the concensus of published surveys of 
tumour prevalence records the sarcoid as the most frequently diagnosed skin 
tumour by clinician and histopathologist. Two surveys from the United Kingdom 
conducted over 17 and 15.5 years report the sarcoid as the histopathological 
diagnosis in 60 per cent (Head, 1965) and 12.9 per cent of cases (Baker and 
Leyland, 1975), respectively. In two reports from the United States carried out over 
10 and five year periods, the sarcoid accounted for 56 per cent (Strafuss, Smith, 
Dennis and Anthony, 1973) and 43.6 per cent of all equine tumours (Sundberg, 
Burnstein, Page, Kirkham and Robinson, 1977), respectively. A third report from 
North America, pertaining to the integument of the horse exclusively, recorded 
sarcoids as comprising 65 per cent of tumours over a two year period (Ragland, 
Keown and Gorham, 1970a). Australian workers also report sarcoids as the most 
commonly diagnosed skin tumour (Murray, Ladds and Campbell, 1978; Pascoe and 
Summers, 1981). 
Mullowney (1985) stressed the difficulty in differentiating fibromas, 
fibrosarcomas and sarcoids and also commented that the majority of squamous cell 
carcinomas, papillomas and sarcoids were diagnosed clinically and could therefore 
be under-represented when analysing tumour occurrence, based on 
histopathological examination. With this in mind, Mullowney (1985) summarised 
ten reports of tumour occurence rates, including a total of 2005 tumours of the 
equine integument. The equine sarcoid accounted for 739 (36.8 per cent) of the 
total and was the sin Ie largest tumour group. Papillomata were the second most 
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1.4. THE SARCOID 
The sarcoid is a neoplasm affecting the skin of horses, donkeys and mules 
(Jackson, 1936; Olson, 1948; Ragland et aL, 1970a; Strafuss et aL, 1973; Genetzky, 
Biwer and Meyers, 1983)) and, although there is no reported sex or age 
predisposition (Ragland et ai., 1970a; Howarth, 1990), the tumour is generally 
observed in younger animals (Scott, 1988). The tumour is considered benign and 
non-metastatic but may infiltrate locally into the surrounding muscle tissue (Lane, 
1977; Tarwid, Fretz and Clark, 1985), especially after surgical intervention (Pascoe 
and Summers, 1981). Sarcoids frequently occur on the site of previous insult to the 
skin (Lewis, 1964; Voss, 1969; Ragland et at., 1970a) but may develop 
spontaneously (Olson, 1948) and it has been suggested that they may be spread 
either by direct contact or by fomites (Jackson, 1936; Olson, 1972). Animals may 
have multiple or solitary sarcoids with the head, ventral abdomen, paragenital 
region and lower limb being most frequently affected (Jackson, 1936; Ragland et 
aL, 1970a, Strafuss et aL, 1973; Murray et aL, 1978). 
1.4.1. Clinical presentation 
There are four clinical manifestations of the sarcoid described in the literature 
(Figures 1, 2, 3 and 4). Ragland et aL (1970a) classified sarcoids into three groups 
(types I, II and III) with a fourth category (type IV) added by Pascoe and Summers 
(1981). Type I or verrucose sarcoids resemble the cutaneous wart-like papillomas 
of bovine papillomavirus (BPV) infection of cattle; type II or fibroblastic sarcoids 
are fibrous nodules occurring within the dermis of the equine skin, although the 
fibroblastic component may sometimes ulcerate through the epidermis; type III 
sarcoids are a combination of types I and II and are termed mixed sarcoids with a 
fibroblastic component and verrucose epidermis; type IV or occult sarcoids are 
flat, slow-growing areas of alopecia containing small hard nodules within the 
dermis. Tvoes I to ITT mav h~ n~(hm{,111Mp.(i or "p""ilp {R ~ul~nrl pt nl 1 a7(l~ '\ 
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of the tumour (Ragland et at., 1970a) and it was suggested by Jackson (1936) that 
the natural progression of the sarcoid development was from type I to type II, with 
eventual ulceration of the fibroblastic component through the epidermis. However, 
many sarcoids may remain quiescent for years with no increase in size and some 
sarcoids are first observed as type II lesions, suggesting that the sequence of events 
proposed by Jackson is not applicable to all cases of the disease (Ragland et at., 
1970a; Brown, 1983). Affected animals rarely reject sarcoids (Voss, 1969), the 
hosts immune system reacting minimally to the presence of the tumour (Gorman, 
1985). 
CHAPTER I 
Figure 2. A type II or fibroblastic sarcoid located in the paragenital region of a male 
donkey. 
CHAPTER I 
Figure 3. A type III or mixed sarcoid located at the commissure of the lips of a donkey. The lesion 
is ulcerated. 
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Figure 4. A type IV or occult sarcoid. There is an area of alopecia and slight nodularity of the skin 
surface. 
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1.4.2. Differential diagnosis 
The equine sarcoid must be differentiated from all nodular and neoplastic 
conditions of the skin. In particular, the following diseases must be considered as 
major differentials (Pascoe and Summers, 1981; Brown, 1983; Tarwid et a!., 1985; 
Howarth, 1990): 
Type I: Squamous papilloma, dermatophytosis, squamous cell carcinoma, 
cutaneous habronemiasis. 
Type II: 
Type III: 
Type IV:' 
Nodular skin disease, fibroma, fibrosarcoma, neurofibroma, 
neurofibrosarcoma, melanoma, granulation tissue, cutaneous 
habronemiasis. 
As for Types I and II. 
Local inflammatory reactions, dermatophytosis, dermatophilosis, 
neurofibroma. 
In many instances, although a tentative clinical diagnosis of sarcoid may be 
made, in order to obtain absolute confirmation, histological examination must be 
carried out (Howarth, 1990). 
1.4.3. Histopathological features of the tumour 
Histopathological changes that are reported vary depending upon the clinical type 
of the tumour and the degree of ulceration and trauma. Although Jackson (1936) 
originally suggested that the epidermis was an essential component for a positive 
diagnosis to be made, Ragland et a!. (1970a) argued that dermal changes alone are 
sufficient for histopathological confirmation of a sarcoid. 
The following features may be present in the epidermis: hyperkeratosis, 
parakeratosis, acanthosis, generalised epithelial hyperplasia and plexiform 
acanthosis (rete-peg formation) (Jackson, 1936; Ragland et a!., 1970a; Baker and 
Leyland, 1975; Pascoe and Summers, 1981; Tarwid et a!., 1985). Pathological 
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1970a; Tarwid et aI., 1985; Murray et aI., 1978; Pascoe and Summers, 1981). In 
particular, the pallisading of fibroblasts and fibrocytes along the dermo-epidermal 
junction giving a picket-fence appearance, is associated with a sarcoid tumour 
(Ragland et aI., 1970a; Baker and Leyland, 1975; Tarwid et aL, 1985). The 
fibroblasts may be plump or spindle shaped and mitotic activity is variable. The 
composition of the dermis in the sarcoid differs from that of normal equine skin 
with type III co1lagen being more abundant (Williams, Heaton and McCullagh, 
1982). This was attributed to the proliferative nature of the dermis in the tumour. 
Figure 5. Histopathological appearance of a type I sarcoid showing characterisitics of a well 
..1~ •. ~1~_~..1 "l-_~_~~;11 ~ Tl. r· rl P 
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1.4.4. The genetic basis for the disease 
The first suggestion that there may be a familial or genetic predisposition to the 
disease came from an epizootic of sarcoid reported by Ragland, Keown and 
Gorham in 1966 where four of five affected animals were members of the same 
family. This observation was supported by James (1968) who recorded the 
occurrence of sarcoids in three offspring out of a sarcoid-affected dam. James 
(1968) also suggested the possibility of vertical transmission of an aetiological 
agent. 
Despite the fact that sarcoids are found in all breeds of horses, donkeys and 
mules, there are notable differences in the disease prevalence amongst different 
breeds. Angelos, Oppenheim, Rebhun, Mohammed, and Antczak (1988) found 
that quarter horses had nearly twice the risk of developing sarcoids as had 
thoroughbreds (Odds Ratio (OR) 1.8, p<0.05), whilst standardbreds had a much 
lower risk of developing sarcoids than other breeds (OR 0.2, p<0.001). More 
recently an association between susceptibility to sarcoids and the Major 
Histocompatibility Complex (MHC) has been demonstrated. In the horse, the 
MHC is known as the Equine Leucocyte Antigen (ELA) system and both class I 
and class II antigens have been reported at the population level in several breeds. 
Lazary, Gerber, Glatt and Straub (1985) recorded that the class I antigen W3 (A3) 
and the class II antigen W13 (B 1) occurred more frequently in sarcoid affected 
horses whilst, in Irish horses with sarcoids, the Wll specificity was better 
represented compared with Swiss and French horses, which frequently were of W5 
specificity. The association with W13 and A3 was confirmed by Meredith, Elser, 
Wolf, Soma, Donawick, and Lazary (1986) in the United States and by Brostrom, 
Fahlbrink, Dubath and Lazary (1988) in Swedish halfbred horses. Gerber, Dubath 
and Lazary (1988), in an analysis of multiple case families and half-sibling groups, 
showed that the W13 ELA haplotypes segregated with susceptibility to disease and, 
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1.4.5. Transmissibility of the sarcoid 
Early experimental work on the equine sarcoid focused on the transmissibility of 
the tumour. Two groups of French workers first described the transmission of 
sarcoid-like tumours from one horse to another in the period prior to widespread 
acceptance of Jackson's term "sarcoid". Cadeac (1901) reported that extracts of a 
papillomatous tumour rubbed into the scarified skin of unaffected horses produced 
tumours in three to four weeks. Montpellier, Badens and Dieuzeide (1937) 
considered tumours observed on six animals to be of neural origin and later 
reported the autologous transplantation of one of the tumours on a mule 
(Montpellier, Dieuzeide and Badens, 1939). 
Olson (1948) demonstrated the autotransplantation of sarcoid tumours into 
scarified equine skin but was unsuccessful in attempts to transfer the lesion by 
intradermal or subcutaneous inoculation of tumour suspension, or to demonstrate 
homotransplantation. Transmission of sarcoids to both affected (one of five) and 
unaffected (two of six) horses by inoculation of cell-free extracts was achieved by 
Voss (1969). However, sarcoid homogenates were also used in the same animals 
(Voss, 1969) and so the homologous transmission of the tumour by cell-free extract 
still required absolute confirmation. The incubation periods for the development 
of tumours in the experimental animals varied from 17 to 170 days in the case of 
autologous transplantations and from 50 to 184 days for transplantations to 
unaffected horses. Voss (1969) also recorded the early regression of both naturally-
occurring and experimentally transferred sarcoids when autologous and 
homologous horses were infected with sarcoid tissue. 
Ragland (1966) was largely unsuccessful in attempts to transmit sarcoids to 
mne unaffected horses, five unaffected donkeys and 12 wart-free calves by 
inoculation of cell-free extracts of sarcoid tumours. Most interestingly, two of the 
five donkeys developed growths, but Ragland, McLaughlin and Spencer (1970b) 
did not consider anv of the 12 2:rowths to be sarcoids. The tumours were a ressive 
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the fibroblasts and fibrocytes at the dermo-epidermal junction. 
1.4.6. Aetiology 
The original description of 44 cases of sarcoid by Jackson (1936) classified the 
lesions together with bovine and canine papillomas due to their gross clinical 
appearance and pathology. The canine wart was purely epithelial, unlike the 
bovine and equine lesions which possessed both epithelial and fibroblastic 
components. The association of the bovine papillomaviruses with the equine 
sarcoid was further supported by the work of Olson and Cook (1951) who 
inoculated bovine wart material intradermally in horses and produced nodules 
which appeared within 12 to 17 days. Some of these tumours resembled sarcoids 
histologically but most regressed spontaneously by 150 days, in contrast to 
naturally-occurring sarcoids which rarely undergo rejection (Voss, 1969). Cook and 
Olson (1951) were unable to induce tumours by inoculation on to scarified skin. 
Only one of the tumours induced in the study behaved biologically like a naturally-
occurring sarcoid, persisting for over 18 months. 
Ragland conducted a series of experiments in attempts to demonstrate BPV 
as the causal agent of the sarcoid (Ragland, 1966). The studies provided 
information on the ability of BPV to induce tumours in the equine integument, 
serological response to BPV inoculation and immunity to BPV infection in the 
horse. The results of these studies (Ragland and Spencer, 1969) showed that 
inoculation of BPV suspensions into young ponies produced lesions histologically 
similar to sarcoids but, unlike the natural disease, the tumours regressed within 
one year. In the same study, inoculation of BPV suspension into adult animals 
produced tumours in all of 21 animals but the lesions lacked the histological 
features of the naturally-occurring sarcoid and were rejected. 
With regard to the serological reponse to BPV infection, Ragland and 
S encer 1968 failed to demonstrate neutralisin antibod to BPV in the sera 
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sarcoids. These animals also produced serum antibodies capable of neutralising 
BPV, unlike the animals with the natural infection. This work supported the 
findings of Segre, Olson and Hoerlein (1955) who demonstrated the presence of 
neutralising antibodies in the sera of horses with growths induced by the agent of 
bovine papillomas but contradicted the results published by Olson and Cook 
(1951) which reported no evidence of acquired immunity in animals inoculated 
intradermally with bovine wart extracts, as experimental horses were susceptible to 
repeated exposure. Ragland and Spencer (1968; 1969) and Ragland et aI. (1970b) 
concluded that whilst BPV should still be considered a candidate for the 
aetiological agent of the equine sarcoid, the results of their studies did not provide 
definitive evidence that sarcoids were caused by BPV. The isolation of infectious 
papillomaviral particles has yet to be achieved (Gorman, 1985; Angelos, 1990) and 
it has been suggested that little advance will be made until a virus or viruses are 
isolated and characterised (Ragland et ai, 1970b). Ragland and Spencer (1969) 
postulated that transmission attempts with viral nucleic acid might be an 
appropriate development of future research. 
In the 1970s and 1980s, an alternative candidate emerged for consideration 
as aetiological agent following the establishment of a transformed cell line (Mc-1) 
from an equine sarcoid (Watson, England and Larson, 1972). A number of reports 
were published based on investigations involving the Mc-1 cell line which 
implicated a retrovirus in the pathogenesis of the tumour. The cells were shown to 
contain a C-type retrovirus (England, Watson and Larson, 1973; Cheevers, 
Roberson and Brassfield, 1982; Fatemi-Nainie, Anderson and Cheevers, 1982) and 
were tumorigenic in athymic nude mice (Fatemi-Nainie et aI., 1984) and in an 
Arabian foal with combined immunodeficiency disease (Cheevers, Roberson, 
Brassfield, Davis and Crawford, 1982). Animals with sarcoids were shown to have 
non-cytotoxic antibody to the Mc-1 cells (Watson and Larson, 1974) and a cell 
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Despite the fact that the retroviral element was subsequently shown to be present 
in normal equine skin cells and therefore presumably endogenous in origin 
(Cheevers, Fatemi-Nainie and Anderson, 1986) the possibilty that the virus is 
involved in the diseases process remains. 
1.4.7. Molecular biology of the disease. 
Investigations into the molecular biology of the sarcoid have supported the 
hypothesis that a BPV-like virus may be involved in the pathogenesis of the 
disease. The presence of papillomaviral DNA has been demonstrated in lesions 
removed from both horses and donkeys (Lancaster, Olson and Meinke, 1977; 
Lancaster, Theilen and Olson, 1979; Amtmann, Muller and Sauer, 1980; Lancaster, 
1981; Trenfield, Spradbrow and Vanselow, 1985; Angelos, 1990; Angelos, Marti, 
Lazary and Carmichael, 1991). Initial studies were performed utilising DNA-DNA 
reassociation kinetics whilst more recent investigations, involving Southern blotting 
and hybridisation, have shown that the papillomaviral DNA does not integrate into 
the host genomic DNA, existing as non-integrated episomes with between 10 and 
450 copies per cell (Amtmann et ai., 1980; Lancaster, 1981; Trenfield et ai., 1985; 
Angelos et ai., 1991). The viral DNA may be present in a number of forms; 
supercoiled, open circle or linear are all demonstrable by Southern blotting and 
hybridisation to cloned BPV-1 or 2 DNA probes (Amtmann et ai., 1980; Lancaster, 
1981; Angelos et ai., 1991). Restriction endonuclease digestion of the DNA 
extracted from the tumours has shown that a variety of restriction fragment 
patterns are present, some identical to BPV-1, some to BPV-2 and others similar 
to, but identical to neither BPV-1 nor 2. However, the high degree of homology 
demonstrated by the hybridisation studies performed at high stringency, suggest 
that the differences observed by Trenfield et ai. (1985) and Angelos et ai. (1991) 
are minor, perhaps differentiating viral subtypes. More recently, Teifke and Wiess 
(1991) utilised the polymerase chain reaction (PCR) to amplify a specific region of 
CHAYfERI 
and, by restriction enzyme digest with Bst XI, could detect no difference between 
the amplified DNA and the corresponding region of the BPV-1 genome. 
1.4.8. Therapy of equine sarcoids 
The therapeutic approach to the sarcoid has been diverse (Roberts, 1970; 
Genetzky et al., 1983). Surgical excision, excision by diathermy, cryotherapy, 
excision by carbon dioxide laser, immunotherapy, hyperthermia, brachytherapy and 
chemotherapy have all been used alone or in combination and the relative merits 
of the various modalities have been reviewed (Roberts, 1970; Howarth, 1990). No 
one technique has been shown to be absolutely successful and the variation in 
responses to treatment may be due to the size, location or type of the lesion 
(Ragland et at. 1970a) and genotype of the animal (Sarcoid Workshop, 1990). No 
definitive comparison studies have been undertaken to elucidate the relationship 
between these factors and therapeutic outcome. 
1.4.8.1. Surgical excision 
Surgical excision using scalpel or diathermy may be performed under general or 
regional anaesthesia. Larger tumours or tumours occurring in less accessible 
anatomical locations usually require the animal to be under general anaethesia 
and the limiting factor in animals with multiple lesions is the duration of 
anaesthesia. Unfortunately, recurrence after tumour removal is frequent. Ragland 
et at. (1970a) reported a 50 per cent recurrence within three years of removal, 
whilst Diehl, Vingerhoets and Stornetta (1988) recorded a 64 per cent recurrence 
with many tumours regrowing before wound healing was completed. Other workers 
reported that the histological examination of tissue sections from the base of the 
tumour may provide guidance for the surgeon, ensuring complete removal of the 
neoplasm (Adams, Calderwood-Mays and Peyton, 1988). Split-thickness 
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1.4.8.2 Cryotherapy 
This modality of treatment has been used with success by several authors (Joyce, 
1976; Lane, 1977; Fretz and Barber, 1980) and has the advantages of comparative 
safety to operator and patient and relative lack of scarring after healing. Several 
cryotherapeutic systems are available but liquid nitrogen is the cryogen of choice 
(Lane, 1977; Mumoe, 1986). Cryotherapy is a destructive process killing both 
healthy and diseased tissue and, as a consequence, care must be taken when 
applying the cryogen which is best administered by spraying directly on to the 
affected area (Lane, 1977). The surrounding tissue should be protected from 
possible damage by applying petroleum jelly around the surgical site and an 
expanded polystyrene mask may be used to avoid liquid nitrogen run-off from the 
treatment area. Wicking materials such as gauze and towels should be avoided 
unless soaked in petroleum jelly (Krahwinkel, Merlkey and Howard, 1976). The 
use of thermocouple needles is advocated in order to monitor the temperature of 
the surrounding healthy tissue. The tumours should be frozen to a minimum 
temperature of -200 C, although some authors report greater success following 
freezing to -300 C (Fretz and Barber, 1980) or -500 C (Rebhun, 1990) during two to 
three freeze/thaw cycles (Mumoe, 1986). Debulking larger tumours may best be 
carried out by diathermy in order to keep the haemorrhage associated with sharp 
excision to a minimum, as excess blood at the freezing site leads to increased 
operating time during cryotherapy. 
Sequelae to cryotherapy are, in general, predictable: Swelling local oedema 
and vasodilation, malodorous discharge often associated with superficial infection 
and eventual sloughing of the eschar occurs within two (Fretz and Barber, 1980) to 
eight weeks (Lane, 1977); cryodestruction of hair follicles and melanocytes may 
result in hair loss and depigmentation of the site. Untoward complications are 
associated with the accidental cryonecrosis of adjacent vital structures, including 
ermanent and tern ora facial nerve aral sis irreversible dama e to tendons 
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Holmberg, 1980), lymphangitis and hind limb pain following the cryotherapy of a 
preputial tumour (Lane, 1977). 
Generalised tumour regression of non-treated tumours has been reported 
following treatment of selected sarcoids (Lane, 1977) and may be due to an 
immune response following the release of altered cellular components. However, 
the spontaneous regression of tumours following cryotherapy is not a consistent 
finding. 
1.4.8.3. Immunotherapy 
Non-specific immunotherapy has recently found a place in the therapy of the 
sarcoid (Houlton, 1983; Schwartzmann, Cantrell, Ribi and Ward, 1984; Zeidner 
and Bracken, 1985; Rebhun, 1987). The Bacillus of Calmette and Guerin (BCG) is 
an attenuated strain of Mycobacterium bovis, an immunomodulator, and is the 
agent most commonly used for immunotherapy. Bast, Zbor and Boros (1974) 
noted a regression in tumours of the skin in patients following the administration 
of the BCG vaccine, the intralesional injection of the BCG inducing an immune 
reaction dependent upon the host's ability to mount a delayed (type IV) 
hypersensitivity response. In the therapy of the sarcoid, the organism has been use 
in a number of different forms: live (Wyman, Rings, Tarr and Alden, 1977), killed 
(Vanselow, Abetz and Jackson, 1988) or purified cell wall extracts (Murphy, 
Severin, Lavach, Hepler and Leuker, 1979; Lavach, Sullins, Roberts, Severin, 
Wheeler and Leuker, 1985) have all been combined or emulsified (Webster and 
Webster, 1985) with a variety of adjuvants and it is this diversity of preparation and 
protocol that makes the success of the technique difficult to assess. (Rebhun, 
1990). Furthermore, the reponse to BCG administration appears to be related to 
the anatomical location of the sarcoid and to the clinical type - periocular sarcoids 
respond well (Wyman, et at., 1977; Murphyet aL, 1979; Owen and Jaggar, 1987), 
whilst sarcoids on the lim and in h "Ila do not Klein 1986· Owen and Ja er 
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tumour prior to immunotherapy. 
The report of anaphylactic shock following second or third injections of 
BeG has led to the recommendation that animals should be premedicated with 
flunixen meglumine, corticosteroids and tripelenamine (Winston, Rings and 
Wyman, 1979; Owen and Jagger; 1987; Vanselow et a!., 1988). A number of 
therapeutic regimens have been described but all require repeated intralesional 
administration of the whole BeG organism or derivative at two to three week 
intervals on up to six occassions, injecting the BeG preparation at a rate of 
approximately 1mlj cm2 (Howarth, 1990). Response to therapy is more noticeable 
after the second or subsequent administration with local inflammation, developing 
to ulceration, necrosis and eventual rejection. Systemic reactions may include 
malaise, colic, diarrhoea, pyrexia, sweating, laminitis and transient leucocytosis 
(Howarth, 1990) with complete resolution of lesions taking up to 12 months. 
Hepler and Leuker (1980) considered the possibilty of anaphylaxis and aerolisation 
of BeG a hazard to both operator and patient. 
Despite having been in use for over a decade, the precise mechanism by 
which the BeG exerts its action is still unclear. It would appear that for successful 
therapy the host must have a relatively small tumour burden and must be 
immunocompetent. An adequate dose of BeG must then be administered to the 
lesion and there must be close association of the BeG with the tumour cells. The 
persistence of the bacterial cell at the site of the tumour may be the stimulus for a 
chronic inflammatory reaction (Bast et a!., 1974) and so the choice of adjuvant may 
affect the success of therapy. The host immune system, which mounts little 
response to the sarcoid (Gorman, 1985), may be stimulated by BeG causing an 
increase in natural killer cells and activated macrophages (Bast et al., 1974; Lavach 
et a!., 1985; Vanselow et at., 1988). Vanselow et a!. (1988) noted that the reponse 
appeared to be specific to tumour cells as the healthy tissue surrounding treated 
sarcoids was unaffect rin m ur re·ection but Owen and Ja er 1987 
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advantages of speed and apparent specificty, Howarth (1990) concluded that the 
cost of repeated visitations and premedication gave no significant economic 
advantage to BCG therapy over cryotherapy. 
Other types of immunotherapy have been reported, in particular, the use of 
autogenous vaccines has been popular with field clinicians. Wheat (1964) proposed 
the use of an autologous vaccine, a suggestion supported by the favourable results 
of Page, Tiffany and Russell (1967) and by the early regression of naturally-
occurring and transplanted sarcoids observed in autologous and homologous 
animals infected with whole sarcoid material by Voss (1969). However, Ragland et 
aL, (1970a) record the use of BPV vaccines as being of no use and Roberts (1970) 
obtained equivocal results using autogenous vaccines alone or in concert with 
adjuvants, cytotoxic drugs, antiviral drugs, BPV or other vaccines. 
1.4.8.4. Chemotherapy 
Cytostatic and cytotoxic drugs such as 5-fluorouracil (Bertone and McClure, 1990) 
and popophyllin (Metcalf, 1971) have been used to treat sarcoids in a number of 
topical applications, but Brown (1983) found their sole use unreliable. The 
technique was more successful when used in conjunction with other modalities. 
1.4.8.5. Hyperthennia 
This procedure has been reported to be successful in a number of cases (Hoffman, 
Kainer and Shideler (1983) but requires specialist equipment. Radiofrequency 
current (2MHz) is applied to a probe inserted in the tumour thus superheating the 
tumour cells and effecting cellular death. The technique may be synergistic with 
radiation therapy (Turrel, Stover and Gyorgyfalvy, 1983). 
1.4.8. 6. Interstitial Brachytherapy 
h rc id im lantin 
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for dedicated premises and the risk to operator and environment from misplaced 
or lost needles, excludes this technique from widespread usage. 
1.4.8.7. Carbon dioxide laser 
The most recent mode of therapy has been the use of carbon dioxide laser 
(Palmer, 1989). No recurrence after surgery was recorded 11 months after surgery. 
Diehl et ai., (1988) reported 81 per cent of 48 cases treated by this method had no 
recurrence of disease one year after surgery, comparing favourably with 64 per 
cent success in the 14 animals treated by cryotherapy after the same period of time. 
After carbon dioxide laser therapy the surgical site is dry with little or no 
haemorrhage. Primary closure may be attempted or the wound may be allowed to 
scab and slough leaving a bed of granulation tissue. The epithelialisation of the site 
may be slow, but the area is usually not painful on palpation (Diehl et ai., 1988). 
1. 4. 8. 8. Summary 
It is evident that no one therapeutic approach is successful but Howarth (1990), 
although recommending cryosyrgery and BeG immunotherapy, comments that the 
long term approach to both treatment and prevention lies in the development of a 
specific equine sarcoid vaccine. Given the accumulating evidence implicating a 
papillomavirus in the disease, the following section contains a summary of salient 
information about papillomaviruses and the state of vaccine development against 
papillomavirus- induced disease. 
1.5. THE PAPILLOMA VIRUSES. 
1.5.1. Introduction 
Papillomaviral infections are of clinical importance and may progress to 
malignancy (zur Hausen, 1985; 1991). The viruses induce a number of lesions in 
human n 1 n v n r a of virolo that is ex andin ra idly 
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cases per year) is greater than the incidence of leukaemia (11,000 new cases per 
year) in women and it is feared that in developing countries, which do not screen 
the female population, the rate may be five or six times that in the United States 
(Schreier, Allen, Laughlin and Gruber, 1988). To be of clinical significance 
papillomaviral associated lesions do not necessarily need to be malignant, as in the 
case of some of the genital lesions in humans (zur Hausen, 1991). Both the penile 
papillomas in cattle (Jarrett, 1985) and laryngeal papillomas in children (Steinberg 
and Abramson, 1985) are benign lesions but cause clinical problems to the afflicted 
and it is well documented that, on occasions these benign lesions may progress to 
malignancy as in the case of epidemodysplasia verruciformis. This is an inherited 
condition which manifests itself by the development of a number of papillomaviral 
induced lesions some of which may, after several years, become malignant (Orth, 
1987). 
The literature concerning the diseases caused by and associated with 
papillomaviruses is extensive and the reader is directed to several substantial 
reviews on both disease aspects as well as the biology and biochemistry of the 
viruses (Pfister, 1984; Howley and Schlegel, 1988; zur Hausen, 1991). The salient 
features with regard to the general properties are summarised in the following 
sections. 
Until recently, the papillomaviruses have been grouped together with the 
polyomaviruses in the same family of Papovaviridiae. However, the two genera 
differ in biological behaviour as well as at the level of molecular organisation 
(Danos and Yaniv, 1983; Pfister, 1984). The polyomaviruses are usually non-
oncogenic in their natural host, require integration of viral sequences into the 
cellular DNA for the transformed state to be maintained and both strands of the 
DNA viral genome code in the lytic cycle. By contrast, the papillomaviruses induce 
epithelial tumours in their natural host and the double-stranded viral genomes 
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Hausen, 1981; Favre, libard and Orth, 1982), as well as in transformed cells in 
culture (Groff and Lancaster, 1984; Law, Lowy, Dvoretsky and Howley, 1981; 
Moar et at. 1981a; Wood and Spradbrow, 1985). The DNA is found in supercoiled, 
open circle or linear forms (vide supra) and in addition, only one strand of the viral 
genome is transcribed (Amtmann and Sauer, 1982). As a result, the viruses are 
now classed as subfamilies of the Papovaviridae and the formal classification of the 
papillomaviruses is based on natural host and genome homology, with viruses 
demonstrating biological differences and less than 50 per cent homology being 
classed as different types. 
The papillomavirus genome is broadly divided into three main domains; an 
early or transforming region, a late or capsid forming region and a non-coding 
region (NCR) also called the upstream regulatory region (URR), which contains 
elements involved in transcriptional control (Danos and Yaniv, 1983; Danos, Giri, 
Thierry and Yaniv, 1984). The early and late regions contain open reading frames 
(ORFs) which code for viral proteins and are responsible for the control of 
transformation, replication and viral assembly. The genomic organisation and 
function of the viruses will be discussed in more detail with specific reference to 
the BPVs. 
1.5.2. Animal papillomaviruses 
The first demonstration of the transmissibility of human warts by cell free extracts 
(Ciuffo, 1907) preceded, by more than two decades, the demonstration by Shope 
(1933) of the ability of the viruses to induce malignancy in rabbits (Shope, 1933). 
The viruses induced skin warts in cottontail rabbits in natural infections and in 
domestic rabbits under experimental conditions. Twenty-five per cent of the 
naturally-occurring and 75 per cent of the experimentally induced warts progressed 
to carcinomas (Rous and Beard, 1935; Syverton, 1952). In the experimental model, 
the a ill m i n f virion and mali nant 
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caused neither papilloma nor carcinoma. Since then, papillomavirus infections 
have been reported in many animal species, e.g., goats (Davis and Kemper, 1936), 
horses (Cook and Olson, 1951), dogs (Cheville and Olson, 1964), monkeys (Koller 
and Olson, 1972), chaffinches (Osterhaus, Ellens and Horzinek, 1977), sheep 
(Gibbs, Smale and Lawman, 1975), mice (Muller and Gissman, 1978), hamsters 
(Graffi, Bender, Schramm, Kahn and Schneiders, 1969), deer (Shope, Mangold, 
McNamara and Dumbell, 1958), European elk (Moreno-Lopez, Pettersson, Dinter 
and Philipson, 1981) and cats (Carney, England, Hodgkin, Whiteley, Adkinson and 
Sundberg, 1990). 
In order to understand the pathogenesis of papillomavirus infection the 
normal physiological development of the mammalian skin must first be considered. 
The epidermis in the mammal generally matures over a ten to 14 day interval with 
vertical differentiation of the basal cells. These cells mature first to the prickle cell 
layer (stratum spinosum) at which point the keratin gene expression commences 
(Franke, Moll, Achstaetter and Kuhn, 1986). This layer in turn matures into the 
granular layer (stratum granulosum) comprising between two and four rows of 
polygonal cells which lie parallel to the skin surface. The death of the epidermal 
cells begins at this stage as they become anucleate leaving the keratin precursor 
derived from the keratohyalin. The terminal layers consist of cells devoid of 
structure and these are continuously desquamated. 
Research into the biology of papillomaviral infection has been hindered by 
the failure to propagate the virus in vitro and, as a consequence, the specific 
mechanisms and processes involved in the viral replicative cycle are poorly 
understood. The transcription, translation and viral assembly is intimately 
associated with the events of the maturing epidermis (Pfister, 1984). Infection of 
the skin by papillomaviruses requires the access to one or more basal cells (Jarrett, 
1985) which proliferate leading to hyperplasia in the stratum spinosum. The virus 
can be demonstra r Ii 1 " tum s inosum and stratum anulosum 
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layers. As the cell structures disintegrate, aggregates of viral particles can be 
demonstrated in the stratum granu[osum, before finally being desquamated in the 
keratinised epithelium. 
1.5.3. The bovine papillomaviruses 
In recent years, there has been extensive research into the identification and 
characterisation of bovine papillomaviruses. To date, nine naturally-occurring 
bovine neoplasms have been associated with six characterised viruses (Campo, 
Moar, Laird and Jarrett, 1981; Jarrett, 1985) The bovine viruses are divided into 
two groups, A and B. Those viruses in subgroup A induce fibropapillomas with 
transformation of both epthelial cells and fibroblasts. Subgroup B viruses induce 
squamous epithelial neoplasms or "true" papillomas, the transformation being 
limited to the keratinocytes. The two groups can be distinguished immunologically 
as well as by the size and organisation of the viral genome and in both sub-groups 
the DNA is in episomal, non-integrated form. This extra chromosomal DNA 
occurs in multiple copies, usually between 10 and 200 copies per cell. 
The viruses (Jarrett, 1985; Lancaster and Olson, 1982; Pfister, 1984) are 
typical of papillomaviruses having a 72 capsomere icosahedral capsid with a 
diameter of 55nm and containing a circular double stranded genome. The viruses 
belonging to subgroup A have many common attributes. BPV-1 has DNA 
sequence homology of 45 per cent to BPV-2 and 5 per cent to BPV-5. The 
molecular weight of the DNA is 5x106 Daltons comprising approximately 7900 
base pairs, the colinear genomes containing two major areas of conserved 
interspecific sequences in the E1 and L1 ORFs. These regions are also found in 
human and rabbit cutaneous papillomavirus. Agar Gel Immunodiffusion, Enzyme 
Linked Immmunsorbent Assay and Peroxidase Anti-Peroxidase demonstrate 
shared antigenic sites when reacted with rabbit sera to disrupted virus (BPV-1, 2 
and 5 or b direct cross-reaction with bovine antisera from naturally infected 
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with the human, rabbit or subgroup A viruses. The genomes of the subgroup B 
viruses are smaller than those of BPV -1, 2 and 5 having a molecular weight of 
approximately 4.5 X 106 Daltons and a length of 7.2 kilobases. BPV-4 and BPV-6 
share 50 per cent homology and BPV-4 and BPV-3, 20 per cent homology, under 
relaxed conditions. BPV-4 and BPV-3 do not possess the interspecific 
papillomavirus antigen. 
The genome of the BPV s are typical of papillomaviruses having early, late 
and URR regions. The early region may contain up to eight ORFs, responsible for 
viral replication and transforming activities and which are expressed in fibroblasts, 
cultured cells and the basal cells of papillomas (Arntmann and Sauer, 1982; Pfister, 
1984; Howley, 1986; Shah and Howley, 1990). The late region has two ORFs which 
code for the major structural proteins of the virus and these are only transcribed in 
the keratinising layers of papillomas and fibropapillomas, where the virus assembly 
takes place (Orth et aL, 1971; Amtmann and Sauer, 1982; Pfister, 1984) 
Campo (1992) reviewed aspects of transformation of the animal 
papillomaviruses laying emphasis on the different means by which the viruses 
achieve transformation of cultured cells. The fibropapillomaviruses BPV -1 and 2 
are able to transform primary cells without the need for additional oncogenes 
(Morgan and Meinke, 1980; Jarrett, 1985) and in this respect differ from the 
purely epitheliotropic viruses such as RhPV and BPV-4 which co-operation of the 
transforming gene with another oncogene, such as activated ras (Jaggar, Pennie, 
Smith, Jackson and Campo, 1990; Schneider, McGlennen, LaBresh, Ostrow and 
Faras, 1991). It is the early region of the papillomaviral genome which is necessary 
for transformation to take place, although the late region plays a significant role in 
some species such as CRPV (Meyers and Wettstein, 1991). In the case of BPV-1, it 
has been shown that the deletion of the entire late region results in no loss of 
. transformation efficiency (Lowy, Dvoretzky, Shober, Law, Engel and Howley, 
e for transformation 
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E8 (Jaggar et aI., 1990; Jackson, Pennie, McCaffery, Smith, Grindlay and Campo, 
1991); of CRPV are E6 and E7 with the E7 playing a minor role in vitro but an 
essential role in vivo. In the case of HPVs, HPV-16 requires E6 and E7, whilst the 
sole oncogene of HPV -8 is E6. 
Of the several domains which have been associated with transformation 
(p 105Rb binding region, casein kinase II phosphorylation sites and zinc binding 
cys-x-x-cys motifs) it is the zinc binding properties of BPV-1 E6 which are involved 
in cell transformation (Barbosa, Edmonds, Fisher, Schiller, Lowy and Vousden, 
1990) and, in addition, the E6 is a putative transcriptional activator capable of 
disrupting gene transcription in the cell (Lamberti, Morrisey, Grossman and 
Androphy, 1990). The second major oncogene of BPV-1, E5, is responsible for the 
activation of EGF and PDGF (Martin, Vass, Schiller, Lowy and Velu, 1989; Petti, 
Nilson and Dimaio, 1991) and is also able to bind the 16K cellular protein 
component of the gap junction and vacuolar proton channel-forming ATPase, 
possibly resulting in the disruption of cell-cell communication and intracellular 
traffic respectively (Goldstein, Finbow, Andresson, McLean, Smith, Bubb and 
Shegel, 1991; Finbow, Pitts, Goldstein, Schlegel and Findlay, 1991). 
1.5.4. Transmission of BPV 
Whilst the exact method of transmission is still unkown, fibropapillomas in cattle 
appear to occur after a traumatic insult to the skin and a concommitant increase in 
mitotic activity. The appearance of tumours in cattle after winter housing may be 
related to areas excoriated by the animals on hay racks, posts or gates. 
Experimentally, calves may be infected with virus after making a deep scratch to 
the dermis, as reviewed by Jarrett (1985). 
However anomolies exist. For instance, the lesions of the teats caused by 
BPV1, 5 and 6 are most commonly found in heifers and calves, suggesting that the 
previous tenet, associating milking machine trauma and calf suckling with 
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circulation of viral genomes. The source and route of infection of BPV-4 lesions in 
the alimentary tract is unknown. 
Latency may also occur (Campo, 1987). Campo and Jarrett (1986) reported 
the occurrence of BPV-2 lesions on calves used in a BPV-4 transmission 
experiment. These calves had been removed from their dams at birth, reared in 
isolation in virgin accomodation and then infected wth BPV-4. BPV-2 lesions 
developed on sites where venipuncture had been performed and on traumatized 
skin of calves immunosuppressed by treatment with azathioprine. By Southern 
blotting and hybridisation, the lymphocytes of these animals were found to contain 
the BPV-2 genome, suggesting that latency in a genomic non-viral form may occur. 
These anomalies require resolution in order to elucidate fully the modes of 
transmission of the BPVs. 
1.5.5. Vaccination against papillomaviral infections 
Vaccination against viral disease is cited as being one of the goals of viral research 
(Schreier et a!., 1988). Although prevention of disease by prophylactic vaccination 
may be the ultimate goal, the related immunotherapies such as therapeutic 
vaccination have an equally important role to play, as their use may be more 
appropriate for ethical, medical, sociological, logistical or economic reasons. 
For many years, inactivated tissue from naturally-occurring tumors has been 
used as a means of vaccination and this has been successful in some instances. 
Olson, Segre and Skidmore (1960) inoculated calves subcutaneously with 
formalinised, noninactivated bovine wart material or BPV propagated in chicken 
embryos. Although there was a variation in response, a good degree of immunity to 
intradermal challenge with BPV material was reported in the groups inoculated 
with formalinised or actively growing wart material, with multiple vaccinations 
providing better protection. The virus passaged in chick embryos was not effective 
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O'Neil, Gaukroger, Laird, Smith and Campo, 1990a) wherein calves vaccinated by 
deep intramuscular inoculation with homogenised tumour induced by BPV-2 or 
purified BPV-2 virus were both resistant to BPV-2 challenge. In contrast, the use 
of BPV-2 transformed fibroblast cultures as vaccines was unsuccessful and Jarrett 
et al. (1990a) concluded that the viral content alone was responsible for the 
protection against challenge. The same authors also suggested that the equivocal 
results obtained by workers in the field of human papillomavirus vaccination 
(Mallison, Morris and Jones, 1982) may have been due to to the heterogenity of 
the viruses involved in papillomaviral lesions, resulting in a vaccine being made 
from tumours induced by a different virus from the original pathogen. This 
possibilty was demonstrated effectively by the immunity of calves vaccinated with 
purified BPV-2, 4 or 6 to reinfection by homologous virus, and by the susceptibilty 
to challenge by BPV-1 of calves immune to BPV-6 (Jarrett, O'Neil, Gaukroger, 
Smith, Laird and Campo, 1990b). Furthermore, calves infected with BPV-2, 5 or 6 
developed and rejected type specific lesions but were still susceptible to infection 
with BPV-4. The experiments indicated that prophylactic immunity to 
papillomavirus infection is type specific. 
This research has progressed to the use of genetically engineered fusion 
proteins as vaccines (Jarrett, Smith, O'Neil, Gaukroger, Chandrachud, Grindlay, 
McGarvie and Campo, 1991). In these studies, the L1 and L2 encoded proteins of 
BPV-2 were expressed as beta-galactosidase fusion proteins and were used to 
vaccinate calves both prophylactically and therapeutically against BPV-2 infection. 
The L1 fusion protein was effective in preventing tumour formation when 
administered before challenge with BPV-2. The L1 was also effective in 
stimulating serum neutralising antibodies, probably accounting for the ability to 
confer prophylactic immunity. All animals vaccinated with the L1 fusion protein 
developed transient fibromas on challenge, findings in agreement with previous 
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these studies also developed small fibromas but these decreased in size in the 
vaccinated animals. In Jarrett's study (1991), vaccination of calves with the BPV-2 
12 fusion protein was found to promote tumour rejection in vaccinated animals 
challenged with BPV-2, irrespective of whether the vaccine was administered pre-
or post-challenge. This was accompanied by a massive infiltration of lymphocytes 
into the BPV -2 induced lesions, thus suggesting that the peptide used as a vaccine 
contained epitopes specific for T -cells involved in tumour rejection. Interestingly, 
Zhou, McIndoe, Davies, Sun and Crawford (1991) have shown that the expression 
of HPV -16 L1 in vaccinia virus can illict a priming of cytotoxic T lymphocytes In 
infected mice. 
The use of molecularly cloned viral proteins as a means of immunotherapy 
has also been applied to those encoded by the early ORFs. Meneguzzi, Cerni, 
Kieny and Lathe (1991) immunised rats with vaccina viruses expressing the E6 and 
E7 proteins and were able to demonstrate the retardation or prevention of 
tumours induced by the inoculation of HPV-16-transformed cells. 
1.6. SUMMARY 
Research into vaccination against papillomaviral infections is advancing rapidly 
with the bovine model providing a system where direct experimentation is possible 
and, like the human disease, a multiplicity of viral types and clinical lesions have 
been characterised. Similarly, the equine sarcoid has several clinical manifestations 
and would appear to be non-permissive for viral replication like the cattle 
alimentary BPV lesions and human genital infections. Molecular investigations 
also suggest that different papillomaviral subtypes may be involved in the 
aetiopathogenesis of the disease. With this in mind, even though the use of bovine 
wart vaccines are considered to be of no (Ragland et aL, 1970a) or limited 
(Roberts, 1970) use, the sarcoid should still be considered as a disease suitable for 
either ro h lactic or thera eutic vaccination. 
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in susceptible horses or donkeys. There have been no investigations into the 
transmission of the sarcoid, nor has the serological response in equids when 
challenged by specific papillomaviruses been researched. All of these subjects 
would require invasive, experimental techniques. 
The Donkey Sanctuary is an animal welfare charity and was the grant 
awarding body of this research project. As a consequence, neither direct animal 
experimentation nor invasive techniques were employed in the investigative 
procedures employed during the course of the studies and, as such, challenge and 
transmission experiments are outwith the scope of this thesis. However, it is 
apparent that there is still a lack of knowledge regarding the epidemiology of the 
disease in large populations of horses and donkeys and it is also possible to 
investigate serological status in vitro, without the need to challenge animals, at least 
in the first instance. Furthermore, no aetiological agent has yet been satisfactorily 
isolated and characterised and there has been no attempt to correlate clinical 
lesions to the viral subtypes identified in molecular studies on the tumours. This 
work is central to an increased understanding of the disease and to any 
consideration of vaccination or immunotherapy. 
The aim of the current project was the assessment of the feasibility of 
producing prophylactic or therapeutic vaccines to prevent or control the sarcoid, 
adopting a multidisciplinary approach to the study of epidemiological, serological 
and molecular aspects of the disease in a single large population of donkeys, with 
the ultimate objective being the improvement of animal welfare. 
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AN EPIDEMIOLOGICAL STUDY OF 
THE EQUINE SARCOID IN THE POPULATION OF DONKEYS 
AT THE DONKEY SANCTUARY 
2.1. INTRODUCTION 
Epidemiology may be defined as the study of a disease in a population and of the 
factors which influence its distribution (Lilienfeld, 1976). Numerous 
epidemiological surveys have been undertaken investigating neoplastic disease in 
humans. In a number of these studies, risk factors have been identified, e.g., 
urinary bladder neoplasia and industrial chemicals (Case, Hosker, McDonald and 
Pearson, 1954), but in the majority of cases there has been no direct causal 
relationship or aetiological agent demonstrated. Epidemiological studies of 
neoplastic disease in domestic animals have been few in number. Bendixen (1965) 
and Jarrett, Murphy, O'Neil and Laird (1978) demonstrated the value of large 
scale surveys leading to the postulation of the viral aetiology of enzootic bovine 
leukosis and the carcinogenic effects of the bracken fern, respectively. 
To date, no aetiological agent has been definitively linked to the occurrence 
of neoplasia in any system of the horse or donkey. There are several examples of 
putative agents: the association of bovine papillomavirus with the sarcoid still lacks 
the experimental reproduction of lesions biologically identical to naturally 
occurring sarcoids; no retrovirus has been identified in connection with equine 
lymphosarcoma, in contrast to the disease in felidae (Jarrett, Crawford, Martin and 
Davie, 1964) and bovidae (Miller, Miller and Olson, 1972). Other factors, such as 
smegma (Thackray, 1978) and ultraviolet light (Hargis, 1981) have been reported 
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factors which may predispose animals to cancer. 
2.1.1. Population 
There are many variables involved in the monitoring and survey of disease. The 
first, and arguably most important, is the definition of the study population. Most 
of the published surveys and reviews are based on the referral populations of large 
specialist, research or teaching establishments and provide a sample of a diseased 
popUlation (Priester and Mantel, 1971; Priester, 1973). The use of case-control 
studies, rare in the veterinary literature, may go some way to redressing the bias of 
this referral selection, but many of the common, easily treated neoplasms, 
encountered by clinicians in the field, are still excluded. In addition, without the 
use of census information, the true population size and consequently prevalence 
and incidence of any disease remain crude estimates. Dorn and Priester (1987) 
referred to the Report of the Surgeon General of the US Army (1939-1941) as 
providing the closest estimate of tumour rates in a normal working population. In 
the Fiscal year 1940, the rate of cancerous and benign tumours per 100,000 horses 
was 40 and 389, respectively, and of the population of horses that died or were 
destroyed, 11 and 6 per 100,000 respectively. This provides some indication of the 
predominance in the horse of non-life threatening benign neoplasms, such as the 
sarcoid. 
2.1.2. Age 
The incidence rate of tumours in man increases with increasing age (Ashley, 1990). 
The estimated relative risk of neoplasia in cats, dogs and cattle also increases as 
the animal ages (Priester, 1973). In the ageing horse, there is also an overall 
increase in estimated relative risk. However, closer analysis of the large scale 
survey of North American and Canadian University Veterinary Schools reveals 
that the rate for benign neoplasms of the skin in the horse actually decreases with 
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benign and malignant neoplasms in the dog which both increase with age (Priester, 
1973). The decreasing rate in the horse was attributed to the large number of cases 
of papillomata in the younger animal. 
2.1.3. Sex 
With the exception of tumours derived from the primary or secondary sex organs, 
there are few reports of sex associated neoplasms in any of the domestic species. In 
human oncology, the occurrence of this class of tumour has generally been related 
to occupation, with males traditionally exposed to more environmental, especially 
industrial, carcinogens (Case et aI., 1954). With regard to equidae, the neoplasm 
with the strongest sex association is the squamous cell carcinoma (SCC). Moore 
and Kintner (1976) reported gastric SCC four times more frequently in males than 
in females; Junge, Sundberg and Lancaster (1984) and King, Priehs, Gum and 
Miller (1991) reported SCC male:female ratios of 2:1 and 1.8:1 respectively. 
Secondly, the adenoma of the pars intermedia of the pituitary is cited as being a 
disease of predominantly aged female animals (Barbet, Baxter and McMullan, 
1991; Heinrichs, Baumgartner and Capen, 1990). However, there have been no 
large scale studies and, until proven otherwise, it would appear that, ahead of sex, 
the major risk factor for the Cushingoid syndrome associated with the neoplasm, is 
age. 
2.1.4. Epidemiology of the equine sarcoid 
The sarcoid is a neoplasm with no reported sex or age predisposition (Ragland et 
al. 1970a, Howarth 1990). Although Ragland et al. (1966) described an epizootic of 
the disease in a small group of horses and there have been several reports 
associating sarcoids with family, breed and leucocyte antigens (James, 1968; Lazary 
et aI., 1985; Meredith et aI., 1986; Brostrom et aI., 1988; Angelos et aI., 1988), there 
have been no data published on the epidemiology of the disease in the donkey nor 
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2.2. THE DONKEY SANCTUARY 
The Donkey Sanctuary is a charitable organisation dedicated to the rescue and 
care of unwanted or neglected donkeys. The charity was founded by Elisabeth 
Svendsen in 1967 and has grown to be the fifth largest animal welfare charity and 
59th largest charity of the 170,000 charities in the United Kingdom. The Sanctuary 
comprises of seven farms in Devon and Dorset in the South-west of England and is 
currently caring for over 3,000 donkeys. 
2.2.1. Source of animals 
Donkeys kept at The Sanctuary are derived from three sources: 
(a) Donations: Donkeys are given to The Sanctuary when owners' circumstances 
change and are no longer compatible with donkey ownership. (b) Bequests: an 
animal may be left to The Sanctuary following the death of an owner. (c) Rescue 
cases: The Donkey Sanctuary supports a national inspectorate which deals with 
cases of cruelty and neglect, either reported directly to The Sanctuary or by liaison 
with other animal welfare charities. 
2.2.2. Admission of animals 
On admission to The Donkey Sanctuary donkeys are housed in the Isolation Unit 
situated close to the centre of the main farm but 800 metres from other donkeys at 
Slade House Farm, which houses the main administration block and the veterinary 
hospital. The maximum size of an isolation group is ten animals and the maximum 
time span from the entry of the first donkey to the entry of the tenth donkey is 
three weeks. The donkeys remain in Isolation for a minimum period of six weeks 
during which time they are monitored for signs of disease or stress. Donkey 
stallions are isolated individually and are castrated before release from Isolation. 
The animals are weighed weekly whilst in Isolation and are blood sampled 
weekly in order to monitor haematological and plasma biochemical parameters. 
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2.2.3. Routine Husbandry 
During the isolation period the donkeys are subjected to two physical 
examinations. The first is performed within three days of admission to The 
Sanctuary and is carried out by two veterinary nurses. The donkeys are examined 
for obvious signs of disease and a record taken of the physical characteristics of the 
animal for identification purposes, including age, sex, colour, size and weight, the 
age being estimated by inspection of the animals incisors. The second examination 
is performed by one of the two veterinary surgeons permanently employed by The 
Sanctuary and takes place within 30 days of admission to the Isolation Unit. In 
addition to confirming the findings of the nurses, this detailed clinical examination 
identifies animals with previous or current disease and conformational 
abnormalities. The veterinary surgeon is responsible for the assignment of the 
donkey to a management group on release from Isolation. These groups are 
designed with the requirements of individual donkeys within a herd management 
structure and include: Blind Group: These donkeys are diagnosed as having a 
deficit in visual function and are kept together on level ground with no obstacles; 
Peat Group: Donkeys with clinical or historical evidence of respiratory disease, 
especially chronic obstructive pulmonary disease, are bedded on peat and fed pre-
soaked hay; Geriatric group; Obese group; Thin Group; Mare and Foal Group; 
Sarcoid Group. 
After admission, the animals are cared for by farm managers receIvmg 
veterinary attention only when necessary. The donkeys are weighed monthly and 
approximately 10 per cent of the animals on anyone farm are randomly selected 
for blood sampling in order to monitor haematological and biochemical 
parameters. Any animal developing a sarcoid lesion is removed to the veterinary 
hospital for therapy and is usually re-allocated to the Sarcoid Group. Throughout 
the remainder of the animal's life a computerised record is kept of all diseases, 
veterinary treatments or change of location. Healthy, good natured animals that 
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"Rehabs" but remain under the care of The Sanctuary and are regularly visited by 
Sanctuary inpectors. 
Donkeys form very close social bonds to one or more donkeys (Svendsen, 
1989). These donkey "friends" may be relation or non-relation and, whenever 
possible such animals are kept together, at The Sanctuary, at Rehab or within the 
veterinary hospital. 
2.3. MATERIALS AND METHODS 
2.3.1. Definition of study populations 
The study population was assembled from the computerised health records of all 
the animals admitted to The Donkey Sanctuary between 1967 and July 1990. A 
"Case" was defined as an animal that was observed to have a sarcoid 6 months or 
more after entering The Sanctuary. The exclusion period of 6 months was used in 
order to ensure that the likelihood of the disease having been contracted before 
entering The Sanctuary was kept to minimum, based on the observations of Voss 
(1969). Any animal presenting with a sarcoid at entry, during the Isolation period 
or within the first six months at The Sanctuary was allocated to a Pre-entry case 
group. The remainder of the animals were assigned to the Control group. 
The three groups of animals identified above, i.e., Controls, Case, and Pre-
entries, contained data from animals inelligible for inclusion in the study: 
a) Direct Relinquishments: These animals were transferred directly from one 
foster home to another and had consequently never physically entered The 
Sanctuary. 
b) Rehabs and returns: The animals in this group were currently, or had been, at 
foster homes and had therefore been exposed to factors outside The Sanctuary. 
There were no reliable or accurate animal histories for the period during which 
they were at not at The Sanctuary. 
c) French Donkeys: Donkeys in this group were located in France and had never 
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and were subject to different husbandry. 
These exclusions were applied to all three groups. In additio~ animals in 
the first six months of their stay at The Donkey Sanctuary were excluded from the 
Control population because at that time it was not known whether the animals may 
develop a sarcoid and so be assigned to the Pre-entry population. In this manner 
three populations were identified: 
I Cases 
II Pre-entries 
III Controls 
2.3.2. Manipulation of electronic data and databases 
Having defined the study populations, access to the clinical details of the individual 
animals at The Sanctuary was required in order to marshal the data in a format 
suitable for interrogation. A database is a structured collection of data stored in a 
consistent fashion within records which have a common format. (Gettinby, Thorpe 
and Anderson, 1989) and the database affords several important facilities central 
to the rapid organisation and interrogation of large data sets. Of particular 
importance is the Query command which may be used to access information 
suitable for statistical analysis. For example, [SEX] = 1 and [AGE] =0.000 .. 0.999 
would be entered to identify all males (geldings) under 1 year of age. In order to 
create databases for each of the three populations described above, i.e., Case, Pre-
entry and Control populations, access to the information stored on The Donkey 
Sanctuary mainframe computer was necessary. Unfortunately, the system in place 
at The Donkey Sanctuary had been installed with the administrative tasks of the 
charity given priority and none of the information relevant to animal health and 
welfare was in a format suitable for easy access or interrogation. In addition, the 
existing system was not compatible with IBM machines and was administered by a 
private company of computer consultants, who were responsible for both hardware 
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Sanctuary's business and without recourse to the computer consultants, all animal 
details should be transferred in a suitable format for manipulation on IBM 
compatible computers, which would allow data analysis to take place in Glasgow. 
In order to achieve this, the clinical records at The Donkey Sanctuary were 
transferred to eight 1.4 megabyte diskettes in ASCII format using a customised 
Pack/Unpack archiving programme. Two discrete files were created and exported 
from The Donkey Sanctuary mainframe. The first was a complete record of all the 
clinical histories of the donkeys at The Sanctuary and was used solely to identify 
those animals which had been diagnosed as having a sarcoid. This was performed 
by importing the data on the diskettes into a proprietary wordprocessing package 
(SmartWareII, Informix Software Inc.) where they were managed as individual text 
files. Each record was then screened for specific strings of characters using the 
GOTO command, locating the specified string, regardless of case. The following 
strings were located: [?sarc?], [?tumour?], [?lump?], [?neop?], [?wart?], [?lip?], 
[?oma?], [?fibro?], [?papill?], [?mass?]. The "?" indicated a wild character or 
characters. On completion of the screening, each case containing one or more of 
the strings was committed to hard copy for inspection and confirmation by the 
clinician involved in making the original diagnosis, in the light of any subsequent 
examinations or histological reports. In this manner all the cases were designated 
either "Sarcoid" or "Non-sarcoid". 
The second ASCII file exported from The Donkey Sanctuary mainframe 
was a complete record of all the animals at The Donkey Sanctuary, and this set of 
data contained the animal's name; number; sex; location; date of birth; date of 
entry; date of death, if applicable; age at July 1990; a list of close friends and 
relatives. The information was sent via the Wordprocessor and Spreadsheet 
modules to the Data manager module and a database constructed containing each 
detail listed above as an individual field within the database. Calculated fields 
containing age at entry and length of time at the Sanctuary were added. The close 
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animal fitted the definition of Case, Pre-entry or Control as outlined previously. 
The Case database, in addition to containing the details described above (i.e., the 
animal's name; number; sex; location; date of birth; date of entry to The Sanctuary; 
date of death if applicable; the age at July 1990) also contained the date the 
sarcoid was first observed. From these data fields the age at entry, the age at which 
the animal was first observed to have a lesion and the length of time spent at The 
Sanctuary until diagnosis of a sarcoid, were calculated. Dead Control donkeys were 
classified according to the age at which they died. 
Thus, three databases were created, one each for Control, Case and Pre-
entry population and the databases were then interrogated extracting data under 
the headings: sex; age at entry; age; age at observation of lesion; length of time at 
The Sanctuary (exposure); age at death. The summary data generated by the 
interrogation was then arranged in a fromat suitable for statistical analysis and the 
three populations compared and any differences tested for significance. 
The possibility of disease transmission within the Isolation Unit was 
investigated by comparing the ratios of Cases and Controls that may have occupied 
the Isolation Unit at the same time as another Case animal, a Pre-entry animal or 
both. This investigation of the risk of being in contact with a sarcoid-affected 
donkey was also extended to those in close contact once outside the Isolation Unit 
by comparing the prevalence of animals defined as close friends and relatives with 
sarcoids to that of the general population. 
2.3.3. Software and data analysis 
All manipulation of electronic data was performed using SmartWareII, Informix 
Software Inc.. This package was considered most suitable because it comprised 
integrated modules and allowed for the transmission of data from one module to 
another with comparative ease. Statistical analysis of the data was carried out on 
MINITAB release 7.1 (Minitab Inc.) and the statistical modelling, employing the 
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Ltd and the Royal Statistical Society). All statistical tests were carried using the 
5 % significance level. 
2.3.4. Disease Model. 
In order to investigate the significance of the different variables outlined by the 
summary analyses, it was necessary to employ linear regression analysis. The use of 
a General Linear Model allows the combination of a number of factors in order to 
create a disease model and it is then possible to assess the risk of disease to an 
individual donkey given the specific animal details required by the model as well as 
assessing the effect of the individual risk factors on the likelihood of disease. The 
variables used in the present study were sex, age at entry and exposure, all of which 
are independent. The age at lesion data were not used in the modelling process as 
this variable may be affected by age at entry and may affect age at lesion i.e., old 
animals entering The Sanctuary will be older animals when they get the disease; 
older animals may have been exposed for longer. 
The GLIM package is a tool for fitting generalised linear models to data, in 
which the modelling process is where the data are matched by a set of theoretical 
values. These theoretical values are derived from a small number of basic 
quantities, or parameters, and are close to the original data. The process requires 
two decisions: first, the choice of the relationship between the theoretical values 
and the underlying parameters; second, the choice of a measure of discrepancy 
which defines how close the theoretical values are to the data. The first of these 
choices relates to the systematic component of the model and has a linear 
predictor, which is a combination of explanatory variables with a set of parameters, 
wherein the predictor is related to the theoretical value by the link function. The 
second choice relates to the random component and allows the data to have a 
specified distribution. In the current project, two types of data were explored, one 
t~ of ni~p.~~p.n ~nim~ 1 .. in whirh thp. .. p1prtpn ni .. trihlltion w~ .. Poi .... ()n 
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defined the models, the GLIM package then fitted the model choosing estimates of 
the parameters with values which minimised the deviance or discrepancy. 
Thus, data concerning three risk variables, viz., sex, age at entry and 
exposure, were entered into a GLIM software program in order to constuct two 
disease models. First, in a log linear regression, the absolute numbers of animals in 
the Case population were entered and the effect of the interaction of the three 
variables deducted. This provided a basic maximal model, which was assessed for 
goodness of fit to the data by the scaled deviance and degrees of freedom on the 
assumption that the scaled deviance was distributed approximately as X 2. If the 
scaled deviance had a value insignificant at given degrees of freedom then the 
maximal model was considered to fit the observed data. Each two-way interaction 
was removed from the model and the significance of the effect of each two-way 
interaction assessed by the ratio of the change in the scaled deviance to the change 
in the degrees of freedom, again by use of X2 distribution. The model which fitted 
the data with the inclusion of fewest terms was considered the minimal modeL This 
process was then repeated entering the proportion of the population affected for 
any given variable in a logit modeL 
The GLIM software was then used to generate a table of the estimated risks 
of sarcoid in specified groups of donkeys, based upon the fact that for small values 
of p (i.e. small risks) the odds ratio (OR) is a close approximation to the ratio of 
the actual risks (relative risk, RR) and so it is possible to use the calculated actual 
risks to assess which animals are most at risk from the disease. Given that the odds 
of an animal having the disease is equal to the ratio of the chance of having the 
disease (p) to the chance of not having the disease (l-p), the log-odds for the 
outcome is lag(p / I-p). The parameter estimates then represent the average 
changes on this scale expected for unit changes in the model variables. For two 
different animals, differing in sex only, the difference in the log odds is due to the 
difference on the logistic scale of being either male (m) or female if) l.e., 
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become: 
therefore, 
therefore, 
log(Pm/ (1-Pm» = a and log (Pf/ (I-Pj» = a + b, 
loge (Pm/ (I-Pm»( (I-p )JPj» = b 
eb = (Pm/ (I-Pm»( (I-Pj) /Pj) = OR 
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As the OR approximates to the RR, using the table of actual risks estimated from 
the model, the estimated relative risks may be calculated. 
2.3.5. Anatomical distribution of lesions 
Each Case donkey was classified according to the anatomical site of the main 
sarcoid lesion. The ratios of the distributions of anatomical sites of the lesions on 
male and female donkeys were examined and tested for statistical significance 
2.3.6. Mortality rates 
The dead/live ratios of Case and Control animals were compared and tested for 
statistically significant difference. 
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2.4. RESULTS 
2.4.1. Populations 
The records were exported from the Donkey Sanctuary hard disk on 17 July 1990. 
At this time 4,126 animals were listed on the Sanctuary records. Of these, 2,647 
(64.2%) were allocated to the Control group, 80 (1.9%) to the Case group, 43 
(1.0%) to the Pre-entry group and 1,356 (32.9%) were excluded from the study. 
The exclusions included animals other than donkeys and all donkeys that were not 
currently in, or had ever been temporarily removed from, The Sanctuary. The 
relationship between the three populations, the exclusions and the total number of 
animals on record at The Sanctuary is illustrated in Figure 6. The data from the 
three databases are presented in full in Appendices I, II and III. The ages of dead 
donkeys are dispalyed in Appendix IV. The prevalence of the sarcoid in all animals 
at The Sanctuary was 4.4 per 100 animals and 2.9/100 when those presenting with 
the disease at entry were excluded. 
Population on computer 4126 
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2.4.2. Population growth and incidence of sarcoids 
The annual incidence of sarcoids developing at The Donkey Sanctuary is shown in 
Figure 7. It was not possible to obtain historical data on the number of animals at 
Rehab or at other locations and complete figures for 1990 were not available. The 
incidence of sarcoid at The Sanctuary peaked at approximately one case per 
hundred animals per year in 1985 and 1986. The incidence was a crude estimate 
due to the fact that the calculation of the animals at risk in any given year was 
based on the cumulative total of animals entering the Sanctuary minus the 
cumulative total of dead animals. The population growth is tabulated in Table 2. 
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2.4.3. Sex 
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All donkeys in the Control, Case and Pre-entry populations were either female or 
castrated males. The numbers of animals of each sex in each population are shown 
in Table 3. The Case population was compared to the Control population and 
there was a significant difference in the ratio of the sexes (X2 = 6.5, df = 1, P < 0.05), 
There was no significant difference in the ratio of the sexes between the Case and 
Pre-entry populations. 
2.4.4. Age at which donkeys entered The Donkey Sanctuary 
The summary data and results of the analyses are presented in Tables 4, 5, 6, 7, 
and 8. It was observed that 8.5% of the 2,647 Controls were aged less than 3 years 
at entry, 12.8% were aged 3 to 6 years, 11.2% were aged 7 to 9 years, 12.5% 10 to 
12 years and 54.9% were aged 12 years or more at entry. This compared with 
43.8%, 17.5%, 12.5%, 7.5% and 18.75% in the Case group and 9.3%, 34.9%, 
16.3%, 7.0% and 32.6% in the Pre-entry animals. Of all animals less than 3 years of 
age at entry, 85.2% were Controls, 13.3% were Cases and 1.5% were Pre-entries. 
In the 3 to 5 year-old group the figures were 92.1%, 3.8% and 4.1 % respectively; 
for the 6 to 8 year-olds, 94.6%, 3.2% and 2.2% respectively; for the 9 to 11 year-
olds 97.4%, 1.8% and 0.9% respectively and for the 12 year olds and over, 98.0%, 
1.0% and 0.9% respectively. Statistical analysis confirmed that the animals in the 
Case population were significantly younger at entry than either the Pre-entry (X2 = 
16.6, df=4, p<O.Ol) or Control donkeys (X2 =123.7, df=4, p<O.OOl) and that the 
Pre-entry donkeys were significantly younger at entry than the Control animals 
(X2 = 21.5, df=4, p<O.OOl). 
2.4.5. Age at which sarcoid tumours were first observed 
The Pre-entry population was not included in this study as the age at which the 
disease was first contracted in these animals was not known. The results of the 
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the highest proportion of clinically affected animals was is in the 2 to 5 year aIds, 
where the disease prevalence was between 15.6 and 25.0 per hundred animals. The 
prevalence peaked in 5 year-aIds and was lowest in the 14 year-olds. The age 
distributions in the two populations were again highly significantly different 
(X2 =249.0, df=5, p<O.OOl) with the Case population being weighted with younger 
animals. 
No. of Donkeys Percent with sarcoids 
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2.4.6. Time taken from entry to observation of lesion, i.e.,exposure. 
The single largest group of animals with sarcoids was that containing those 
presenting at The Sanctuary with the disease, i.e., the Pre-entry population 
Sanctuary, and so the sarcoids could not possibly be related to risk factors 
associated with living in The Sanctuary. As a consequence they were excluded from 
further consideration. With regard to the donkeys in the Case population, animal 
the length of time between entry and a Case animal being observed with a sarcoid 
was very variable (Figure 9), ranging from less than a year to in excess of 15 years 
(Table 11). There was a significant difference (X2 =52.9, df=7, p<O.OI) between 
the Exposure distributions of the Case and Control populations (Table 12) with the 
Case population being better represented in the donkeys with a shorter exposure 
time. The highest disease prevalence (5.9 per hundred) was in the animals that 
had been at The Sanctuary for between 2 and 3 years (Table 11) Historically, the 
overall trend was for the Exposure time to become shorter in more recent years 
(Figure 9). The crude incidence rate for the disease in the population was 0.6 cases 
per hundred animals per year (619/100,000 animal-years). 
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2.4.7. Cluster analysis: The Isolation period as a source of infection or 
dissemination of the disease. 
The data and statistical analyses concerning the cluster analysis are presented in 
Table 13 and depicted graphically in Figure 10. No significant association was 
demonstrated between the period spent in isolation and the likelihood of 
developing a sarcoid. One of the 80 Cases and 13 of the 2647 Controls were born 
at The Sanctuary and never entered the Isolation Unit. Any animal entering the 
Isolation Unit within three weeks of another may have been allocated to the same 
Isolation group In the remaining Control population (2634), 977 (37%) donkeys 
were shown to have been in the Isolation Unit within three weeks of a Pre-entry 
donkey and 1357 (52%) within three weeks of a donkey that subsequently 
developed sarcoids (Le. a Case). In addition, 1654 (63%) of the donkeys were in 
Isolation within three weeks of either a Pre-entry or a Case. These figures compare 
with 22 (28%), 43 (54%) and 51 (65%) in the remaining 79 Case donkeys. X2 
analysis of these data sets showed no significant difference between the Case and 
Control populations. A contiguous association of Cases with Pre-entries, wherein a 
Case could be linked to a Pre-entry animal by way of another Case donkey, was 
demonstrable in only 25 (32%) of the 79 Cases. 
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Figure 10. Temporal clustering in the Isolation Unit of Potential Cases (animals that go on to 
develop sarcoids whilst at The Sanctuary) and Pre-entry animals (those with sar~oids. at e~try to the 
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2.4.8. Close in-contacts and relatives 
A close in-contact was defined as being a donkey listed in the animal records and 
having an affinity for a donkey in the Case population. Of the 80 cases, 18 animals 
were identified as having no close relationship with another animal or animals. 
The remaining 62 donkeys were listed as having between one and four close 
relationships and these were defined as either "relation" where there was a known 
familial relationship, or as "non-relation" otherwise. Forty-two donkeys had one 
relationship, 11 with relations and 31 with non-relations; 14 animals had two 
relationships, three with relations and 25 with non-relations; four donkeys had 
three relationships, three with relations and nine with non-relations; two donkeys 
had four relationships, two with relations and six with non-relations. In total, there 
were 78 animals associated closely with sarcoid-affected donkeys, 19 of which were 
relations and 59 non-relations. In only six of the 78 relationships was the listed 
animal also sarcoid-affected. Two of the six were relations and four were non-
relations of the animals in the Case population. In summary, four of the 59 Case-
non-relation relationships were between two Case animals and two of the 19 Case-
relation relationships were between two Case animals. This is illustrated in Figure 
11. 
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Unfortunately, it was not feasible to obtain the relationship data for the Control 
population from the database constucted and so in order to assess the significance 
of contact with a sarcoid-affected animal, a X2 analysis was performed, comparing 
the prevalence of the disease in the in-contact population with the prevalence in 
the population as a whole, i.e., 6/78 versus 80/2727. The result of this analysis 
showed that the in-contact animals were significantly more likely to have sarcoids 
than an animal in the general population (X2 =5.8, df= 1, P < 0.05). 
The comparison of the prevalence of the disease in the relation and non-
relation animals, i.e., 2/19 versus 4/59, was performed using Fishers Exact Test 
because of the small group sizes and it was shown that the probability (P) of the 
disparity in the disease rates having arisen by chance was P = 0.63 ("Two-tailed" 
test). Thus, there was no significant difference between the two very small groups. 
2.4.9. The Disease Model 
The descriptive statistics described above outlined three selected explanatory 
variables associated with the likelihood of an animal developing sarcoids. In order 
to construct a disease model based on the sex, age at entry and the time spent at 
the Sanctuary before the animals were observed to have a sarcoid (exposure), the 
data from the Case population were arranged into two tables, one for males, one 
for females, classifying each animal by age at entry and exposure time (Table 14 
and 16). However, due to the sparsity of the data, Tables 14 and 16 were collapsed, 
condensing the data into Tables 15 and 17. Two disease models were then 
constructed and tested using the GLIM software, one based upon the numbers of 
Case animals, the other upon the proportions of affected donkeys in the 
population. 
In the first of these, the distribution was Poisson, due to the sparsity of the 
data, and the link function log linear. The maximal model, consisting of the main 
effects and the two-factor interactions, had a scaled deviance of 8.941 with 6 
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removal of the [sex x age at entry] interaction and the [age at entry x exposure] 
interaction produced a model with no significant difference to either the maximal 
model or the full modeL The linear predictor of the mimimal model describing the 
disease at the Sanctuary was selected to be: 
1 + sex + age at entry + exposure + [sex x exposure] 
(Scaled deviance = 13.19, df= 15) 
The differences between the scaled deviances degrees of freedom of this model 
and the maximal model were 4.251 and 9, respectively, showing no significant 
difference from the maximal model or the full model. 
When proportions of animals affected in each category were entered, in the 
creation of a model wherein there was a Binomial distribution and the link 
function was logit, the full model had a scaled deviance of 8.189 with 6 degrees of 
freedom. The removal of the [sex x exposure] interaction indicated that, again, this 
was the most significant two-way interaction and that neither the [sex x entry] nor 
[entry x exposure] interactions significantly affected the model. The linear 
predictor for this model was selected to be: 
1 + sex+ age at entry + exposure + [sex x exposure] 
(Scaled deviance = 16.732, df = 15) 
Using the general linear model, the risks were estimated and are displayed 
in full in Table 18. For example, the ratio of the estimated actual risks of males 
and females within the the first three years of life at entry and within the first three 
years of exposure was 0.238/0.121 = 1.967, i.e., being male increased the risk of 
sarcoids by a factor of approximately 2.0 or being female halved the risk of having 
sarcoids. In order to put confidence limits on the estimate of the odds ratios, the 
exponential of the appropriate parameter was taken plus and minus two standard 
errors (SEs). Thus, for males and females in the present model the estimated 
difference due to being male, in all groups, was 0.8182. Generating the 
exponentials plus and minus two SEs roduced a lower limit of 0.2204 and an 
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By taking the reciprocals of these figures, the results were easier to interpret in 
clinical terms and indicated that being male increases the odds of having sarcoids 
by a factor of at least 1.132 and possibly by a factor as big as 4.537. 
2.4.10. Anatomical distribution of sarcoid tumours 
The numbers of male and female Case donkeys and the anatomical site of the 
primary lesion are summarised in Table 19. Of the 80 Cases, 32.5% had lesions 
located in the paragenital region, 22.5% had lesion on the head (other than 
periocular) and 15.0% had periocular lesions. There was a significant difference 
between numbers of male and female with lesions in the paragenital region 
(X2 =9.6, df=l, p<O.Ol) and between male and females with lesions on the ventral 
abdomen (X2 = 5.8, df = 1, P < 0.02). The single largest group of affected animals was 
males with paragenital sarcoids (22/80) although when the animals with head and 
periocular lesions were combined, they accounted for 19 of the 80 animals. Seven 
of the 80 Cases had lesions at an anatomical site other than the primary site, i.e., 
had multiple lesions. 
2.4.11. Mortality rate 
Comparison of the dead/live ratios of the Case and Control populations 
demonstrated a significant difference (X2 =4.7, df = 1, P < 0.05) with the Case 
population having higher ratio (10:70) than the Control population (602:2045). 
The results are presented in Table 20. 
2.5. DISCUSSION 
The present study is concerned with animals that develop sarcoids at The Donkey 
Sanctuary. Eighty such cases were reported, a crude incidence rate of 0.6 cases per 
hundred animals (619/100,000), a figure significantly higher than the 389/100,000 
for all beni n tumours in a 0 ulation of arm horses re orted b the Sur eon 
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in donkeys kept in the rest of the country but if Dorn and Priesters' figure is an 
approximate estimate for the general equine population in the United Kingdom, 
the disease is a cause for concern at The Donkey Sanctuary. 
This finding was borne out by the observations of the clinicians at The 
Sanctuary, who prompted the present study in 1987. Interestingly, the highest 
incidence of the disease at The Sanctuary was in 1985 and 1986 and it was 
presumably this increase in case-load, noticed by the clinicians that led to the 
commission. Although the incidence has decreased since 1986, the economic 
impact of the disease is considerable, each case requiring perhaps two or three 
operations to effect a cure which is both expensive and time consuming. However 
it is the implication to individual animal welfare which justifies the further 
investigation of the epidemiology of the disease at The Sanctuary. 
Despite the fact that there has been no reported sex predisposition, the 
present study has demonstrated that sarcoids were more likely to affect males than 
females at The Sanctuary. However, this bias towards males was also noted in 
those animals presenting with the disease at entry to The Sanctuary and so this 
may be a feature of donkeys in the population at large in the United Kingdom. 
Certainly, there is insufficient evidence to suggest that the sex predisposition is a 
result of management or exposure variables peculiar to The Donkey Sanctuary. 
More general factors, which may explain the prevalence in male donkeys, will be 
discussed later in this chapter and in Chapter VIII. 
The Control, Case and Pre-entry populations differed significantly in their 
age at entry. Most animals that developed sarcoids at The Sanctuary entered as 
young animals; those presenting at The Sanctuary with sarcoids were generally 
older than Case animals; the majority of Control animals were over 12 years or 
more. In addition, the age-specific disease prevalence suggests that the sarcoid is a 
disease of the younger animal and this finding may explain why the donkeys 
comprising the Pre-entry population were generally older at entry than those that 
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(Pre-entries), have recovered from the disease or be resistant to the disease 
(Controls); younger, susceptible animals will develop the disease (Cases). 
Given the putative viral aetiology of sarcoids and that an epizootic of 
sarcoids has been reported (Ragland et aL 1966), it might be expected that the 
animals most closely associated with sarcoid-affected donkeys would be at an 
increased risk of developing the disease. The possibility that the Isolation Unit may 
have been a source of infection, or responsible for the spread of the disease, can be 
refuted on the grounds that the animals that occupied Isolation at the same time as 
those 
i) donkeys with the disease (Pre-entries), 
ii) donkeys subsequently developing the disease (Cases), 
iii) both (i) and (ii), 
were no more likely to develop sarcoids than animals that had not come into 
contact with these groups. Furthermore, there was a contiguous link between Cases 
and Pre-entries demonstrable either directly (within 21 days of a Pre-entry), or 
indirectly (through a Case), in only 32% of cases. It may be concluded that the 
animals that develop sarcoids at the Sanctuary are unlikely to be acquiring the 
disease solely due to being associated either with donkeys with sarcoids at entry, or 
with other animals that develop the disease subsequently, and may therefore have 
been carriers. 
However, other factors encountered at the time of Isolation may playa part 
in the disease process as evidenced by the significant association between 
exposure, i.e., time at The Sanctuary, and the development of disease. This may be 
attributable to some event or environmental factor encountered whilst in Isolation, 
but although this is a possibility, peak prevalence occurred in animals that had 
been at The Sanctuary for between 2 and 3 years which is longer than would be 
expected for the development of most papillomavirus induced tumours (Voss, 
1969) Furthermore, there is considerable range of exposure values, with animals 
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observer related effect and the heavy coat of the donkey and herd management at 
The Sanctuary may mean that tumours are not being detected until an appreciable 
size. However, it does seem that the variable time to the development of the 
disease and the results of the cluster analysis point towards the fact that Isolation is 
unlikely to be responsible for the propagation of the disease at The Sanctuary. It 
also calls into question the transmissibilty of the sarcoid in animals kept together in 
confined accommodation, as suggested by Ragland et aI. (1966). 
Once the animals have left Isolation, the group of donkeys likely to be most 
at risk, assuming a transmissible agent, are those in contact with affected donkeys 
on a daily basis. The Sanctuary has identified these so called "donkey-friends", 
which may be blood relation or non-relation, and the animals are intimately 
associated together. If the disease is passed from one animal to another, a high 
prevalence of the disease in the donkey-friends may be expected. Considered as a 
whole, these close in-contacts were significantly more likely to have sarcoids than 
animals in the general population and this may indicate that a transmissible agent 
is involved in the aetiology of the disease, as suggested by Ragland et aI. (1966). 
However, the comparison of disease rates in relations and non-relations indicated 
that the relations were no more likely than the non-relations to have sarcoids and 
this result is particularly surprising in the light of previous work associating 
sarcoids with breed and specific leucocyte antigens, i.e., genotype (James, 1968; 
Lazary et aI., 1985; Meredith et aI., 1986; Brostrom et aI., 1988; Angelos et aI., 
1988), which would suggest that the relations would show increased susceptibility 
to the disease when compared to non-relation in-contacts. The analysis is based on 
a very small data set and although statistical manipulations may be performed to 
show significance, it would be inappropriate and foolish to attempt to draw any 
conclusions from these data. In view of the size of the groups, it would be necessary 
to examine the nature of the familial relationship, e.g., mother-daughter, full-
commentin!! further. This is a lo!!ical develooment of 
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As can be seen, interpretation of the effects of any single variable 
mentioned above is difficult and it is likely that no single factor will be associated 
with the disease to the exclusion of all the others. In order to assess the effect of 
each main variable and the interactions between the variables to the risk of 
developing sarcoids, a log linear model was employed. The interactions between 
the variables differ in their significance to the model and the most effective disease 
model is one in which factors playing no significant role are removed. In the 
present study, the main variables were judged to be sex, age at entry and exposure 
and it was these variables that were used in the generalised linear models. The 
removal of the [sex x entry] and [entry x exposure] interactions did not significantly 
alter the reliability of the model as indicated by the ratio of the differences of the 
scaled deviance and degrees of freedom, whilst removal of the [sex x exposure] 
produced a poorer model. However, although the model constructed from the 
absolute number of cases was a description of the diseased animals' relationship to 
each other, it did not take into account the Control population. As it transpired, 
the model arising from the analysis of the proportions of affected animals 
compared to the healthy controls was identical to the first model (i.e., only the [sex 
x exposure] interaction was of significance) and although both models can be used 
as a means of predicting disease occurrence, the second model is better suited to 
predicting risks relative to the healthy population, and as such, may be employed 
as a management tool. This is achieved by the use of the odds ratios and relative 
risks. 
By applying the model, it is evident that males are at best 1.1 times more at 
risk from sarcoids and at worst 4.5 times more at risk than females. Consultation of 
the estimated actual risks indicates that in males the disease has the highest rate 
amongst the 0-3 year olds and followed by the 3-6 year olds in the first three years 
at The Sanctuary. The disease model used in this manner is directly applicable as a 
management tool for the clinicians at The Donkey Sanctuary who must identify 
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each donkey, and judging by the animals which presented for surgical therapy, in 
many instances the sarcoids are well developed before diagnosis. By consulting the 
table of risks generated above, the group management of the donkeys can now be 
adapted to include more regular and more detailed clinical examinations of the 
animals in the high risk groups, thus increasing the likelihood of earlier diagnosis 
and treatment. This will have several advantages: Not only will it decrease the 
scale of trauma of the invasive procedures used to treat sarcoids and thus benefit 
the donkey, but it will also provide material for investigation from an earlier stage 
in the disease process. 
This chapter has shown that sarcoids at The Donkey Sanctuary are most 
likely to affect younger, male animals in their first 3 years at The Sanctuary. It has 
also been shown that, in male animals, the lesions are most frequently observed in 
the paragenital region. The Isolation Unit does not appear to playa significant role 
in the spread of the disease but there is an indication that close in-contact animals, 
by virtue of the fact that they are associated with the Case population are more 
likely to have sarcoids, than by chance alone. This may indicate that the disease is 
caused, at least in part by a transmissible agent, or that the animals encounter 
some event that may pre-dispose them to the disease. 
The association of the sarcoid with an area of previous insult to the skin is 
well documented (Voss, 1969; Ragland et aL, 1970a; McMullan, 1982). All of the 
male animals that enter The Donkey Sanctuary are castrated to prevent them from 
breeding and to reduce testosterone related behaviour. This is common practice 
outside The Donkey Sanctuary and the older animals presenting at The Sanctuary 
are more likely to have been castrated by a previous owner (J.N. Fowler, personal 
communication). The sarcoids occurring in the paragenital region do not occur 
exclusively on the site of the scrotal incision and it is unlikely that surgery per se is 
responsible for the introduction of an aetiological agent. However, the trauma of 
surgical preparation may predipose the site to the post-operative entry of an 
61 
CHAPTER II 62 
reaction (see Chapter VII) demonstrated the presence of papillomaviral DNA on 
some obstetrical instruments used in the management of patients with human 
papillomavirus infections, even after the instruments had been sterilised in Savlon 
or ethanol, thus suggesting that potential pathogens my be transferred from animal 
to animal at surgery (Ferenczy, Bergeron and Richart, 1989). It is also the case that 
donkeys and their close friends are castrated at the same time increasing the 
likelihood of an agent being transferred from a diseased animal to an healthy 
animal kept in close contact, post-castration. 
This theory does not explain why sarcoids affect female donkeys or other 
parts of the body (perhaps with the exception of the eye which also attracts flies) 
but it is supported by the age distribution of affected animals as well as the sex, 
exposure and age at entry variables of the disease model, assuming that the lesions 
are not noticed until well progressed. 
The difference in the mortality rates of Control and Case populations is, 
perhaps, the most difficult to explain. Animals that have received any type of 
veterinary attention in the past receive close follow-up inspections by lay and 
veterinary staff. With specific reference to sarcoids, animals that are diagnosed as 
having the disease and receive therapy are kept in a group together, allowing close 
monitoring of tumour recurrence. This group of donkeys is located nearer the 
centre of The Sanctuary and is much smaller in size than most of the other groups. 
The change in husbandry may lead to closer attention being paid to the general 
well-being of these animals, with the result that other life-threatening conditions 
may be diagnosed and treated earlier than if the donkeys were in a group of 200 
animals, thus decreasing mortality rates. 
The original reasons for grouping the sarcoid-affected animals together 
were to facilitate post-operative inspection and follow-up examinations as well as 
an attempt to limit the spread of the disease, assuming a transmissible agent. 
However, the herd management system employed by The Sanctuary inevitably 
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viral, pathogen then the serological status of the animals may provide further 
epidemiological information with regard to the equine sarcoid and was the basis 
for the investigations described in the following chapter. 
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Table 2. Estimated number of donkeys at The Donkey Sanctuary. on 31 December each year, 
illustrating the rapid growth in the donkey population .. 
Year 
1968 
1969 
1970 
1971 
1972 
1973 
1974 
1975 
1976 
1977 
1978 
1979 
1980 
1981 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
No. of donkeys 
1 
2 
3 
3 
4 
42 
138 
197 
243 
283 
348 
413 
523 
669 
780 
915 
1056 
1260 
1449 
1615 
1832 
2116 
Table 3. Distribution of the sexes in Control, Case and Pre-entry populations. All male animals 
were castrated. 
No. of donkeys 
Population Male Female Totals 
Controls 1175 1742 2647 
Cases 47 33 80 
Pre-entries 30 13 43 
Totals 1252 1518 2770 
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Table 4. Summary classification of the Control, Case and Pre-entry populations by age at entry to 
The Donkey Sanctuary. 
Age at Entry No.of Donkeys 
(Years) Controls Cases Pre-entries Totals 
0.5 to < 1 97 8 0 105 
1 to <2 69 14 0 83 
2to <3 58 13 4 75 
3 to <4 78 5 5 88 
4 to <5 129 6 8 143 
5 to <6 133 3 2 138 
6 to<7 101 5 6 112 
7 to <8 99 2 1 102 
8 to <9 97 3 0 100 
9 to < 10 95 3 0 98 
10 to < 11 158 2 1 161 
11 to < 12 79 1 2 82 
12 to < 13 131 2 2 135 
13 to < 14 76 0 1 77 
14 to < 15 99 2 0 101 
15+ 1148 11 11 1170 
Total 2647 80 43 2770 
Table 5. Summary classification of the Control, Case and Pre-entry populations by age at entry to 
The Donkey Sanctuary. The age groupings were structured to allow statistical analysis. 
Population 
Controls 
Cases 
Age Group (years) 
0.5 to < 3 3 to < 6 6 to < 9 9 to < 12 
224 
35 
340 
14 
297 
10 
332 
6 
12 + 
1454 
15 
Total 
2647 
80 
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Table 6. Percentage composition of the Control, Case and Pre-entry populations by age group at 
entry. Each figure is the percentage contribution of donkeys of a given age at entry to the total 
number of animals in the specified population. 
Population Age Group (years) 
0.5 to<3 3 to <6 6 to <9 9 to < 12 12 + 
Controls 8.5 12.8 11.2 12.5 54.9 
Cases 43.8 17.5 12.5 7.5 18.8 
Pre-entries 9.3 34.8 16.3 7.0 32.6 
Table 7. Percentage composition of age groups at entry by population. Each figure is the 
percentage contribution of the animals in the specified population to the total number of animals in 
that age group. 
Population Age Group (years) 
0.5 to<3 3 to <6 6 to <9 9 to < 12 12 + 
Controls 85.2 92.1 94.6 97.4 98.0 
Cases 13.3 3.8 3.2 1.8 1.0 
Pre-entries 1.5 4.1 2.2 0.9 0.9 
Table 8. Results of the statistical analyses of the relationships between the age at entry distributions 
of the Control, Case and Pre-entry populations. 
Population 
Case/ Control 
Pre-entry/Control 
Case /Pre-entry 
123.7 
21.5 
16.6 
df 
4 
4 
4 
Significance 
p<O.OOl 
p<O.OOl 
p<O.Ol 
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Table 9. Age-specific disease prevalence of the sarcoid in donkeys at The Donkey Sanctuary. The 
donkeys in the Case population were classified according to the age at which a sarcoid was first 
observed .. 
Age Group No.of Donkeys Prevalence 
(Years) Controls Cases Totals (per 100) 
0.5 to < 1 0 0 0 
1 to <2 17 1 18 5.6 
2 to <3 27 5 32 15.6 
3 to <4 28 8 36 22.2 
4 to <5 24 8 32 25.0 
5 to <6 48 15 63 23.8 
6 to<7 55 1 56 1.8 
7 to <8 52 6 58 10.3 
8 to <9 55 4 59 6.8 
9 to < 10 50 5 55 9.1 
10 to < 11 71 1 72 1.4 
11 to < 12 89 4 93 4.3 
12 to < 13 80 3 83 3.6 
13 to < 14 101 1 102 1.0 
14 to < 15 110 0 110 0.0 
15+ 1840 18 1858 1.0 
Total 2647 80 2727 
Table 10. Summary classification of the age-specific disease prevalence of the sarcoid in donkeys at 
The Donkey Sanctuary. The age groupings were structured to allow statistical analysis. 
Age Group 0.5 to <3 3 to <6 6 to <9 9 to <12 12 to <15 15+ Totals 
Controls 44 100 162 210 291 1840 2647 
Cases 6 31 11 10 4 18 80 
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Table 11. Exposure specific disease prevalence of the sarcoid in the donkeys at The Donkey 
Sanctuary. The animals were classified according to the number of years spent at The Sanctuary. The 
Case animals were classified according to the number of years spent at The Sanctuary up until the 
observation of a sarcoid. 
Exposure N o.of Donkeys Prevalence 
(Years) Controls Cases Totals (eer 100) 
0.5 to < 1 436 12 448 2.7 
1 to <2 393 15 408 3.6 
2 to <3 272 17 289 5.9 
3 to <4 264 9 273 3.3 
4 to <5 264 11 275 4.0 
5 to <6 174 5 179 2.8 
6 to<7 173 1 174 0.6 
7 to <8 132 3 135 2.2 
8 to <9 139 4 143 2.8 
9 to < 10 117 1 118 0.8 
10 to < 11 50 2 52 3.8 
11 to < 12 56 0 56 0.0 
12 to < 13 37 0 37 0.0 
13 to < 14 44 0 44 0.0 
14 to < 15 38 0 38 0.0 
15+ 58 0 58 0.0 
Total 2647 80 2727 
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Table 12. Exposure specific disease prevalence of the sarcoid in the donkeys at The Donkey 
Sanctuary. The animals were classified according to the number of years spent at The Sanctuary. The 
Case animals were classified according to the number of years spent at The Sanctuary up until the 
observation of a sarcoid. The age groupings were structured to allow statistical analysis. 
Exposure 0.5 to <1 1 to <2 2 to <3 3 to <4 4 to <5 5 to <10 10 + Totals 
Controls 436 393 272 264 264 735 283 2647 
Cases 12 15 17 9 11 14 2 80 
Totals 448 408 289 273 275 749 285 2727 
X2=52.9 (df=7, p< 0.01) 
Table 13. The numbers and statistical significance of donkeys in the Control and populations 
housed in the Isolation Unit within three weeks of a Pre-entry donkey, a Case donkey and either a 
Pre-entry or a Case Donkey. 
Population Link Controls Cases Analysis 
Yes 977 22 X2=2.8 
With Pre-entries df=l 
No 1657 57 p>0.05 
Yes 1357 43 X2=0.3 
With Cases df=l 
No 1277 36 p>0.05 
Yes 1654 51 X2=0.1 
With Cases or Pre-entries df=l 
No 980 28 p>0.05 
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Table 14. Distribution of male donkeys developing a sarcoid at The Donkey Sanctuary (i.e., male 
Cases). The animals are classified by the year of life during which they entered The Sanctuary and the 
year after entry during which the lesion was fIrst observed. 
Age 
at Exposure (Years) 
Entry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 15+ 
1 1 0 1 0 100 000 0 0 0 000 
2 242 1 4 1 000 0 0 0 0 000 
323 1 0 000 000 0 0 000 0 
4 003 1 000 000 0 0 0 000 
5 1 100 000 000 0 0 000 0 
600 1 0 000 100 0 0 0 000 
710 100 1 000 0 0 0 0 000 
8 0 100 100 0 0 0 0 0 0 000 
900 0 1 000 000 0 0 0 000 
10 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
11 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
15 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
15 + 2 1 1 0 1 1 0 0 0 0 1 0 0 0 0 0 
Table 15. Distribution of male donkeys developing a sarcoid at The Donkey Sanctuary (i.e., male 
Cases). The animals are classified according to the year of life during which they entered The 
Sanctuary and the year after entry during which the lesion was fIrst ob served. The fIgures in brackets 
are the numbers of Control male donkeys in the same category. 
Age at 
Entry 
(Years) 
0.5 to <3 
Exposure (Years) 
0.5 to <3 3 to <6 6 and over 
16(44) 7(25) 0(40) 
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Table 16. Distribution of female donkeys developing a sarcoid at The Donkey Sanctuary (i.e., 
female Cases). The animals are classified by the year of life during which they entered The Sanctuary 
and the year after entry during which the lesion was fIrst observed. 
Age 
at 
Entry 1 2 3 4 5 6 
Exposure (Years) 
7 8 9 10 11 12 13 14 15 15+ 
1 000 1 0 1 0 1 2 0 0 0 0 000 
2 000 0 000 000 0 0 0 000 
3 022 1 0 1 1 000 000 000 
4 0 100 0 0 0 000 0 0 0 000 
5 200 1 0 1 0 0 0 0 0 0 0 000 
6 000 1 0 0 0 0 0 0 0 0 0 000 
700 1 1 0 0 000 0 0 0 0 000 
8 000 0 0 0 000 0 0 0 0 000 
9 100 0 0 0 0 001 000 000 
10 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
11 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
12 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
13 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
15 + 0 1 0 0 2 0 0 1 0 0 0 0 0 0 0 0 
Table 17. Distribution of female donkeys deVeloping a sarcoid at The Donkey Sanctuary (i.e., 
female Cases). The animals are classified according to the year of life during which they entered The 
Sanctuary and the year after entry during which the lesion was fIrst observed. The fIgures in brackets 
are the numbers of Control female donkeys in the same category. 
Age at 
Entry 
(Years) 
0.5 to <3 
3 to <6 
L ..... _ ..,;" 
0.5 to <3 
4 (39) 
3 (57) 
Exposure (Years) 
3 to <6 
4 (22) 
3 (34) 
6 and over 
4 (54) 
0(100) 
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Table 18. Estimated actual risks, generated by GUM, for male and female donkeys at a given age 
of entry and length of exposure. The estimated actual risks for female donkeys are given in brackets. 
Age at Exposure (Years) 
Entry 
0.5 to <3 3 to <6 6 and over (Years) 
0.5 to <3 0.238 (0.121) 0.201 (0.157) 0.024 (0.069) 
3 to <6 0.082 (0.038) 0.067 (0.050) 0.007 (0.021) 
6 to <9 0.070 (0.032) 0.057 (0.043) 0.006 (0.018) 
9 and over 0.020 (0.009) 0.016 (0.012) 0.002 (0.005) 
Table 19. Numbers of male and female donkeys, of the Case population, categorised by the 
anatomical site of the primary sarcoid tumour. 
Anatomical site 
Sex Peri- Other Ventral Para- Limb Other Totals 
ocular head abdomen genital 
Male 7 12 2 22 4 0 47 
Female 5 6 9 6 4 3 33 
Totals 12 18 11 28 8 3 80 
Table 20. Numbers of donkeys alive and dead in the Control and Case populations. 
Population Dead Live Totals 
Controls 602 2045 2647 
Cases 10 70 80 
Totals 612 2115 2727 
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CHAPTER III 
SEROLOGICAL STUDIES: 
DETECTION OF ANTIBODIES TO PAPILLOMAVIRAL 
ANTIGENS IN THE SERA OF DONKEYS 
WITH AND WITHOUT SARCOIDS. 
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CHAPTER III 
SEROLOGICAL STUDIES: 
DETECTION OF ANTIBODIES TO PAPILLOMAVIRAL 
ANTIGENS IN THE SERA OF DONKEYS 
WITH AND WITHOUT SARCOIDS. 
3.1. INTRODUCTION 
Investigation into the humoral response of animals to foreign antigen can provide 
information regarding exposure to the antigen, the prevalence of infection, but not 
necessarily clinical disease, in a population. Serological assays to measure the 
prevalence of HPV infection have been hindered by the lack of a adequate supply 
of viral antigen (Galloway, 1990). There are three reasons for this shortage of 
antigen: First, genital HPV lesions produce few virus particles (Pfister, 1984); 
secondly, non-genital lesions, such as plantar warts, which produce large amounts 
of virus, are seldom removed surgically; thirdly, there is currently no in vitro 
method of propagating large quantities of papillomavirus. These difficulties have 
recently been overcome, to an extent, by the expression of HPV ORFs in bacteria, 
and the fusion proteins produced in this manner have been used as target antigens 
in serological assays. This technique is being used to conduct seroepidemiological 
investigations into the prevalence of HPV infection (Galloway and Jenison, 1990; 
Jenison, Yu, Valentine, Koutsky, Christiansen, Beckmann and Galloway, 1990; 
Steger, Olszewsky, Stockfleth and Pfister, 1990). 
Unlike HPV infections, BPV-1 and 2 lesions produce large amounts of virus 
and the tumours are readily available from abbatoirs. It has been shown that 
polyclonal antibodies raised against intact PV virions cross-react with closely 
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Olson, Pass, Lancaster and Shah, 1980). Genus-specific, cross-reactive and type-
specific epitopes have been identified by the use of monoclonal antibodies raised 
to disrupted BPV-1 (Gorra, Lancaster, Kurman and Jenson, 1985; Nakai, 
Lancaster, Lim and Jenson, 1986 Cowsert, Lake and Jenson, 1987). Gorra et aL, 
(1985) and Nakai et aL, (1986) demonstrated a BPV-1 specificity in some 
monoclonal antibodies raised to disrupted BPV-l. Cowsert et aL (1987) defined the 
BPV -1 epitopes as external conformational, external linear and internal linear 
depending upon reactivity with intact virions alone, intact and disrupted virion or 
disrupted virion alone. In addition, as in HPV research, the cloning and expression 
of BPV-1 (Pilacinski, Glassman, Krzyzek, Sadowski and Robbins, 1984) and BPV-2 
(Jarrett et aL, 1991) ORFs have allowed the production of large amounts of viral 
protein. This has provided an additional tool for the detection of antibodies to 
BPV infection as well as providing viral protein in sufficient quantities for 
prophylactic and therapeutic vaccination studies (Pilacinski et aL 1986, Jarrett et aL 
1991). 
The experiments in this chapter investigated whether or not donkeys, with 
or without sarcoids, at The Donkey Sanctuary had circulating antibody directed 
against papillomaviral antigens and, secondly, if the antibody detected was capable 
of neutralising the transforming activity of BPV-2 in vitro. 
Polyacrylamide gel electrophoresis (PAGE) formed the basis of the first 
part of the serological investigation. The first experiments assayed donkey sera 
from animals at The Donkey Sanctuary against the antigens present in the 
disrupted BPV-2 virion. The virus used as the target antigen was extracted from 
BPV-2 lesions by the rate zonal method described in Chapter IV may have 
contained small amounts of contaminating bovine cellular material. It is also 
known that the molecular weights of cytokeratins in mammalian skin are between 
40 to 70kDa (Franke, Schmid, Osborn and Weber, 1978; Franke, Appelhans, 
Schmid, Freudenstein, Osborn and Weber, 1979; Hoshimoto, Eto, Matsumoto and 
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1984). Thus, in order to rule out the possibility that the antibodies detected by 
immunoblot were directed against a bovine cytokeratin, the donkey sera were also 
assayed against the L1 fusion protein of BPV-2. The immunoblot assays (Jarrett et 
aI., 1990b) used in the two experiments were similar. A brief description of the 
standard gel casting technique, modified from Laemmeli (1970), is given and the 
formulations listed. 
The latter part of this chapter describes the assay of the donkey sera for the 
presence of neutralising antibody against BPV-2. The presence of neutralising 
antibodies in serum samples was measured in a quantal assay by the ability of the 
sera to inhibit the transformation of bovine fibroblasts by BPV-2 when the serum 
was mixed with a known amount of virus, before the addition of the virus to the 
indicator cells. The methodology (Jarrett at aI., 1990a) is described below. 
3.2. MATERIALS AND METHODS 
3.2.1. Source of donkey sera 
The donkeys at The Donkey Sanctuary are routinely bled in order to monitor 
haematological and plasma biochemical parameters. All samples of serum used in 
this study were obtained at the same time as the routine samples for The 
Sanctuary's health monitoring programme. Ten ml of blood were collected and 
allowed to clot. Serum was removed from the sample and centrifuged briefly in a 
bench-top centrifuge to pellet any remaining erythrocytes. The serum was stored in 
1ml aliquots at -200 C, until required. 
3.2.2. Detection of antibody against papillomaviral antigens by immunoassay. 
3.221. Preparation of antigen 
Two different sources of antigenic material were prepared for polyacrylamide gel 
electrophoresis. 
Disrupted virion: Three hundred ul of BPV-2 virions, purified by the rate zonal 
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(Laemmeli 1970) heated to 9SoC and cooled on ice immediately prior to 
electrophoresis. 
L1 fusion protein: The BPV-2 L1 ORF, molecularly cloned in two fragments into 
pUR vector series (Jarrett et al. 1991), was used to produce two polypeptides: a 
truncated N-terminal half and a C-terminal half of the L1 protein. The following is 
an account of the method used to produce sufficient quantities of the protein for 
use in the immunoblot assays. Two hundred ul of competent E. coli JM109 cells 
were inoculated into 1ml L broth and incubated overnight at 370 C with shaking at 
22Sg. Approximately 100u1 of this overnight culture was seeded into 100ml L broth 
and the incubation continued for a further 2 hours. The bacteria were then 
pelleted by centrifugation in a Beckman J2-21 centrifuge at 2000g at 40 C. The 
pellet was resuspended in one fifth volume of SOmM calcium chloride and allowed 
to stand on ice for 20 minutes. The centrifugation was repeated and the pellet 
resuspended in one twentieth volume SOmM calcium chloride solution. The 
competent cells were then aliquoted into 100u1 volumes and stored for no longer 
than 48 hours at 40 C. 
For each plasmid containing a fragment of the L1 ORF of the BPV-2 
genome, the plasmid DNA was diluted to a concentration of 1ng/ul in TE buffer. 
Ten ul of DNA was added to 100u1 of competent cells and allowed to stand on ice 
for 20 minutes. The cells were then heat shocked for 90 seconds at 420 C with 
shaking followed by the addition of 400u1 L broth and the suspension incubated at 
370 C for 60 minutes. Fifty to 100u1 were then plated out on to agar plates 
containing ampicillin at a concentration of 100ug/ml. The plate was incubated at 
370 C overnight in an inverted position. 
A single bacterial colony from the overnight culture was picked up with a 
platinum loop and inoculated into Sm1 L broth containing ampicillin at a 
concentration of 100ug/ml. This was incubated at 370 C overnight as before. One 
hundredth of this culture was seeded into 400ml L broth with ampicillin and the 
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continued for 30 minutes. The bacterial pellet was recovered following 
centrifugation at 5000g for 10 minutes at 40 C and resuspended in 14.4m!lysozyme 
buffer (25 per cent sucrose, 50 mM Tris-HCI, pH 8.0). To this suspension, 1.3m! of 
lysozyme solution (lOmgjm! in lysozyme buffer) was added and the mixture stored 
on ice for 15 minutes. The bacteria were then lysed by the addition of 6m! of lysis 
buffer (1 per cent Nonidet P40, 0.1 per cent sodium deoxycholate, O.lM sodium 
chloride, lOmM Tris-HCI (pH 8.0) into 30m! corex tubes. The bacterial debris was 
pelleted by centrifugation at 10000g for 10 minutes and the supernatant retained. 
The pellet was washed with guanidinium hydrochloride in 1M sodium chloride and 
1 per cent Triton X-IOO. Centrifugation was repeated and the pellet washed in 
lOmM Tris-HCI (pH 8.0) a further two times. The protein pellet was resuspended 
in 15m! of sample buffer and heated to 980 C for 15 minutes. The two portions of 
the L1 encoded protein were combined in equal quantities and were referred to as 
the L1 fusion protein. 
3.222 SDS-Polyacrylamide Gel Electrophoresis 
AcrylamidejBis : 37.5g acrylamide and 1.0g BIS dissolved in 125g distilled water. 
Running Gel (10 per cent) 
Acrylamide jBis 12g 
Buffer 9m! 
Distilled water 18m! 
TEMED 40u1 
Ammonium persulphate(10%) 300ul 
Tris base 
Running gel buffer 
18.2g 
Stacking Gel (5 per cent) 
2g 
3m! 
7m! 
30u1 
60u1 
Stacking gel buffer 
5.9g 
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Electrophoresis buffer (lOx): 63.2g Tris base, 1O.Og SDS, 40.0g glycine dissolved in 
800ml distilled water. Volume made up to 11. 
Blotting buffer: 9.09g Tris base, 43.2 g glycine dissolved in 2800ml distilled water. 
Volume made up to 3 litres. To use, 1600ml buffer was diluted with 400ml 
methanol. 
Sample buffer: l.Sg Tris base, 2.1g SDS, 10ml gycerol, Sml mercaptoethanol, O.lml 
bromophenol blue dissolved in 80ml distilled water. Volume was adjusted to 
100ml. 
The Protean II Gel Electrophoresis System (Biorad) was used according to the 
manufacturer's instructions for all SDS-P AGE procedures. Two 16cm x 20cm and 
18.2cm x 20cm glass plates were washed with alcohol. The plates were sandwiched 
together, so that the lower edges were flush, and screw clamps applied. The unit 
was fitted into the casting slot over a rubber strip to form a seal which was tested 
by adding water. A 10 per cent polyacrylamide slab gel was poured and left to 
polymerise for a minimum period of 30 minutes. Ammonium persulphate (APS) 
initiated the polymerisation whilst N,N,N',N'-tetramethyl ethylene diamine 
(TEMED) catalysed the reaction. A small amount of butanol was added to remove 
the bubbles at the air/gel interface and to exclude air, allowing polymerisation. 
Once set, the butanol was washed off with distilled water and the water drawn off 
with a syringe and needle. A 5 per cent stacking gel was poured and a preparative 
well comb with individual marker well was inserted. The different pH and gel pore 
size caused the proteins to stack producing a sharp band at the start of the running 
gel at which point resolution of the proteins started. The gel was allowed to 
polymerise for a minimum period of 30 minutes after which time the comb was 
removed and any unpolymerised gel mixture removed by washing with distilled 
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the upper chamber. The whole assembly was placed in the buffer tank and 
electrophoresis buffer added to the upper and lower chambers, ensuring the gel 
plates were covered to a depth of approximately 2cm. Air bubbles along the 
bottom of the plate were removed by a syringe. Sample buffer was added to all 
samples and standard molecular weight markers were run alongside the samples. A 
linear plot of the distance migrated (electrophoretic mobility) against known 
molecular weight was plotted on semi-logarithmic graph paper, enabling the 
weights of sample proteins, run simultaneously to the standards, to be estimated by 
interpolation. Electrophoresis was carried out at a constant 30mA for 3 to 6 hours 
or until the dye front was O.5cm from the bottom of the gel. Following 
electrophoresis, the gel was allowed to equilibrate in blotting buffer for 30 
minutes. A vertical strip of the gel was removed and stained for one hour in 
Coomassie blue (0.2 per cent Coomassie Blue, 50 per cent methanol, 12 per cent 
acetic acid) on a rocking platform. This was followed by several washes in destain 
solution (7 per cent acetic acid) to reveal the banding pattern of the proteins. The 
gel strip was then dried under vacuum on a Biorad Model 483 gel dryer at 800 C for 
2 hours. 
In order to allow the detection of specific proteins by immunochemical 
techniques, it is convenient to transfer the protein profile to a solid support. 
Applying an electric current forcibly elutes the proteins from the gel and binds 
them to a membranous support such as nitrocellulose acetate (Towbin, Staehelin 
and Gordon, 1979). The Trans-Blot Cell (Biorad) was used, transferring the 
proteins from cathode to anode. 
Assembly of the gel holder was carried out in a tray filled with blotting 
buffer ensuring the pads, paper and nitrocellulose acetate membrane were all 
saturated with the buffer. The gel holder was assembled from cathode to anode 
comprising, in order, 'Scotchbritepad' (3M), filter paper (3MM chromatography 
Whatman), gel with orientation marker, nitrocellulose acetate (Hybond-C, 
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hands only. The holder was then inserted into the blotting tank and approximately 
31 of blotting buffer added. Transfer was performed at 40 C overnight at a constant 
135 rnA with mixing. Non-specific adsorption sites were blocked by immersing the 
membrane in Blotto (5 per cent (wjv) milk powder in PBS (pH 7.4)) for 3 hours at 
room temperature with agitation. After blocking, the membrane was dried at 800 C 
for 2 hours, cut into numbered strips and stored at -200 C between two sheets of 
filter paper and encased in Parafilm. 
3.223. Immunoblot assay 
The strips of nitrocellulose were placed in individual 15ml Falcon tubes and 
incubated at 40 C overnight with donkey sera diluted 1:50. in Blotto. Rabbit 
antiserum (conjugated to horseradish peroxidase (HRP) or alkaline phosphatase 
(AP)) to BPV-2 was used (1:1000) as a positive control. The strips were then 
washed for three 10 minute periods in PBS (pH 7.4)jTween 20 (200:1) and then 
incubated for 90 minutes at room temperature with goat anti-donkey IgG (1:500). 
The washing was repeated and the strips incubated with a horseradish peroxidase 
HRP or AP conjugated rabbit anti-goat IgG (1:1000) in Blotto for 90 minutes at 
room temperature. The strips were then washed again and those which had been 
incubated with a secondary antibody conjugated to HRP were incubated in a 
solution containing 0.05 per cent (w jv) 3,3' diaminobenzidine (DAB) and 1 per 
cent (vjv) hydrogen peroxide in Tris buffer. The development of a signal was 
monitored and the reaction stopped by the addition of tap water. When a 
secondary antibody conjugated to AP was used, the strips were equilibrated in AP 
buffer containing 100mM sodium chloride, 5mM magnesium chloride and 100mM 
diethanolamine (pH 9.5). Two stock solutions containing 0.5g nitroblue 
tetrazolium (NBT) in 10ml of 70 per cent dimethylformamide and 0.5g 
bromochloroindolyl phosphate (BCIP) in lOml of 100 per cent dimethylformamide 
were prepared. To 10ml of AP buffer was added 66ul of NBT stock and 33ul of 
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to 30 minutes and was stopped by the addition of PBS (pH 7.4) containing 20mM 
EDTA Selected serum samples were pre-incubated with BPV-2 virion, Ll fusion 
protein, uninduced E. coli proteins or beta-galactosidase at 40 C overnight and then 
assayed against the appropriate target antigens as described above in order to 
demonstrate that any antibody detected could be adsorbed by pre-incubation with 
specific antigen resulting in a reduced signal intensity. 
3.2.3. Detection of neutralising antibodies. 
In the transformation and neutralisation assays described below (Jarrett et aL, 
1990a), the normal additives of sodium bicarbonate (3.7g/l) and L-glutamine 
(0.396g/l) were added to the Dulbecco's modification of Eagle's medium used in 
the assays. 
3.23.1. Transformation assay 
Skin fibroblasts were obtained from bovine fetuses and were tested for their ability 
to exhibit a transformed phenotype when infected with BPV-2. Suitable primary 
cell cultures were amplified and stored. A large stock virus preparation from 
bovine skin lesions (Section 4.2.) was prepared and tested on the bovine fetus cells 
to determine the 50 per cent tissue culture transforming dose (TCfDso). The cells 
were plated out into a 24-well culture plate at a density of 3xl04 cells per well in 
Iml of DMEM containing 10 per cent fetal calf serum (FCS). The medium was 
removed 24 hours later and replaced by DMEM containing 10 per cent FCS and 
doubling dilutions of the viral stock preparation down to a concentration of 1: 1280. 
Each dilution was prepared in sextuplet. The virus/medium mixture was incubated 
with the cells for overnight at 370 C and in 5 per cent carbon dioxide. The medium 
was then removed completely and replaced with DMEM containing 10 per cent 
FCS and gentamycin (50ug/ml). The medium was changed every 48 hours until 
transformation was observed. 
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3.2.3.2. BPV-2 neutralisation assay. 
The donkey sera were filter sterilised through a 0.2um filter and complement in-
activated by incubation at 550 C for 30 minutes. Doubling dilutions of each serum 
sample were prepared in DMEM (without FCS) down to a dilution of 1:320. BPV-
2 at a concentration twice that of the TCfD was added to the serum dilutions 
50 
and, after mixing, the mixtures incubated overnight at 4°C. The virus/serum 
mixtures were then added to the indicator cells which had previously been 
inoculated into a 24-well culture plate as described for the transformation assay 
(section 3.2.3.1.). One ml of the virus/serum mixture was added to each well and 
allowed to remain in contact with the cells overnight at 370 C in an atmosphere 
containing 5 per cent carbon dioxide. The virus/serum mixture was removed and 
replaced with DMEM containing 10 per cent FCS and gentamycin (50ug/ml). This 
was replaced every 48 hours for 14 days or until the positive control cells exhibited 
transformation. The medium was then decanted from the wells and the cells 
washed gently in phosphate buffer (pH 6.8). The cells were fixed in methanol for a 
minimum period of 15 minutes and then stained with prefiltered Giemsa stain for 
30 minutes. The wells were then washed gently with water and air dried. Assays 
were read using an inverting microscope. The controls used in the neutralisation 
assays were: 1:10 dilution donkey serum with DMEM (negative); DMEM alone 
(negative): transforming titre of BPV-2 virus in DMEM (positive). One ml of each 
of these controls was used in an identical manner to the virus/serum mixtures. 
3.3. RESULTS 
3.3.1. Immunoblot assay 
The results of the immunoblot assays are summarised in Table 21 and presented in 
full in Table 22 and the appearance of the nitrocellulose strips after the assays is 
displayed in Figure 12. In total, 45 serum samples from 39 donkeys were assayed 
for the presence of antibody. When animals were sam led on more than one 
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Of the 33 sera from 27 donkeys assayed against disrupted virion, 32 samples 
from 26 donkeys contained antibodies against antigens 55 and 65kDa in size 
(Figure 12). Fourteen of these donkeys had no evidence or previous history of 
sarcoids. All samples from sarcoid-affected animals were positive for antibody to 
the two antigenic bands. One of the fourteen healthy donkeys was a pre-colostrum 
neonate foal and was negative for antibody reactive with either antigen band. A 
demonstrable reduction in signal intensity was obtained by pre-incubating positive 
samples with whole BPV-2 virion. Some of the serum samples contained antibody 
to a 76kDa fragment, but this was an inconsistent finding and was dependent upon 
the blot that was used for the assay, rather than the serum sample. The control 
sample (antisera to BPV-2 raised in a rabbit) only reacted with a broad antigenic 
band approximately 55kDa in size. 
Of the 45 samples, 43 sera from 37 donkeys were assayed against the 
molecularly cloned L1 fusion protein. Thirty-eight of the samples from 32 donkeys 
contained antibody reactive with antigenic bands which corresponded 
approximately with the N-terminus (144kDa) and C-terminus (139kDa) fragments 
of the L1 protein. All samples, bar one, from sarcoid-affected donkeys were 
positive. Eighteen of twenty-two healthy donkeys were also positive for antibody. 
Four donkeys, all healthy animals, including a serum sample from a pre-colostrum 
neonate foal, were negative for antibody against both fragments (Figure 12). All 
samples assayed were either positive or negative for both fragments. Samples 
incubated with the L1 fusion protein prior to assay demonstrated a reduced 
intensity of signal but it was not possible to remove the signal absolutely. Pre-
incubation of the sera with uninduced E. coli or beta-galactosidase did not reduce 
the signal intensity in the region of the fusion proteins. 
Thirty-two of the samples were assayed against both fusion protein and 
disrupted virion and results were consistent between the two assays, i.e., samples 
positive for antibody against the L1 fusion protein were also positive for antibody 
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BelP /NBT / AP detection systems was noted in 19 samples assayed using both 
systems (Figure 12). 
Table 21. Summary of immunoblot assays for the presence of antibodies, reactive with one or more 
papillomaviral antigens, in serum samples from donkeys at The Donkey Sanctuary. 
Ll fusion protein Disrupted virion 
Sera Donkeys Sera Donkeys 
No. Assayed 43 37 33 27 
No. Positive 38 32 32 26 
% Positive 88 86 97 96 
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Table 22. Immunoblot assays for donkey serum antibody, in donkeys, reactive with the two 
fragments of the molecularly cloned L1 fusion protein and against disrupted virion (continued~. 
Animal Antibody vs. L1 fusion protein Antibody vs. disrupted virion Disease 
No. N-terminus C-terminus 55kDa 65kDa Status 
2087i + + + + Sarcoid 
2087ii + + + + Sarcoid 
3590i + + + + Sarcoid 
3590ii + + + + Sarcoid 
2074 + + + + Healthy 
2077i + + + + Sarcoid 
2077ii + + + + Sarcoid 
2077iii + + + + Sarcoid 
513 + + N/A N/A Healthy 
514i + + + + Sarcoid 
514ii + + + + Sarcoid 
2530 N/A N/A Healthy 
3075 + + + + Sarcoid 
3472i + + + + Healthy 
3472ii + + + + Healthy 
3459 + + + + Sarcoid 
3675 + + + + Healthy 
2073 + + + + Healthy 
863 N/A N/A Sarcoid 
864 + + + + Healthy 
865 N/A N/A Healthy 
3529 + + + + Sarcoid 
1708 + + + + Sarcoid 
1709 + + N/A N/A Healthy 
N / A: not assayed. 
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Table 22. (continued) Immunoblot assays for donkey serum antibody, in donkeys, reactive with the 
two fragments of the molecularly cloned L1 fusion protein and against disrupted virion. 
Animal Antibody vs. L1 fusion protein Antibody vs. disrupted virion Disease 
No. N-terminus C-terminus 55kDa 65kDa Status 
3037 + + + + Sarcoid 
2428 + + + + Sarcoid 
3485 + + + + Healthy 
3674 + + + + Healthy 
2529 + + + + Sarcoid 
2085 + + + + Healthy 
3676 + + + + Healthy 
3470 + + + + Sarcoid 
876 + + + + Sarcoid 
877 + + N/A N/A Healthy 
878 + + + + Healthy 
3672 + + N/A N/A Healthy 
1131 N/A N/A Healthy 
3486 + + + + Healthy 
2075 + + N/A N/A Healthy 
3776 N/A N/A + + Healthy 
3579 N/A N/A + + Healthy 
2515 + + N/A N/A Sarcoid 
Pre-
4107 colostral 
513 + + N/A N/A Healthy 
N/A 
Healthy 
4044 + + N/A foal 
N / A: not assayed. 
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Figure 12. Nitrocellulose strips after immunoblot assay using HRP jDAB (A) and AP j BCIP jNBT 
(B and C) detection systems. The antigenic targets used were disrupted BPV-2 virion (A and B) and 
the combined N- terminus (-4) and C-terminus (4) fusion proteins encoded by L1 open reading frame 
of BPV-2 (C). The test sera were:(a and 1) antisera to BPV-2 raised in a rabbit; (i) antisera to L1 
fusion proteins raised in a rabbit; (b, 2 and ii) sarcoid-affected donkey serum;(d, 4 and iv)healthy 
donkey serum; (e and v) neonate (pre-colostrum) donkey serum; (c) sample from b preadsorbed with 
BPV-2 virion; (iii)sample from ii preadsorbed with L1 fusion protein. 
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3.3.2 Transformation assay 
The TCTD 50 was found to be 1:320 and in all subsequent neutralisation assays the 
virus stock was diluted 1:160. 
3.3.3. Neutralisation Assay 
The sera assayed for the presence of neutralising antibody to BPV-2 were the same 
as those assayed in the immunoblot experiments. A total number of 45 sera from 
39 donkeys were screened and all were found to be negative for neutralising 
antibody to BPV-2. Seven assays were performed using four different indicator 
primary cell cultures of bovine fibroblasts, viz., F6 CL3 (twice), F29 P6 (twice), F18 
P9 (three assays). The assays lasted between 14 (F18 P9) and 21 days (F6 CL3). All 
cultures were at passage 12 or less. Assays one to three produced equivocal results 
as there was little discernible difference between negative and positive controls. 
Assay four was abandoned after 16 days due to fungal contamination of the cells in 
the control wells. In assays five, six, and seven (cell line F18 P9) transformation of 
the cells occurred in all wells which had contained the donkey sera and virus 
mixture (Figure 13). Transformation did not occur in cells that had been incubated 
with medium alone or donkey serum alone. 
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Figure 13. Two 24-well plates after the neutralisation assay. Incubation was at 40 C over night with 
the following mixtures: Si, wells containing bovine fetal fibroblasts incubated with BPV-2 and donkey 
serum from a clinically normal donkey; S2-S4, wells containing bovine fetal fibroblasts incubated with 
BPV-2 and serum from three sarcoid-affected donkeys; Vi-V3, wells containing bovine fetal 
fibroblasts incubated with BPV-2; C, wells containing bovine fetal fibroblasts incubated with neither 
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3.4. DISCUSSION 
3.4.1. Immunoblot assay 
The immunoblot assays described in this chapter have demonstrated the presence 
of antibodies reactive with disrupted BPV-2 virion and the Ll fusion protein of 
BPV-2 in the vast majority of sera from both sarcoid-affected and clinically normal 
donkeys. Detection rates against virion and Ll fusion protein were 86 and 96 per 
cent in sarcoid-affected and healthy animals combined. No antibody was 
demonstrable in the serum from a precolostrum donkey foal and as the donkey 
neonate receives its passive immunity from its dam's colostrum, not via the 
placenta, this foal may be considered to have been immunologically naive. Assay 
against dirupted virion demonstrated antibodies to a 55kDa antigen and a 65kDa 
antigen. The stronger signal was detectable at the 55kDa size and this corresponds 
to the Ll component of the major capsid protein. The 65kDa antigenic band is 
approximately the expected size of the L2 encoded capsid protein of BPV-2. 
Unfortunately, no assays using the L2 encoded fusion protein were carried out to 
confirm that the immune system of the donkeys recognised viral L2 encoded 
proteins, as suggested by the 65kDa apparent when disrupted virion was used as 
the target antigen. However, the fact that the control rabbit antisera only reacted 
with the 55kDa antigen may indicate a difference either in host response or 
between experimental and natural infection or that the 65kDa band is artefactual, 
possibly related to the cytokeratins of the bovine skin. More work, using the cloned 
L2 fusion protein would provide the additional information necessary to resolve 
this query. 
The demonstration of antibody to the Ll fusion protein, in addition to the 
pre-incubation and adsorption data, suggest that the antibody reactive with the 
disrupted virion is indeed directed at the papillomaviral antigen and not at the 
cytokeratins that may have been present. The assays against the two components of 
the Ll fusion protein also indicate that epitopes are located on both the C 
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In view of the herd management at The Donkey Sanctuary, it was 
impossible to identify animals that had never been in contact with a sarcoid-
affected donkey but it appears that presence or absence of antibody to 
papillomaviral antigen was unrelated to clinical status. The proportion of animals 
with antibody to the antigens used in the immunoassays is, at first consideration, 
surprisingly high. On purely clinical grounds from observations made in the human 
population, it is known that HPV infection occurs commonly in the general 
population and that immunosuppressed patients are at a high risk of developing 
HPV related disease (Benton, Shahidullah and Hunter, 1992). This occurs in 
patients with AIDS (Valle, 1987) and also in patients in receipt of a renal allograft, 
and who are consequently receiving immunosuppressive drugs: Barr, Benton, 
McLaren, Bunney, Smith, Blessing and Hunter (1989) reported a 77 per cent 
prevalence of viral warts in patients with a graft life of five to 22 years and it would 
appear that papillomaviruses are therefore widely encountered by the human 
population. The ubiquitous nature of the papillomavirus is also supported by 
unpublished data of Jarrett and O'Neil. These workers detected antibody to 
disrupted BPV-2, employing the methodology described in this chapter, in 70 to 80 
per cent of calves that were screened for previous exposure to papillomavirus, 
prior to use in vaccination studies. The calves were purchased when only a few 
months old and it is probable that, had the animals been older at purchase, a 
higher proportion would have had detectable antibody to BPV-2. The donkeys 
sampled in the present study were of various ages but, with the exception of the 
foals, all were in excess of one year old and had been kept in large groups. If 
papillomaviral infection at The Donkey Sanctuary is as widespread as would 
appear to be the case in bovidae, then there is a high probability that older 
donkeys, managed under herd conditions, will have been exposed to viral antigen. 
The conclusion based on the immunoblot results that there is a high 
revalence of papillomavirus infection in the donkey is supported by serological 
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(1990) demonstrated antibody against the late proteins of HPV-6 in approximately 
60 per cent of subjects, against HPV-16 in over 50 per cent of subjects and against 
HPV -18 in 25 per cent of subjects. Again, there was no statistically significant 
difference between adult patients, at a clinic for sexually transmitted diseases, and 
children and it appears that there are differences in the prevalence of infection of 
viral types. However, there are also differences between the results of different 
research groups. Whilst the findings of Li, Shah, Seth and Gilden (1987) were in 
agreement with those of Jenison et aL (1990), the work of Strike, Bonnez, Rose 
and Reichmann (1989) failed to demonstrate antibodies to HPV-6 Ll and 12 
proteins in the sera of 38 patients with HPV -6 infections and in 22 uninfected 
controls. There may be several reasons for this discrepancy (e.g., epitope 
availability in the fusion protein construct, assay sensitivity) but it is evident that 
there are still drawbacks in the use of fusion proteins for serological assay 
(Galloway, 1990). 
Regardless of the differences between different groups of workers, the 
single biggest deficit of this approach to seroepidemiology is the inability to detect 
antibodies directed against the conformational epitopes of the papillomaviruses. 
Jarrett et aL (1991) demonstrated that antisera from calves and rabbits injected 
with the fusion proteins used in the present study were reactive with both 
engineered and viral Ll proteins and, that reciprocally, antisera raised against 
disrupted virus was reactive with the fusion proteins. This suggests that the fusion 
proteins share epitopes with virus which are recognised by the host immune 
system. These findings support the theory that the antibodies detected in the 
immunoblot assays were directed against papillomaviral antigen. However, the 
work of Steele and Gallimore (1990) emphasises the need for caution when 
interpreting serological assays based on linear epitopes. These workers compared 
the results of serological assay by Western (immuno) blot, which utilises linear 
epitopes, to immunoprecipitation and ELISA, both of which utilise conformational 
93 
CHAPTER III 
when disrupted virion was used as the antigen in an ELISA, the detection rate was 
only 9/83. In the present study, it may therefore be the case that the exceptionally 
high detection rates of 86 per cent and 96 per cent in the donkey are in fact under-
estimates, as both assays utilised linear epitopes. In addition, the reduction in 
signal intensity by pre-adsorption of sera with BPV-2 virion and BPV-2 L1 fusion 
protein (but not by E. coli proteins nor beta-galactosidase) gives reasonable 
grounds for concluding that the antibody detected in the immunoblot assay was 
directed against papillomaviral antigen. 
When the health status of the donkeys is considered, all donkeys except one 
(863) with sarcoids or a history of sarcoids were positive for antibodies against the 
antigen targets. It is difficult to explain why this one animal should be antibody 
negative but a number of possibilities may be considered: first, even though the 
assays were repeated, the serum came from a single sampling and consequently if 
the sample had been exposed to excessive heat the antibody may have been 
denatured; secondly, the diagnosis of sarcoid in this particular case may have been 
incorrect and the donkey was, in fact, healthy; thirdly an administrative error may 
have occurred ascribing the wrong animal number to the sample; lastly, the assays 
may be detecting a papillomaviral antigen which has nothing to do with the 
development of sarcoids. Of the healthy animals, excluding the pre-colostrum 
neonate, 13/13 were positive for antibody reactive with disrupted virion and 18/21 
(81 per cent) were positive for antibody reactive with the L1 fusion protein. 
Although this difference is not significant and it should be remembered that the 
five of the animals proving negative for antibodies to the L1 were not assayed 
against the disrupted virion, a larger sample population and more accurate animal-
contact histories would benefit the study. 
In conclusion, the majority of donkeys assayed, whether healthy or sarcoid-
affected, appear to have encountered a papillomaviral or papillomaviral-like 
antigen, but this does not appear to be related to clinical development of sarcoids. 
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presence of antibody to conformational epitopes, providing an antigen target 
similar to that encountered in vivo; further purification of the fusion proteins, 
including the removal of the beta-galactosidase would produce cleaner blots; 
assays against the 12 encoded fusion protein, or those encoded by the early ORFs, 
may produce more data of immunological and epidemiological significance. 
However, until the clinical disease can be definitively related to an aetiological 
agent it is debatable whether it is worth pursuing this line of investigation. 
3.4.2. Neutralisation assay 
No neutralising antibody to BPV-2 was detected in the donkey sera assayed in the 
present study. The failure of the donkey sera to prevent transformation of the 
bovine fetal fibroblasts indicates that the antibody demonstrated by Western blot 
does not neutralise the transforming activity of BPV-2 in vitro. Previous work 
carried out on immunity to BPV infection in equidae is difficult to interpret. Cook 
and Olson (1951) were able to produce sarcoma-like tumours in 10/11 horses by 
the inoculation of material derived from bovine papillomas. There was also no 
evidence of acquired immunity as the horses were susceptible to repeated 
exposure. This finding was in contrast to those of Segre et aL (1955) and Ragland 
and Spencer (1968) who reported that horses with BPV induced tumours produced 
serum antibodies capable of neutralising BPV. 
Unfortunately, all of these studies were performed before the identification 
of the various bovine papillomaviral types and it is possible that mixed 
papillomaviral types were inoculated. Segre et aL (1955) also noted that there was 
a variation in the response of different animals to inoculation as well as variation 
in the pathogenicity of viral isolates from different sources. In addition, the 
neutralising properties of the test sera were assayed by a brief incubation with an 
unspecified amount of virus followed by inoculation into the skin of susceptible 
horses. These limitations raise the question of the role of host susceptibility, purity 
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animals in any assay is likely to provide a variety of responses. Indeed, one 
clinically normal test horse was observed to have a non-heat labile neutralisation 
factor in its serum (Segre et aL, 1955). Further cause for concern in Segre's study 
(1955) is the failure of calves inoculated with BPV to produce neutralising 
antibody to the virus, a finding which contradicts work done before and since (Post 
and Terpestra, 1947; Jarrett et aL 1990a). 
Ragland and Spencer (1968) were unable to demonstrate the presence of 
neutralising antibody to BPV in the sera of horses with sarcoid tumours and when 
BPV was inoculated intradermally into noramal and saroid-affected horses, both 
groups of animals developed fibroblastic nodules as well as neutralising antibody 
to BPV. They concluded that this evidence failed to support the theory that equine 
sarcoid was caused by BPV. 
The present study has shown no neutralising antibody to BPV-2, detectable 
in vitro, in the serum of sarcoid-affected or clinically normal donkeys at The 
Donkey Sanctuary. There are several interpretations of this finding: First, BPV-2 is 
not the aetiological agent of the donkey sarcoid; secondly, antibody to BPV-2 in 
the donkey sera is not directed against the neutralising epitope of BPV-2 and 
immunity to sarcoids is determined by other components of the immune system; 
thirdly, the antibody detected by immunoblotting is an artefact caused by the 
disruption and absence of the conformational epitopes. However, the work of 
Jarrett et aL (1991) and the reduction of the signal intensity by pre-adsorption of 
the sera with BPV-2 virion or BPV-2 L1 indicate that this is unlikely. 
3.5. SUMMARY 
It seems most likely that there has been widespread exposure of the sarcoid-
affected and clinically normal animals at The Donkey Sanctuary to a 
papillomaviral or a papillomaviral-like antigen. Antibodies which are reactive to 
this antigenic material do not neutralise the transforming activity of BPV-2 in vitro. 
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antigen also remains a matter for speculation. Although donkeys at The Sanctuary 
have no contact with cattle, previous exposure to infected bovidae or 
accomodation associated with cattle may have occurred and despite the fact that 
all animals wear fly-repellant tags, the climate at The Sanctuary in the south-west 
of England supports a large fly popUlation. These matters will be discussed in more 
detail in Chapter VIII. 
Seroepidemiology can provide much information about a disease, but 
investigations into the sarcoid still await the isolation of an aetiological agent. The 
demonstration of virions from naturally-occurring sarcoids has not been reported. 
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ATfEMPTS TO ISOLATE AN AETIOLOGICAL AGENT: 
EXTRACTION OF PAPILLOMAVIRAL VIRIONS 
FROM SARCOID TUMOURS. 
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CHAPTER IV 
AITEMPTS TO ISOLATE AN AETIOLOGICAL AGENT: 
EXTRACTION OF PAPILLOMAVIRAL VIRIONS 
FROM SARCOID TUMOURS. 
4.1. INTRODUCTION 
In order to fulfill Koch's postulates it is necessary to identify a potential 
aetiological agent before attempts can be made to transmit the disease to another 
animal by inoculation of the isolated agent. There have been several attempts to 
isolate papillomavirus virions from sarcoid material, but none has been successful 
(Pfister, 1984; Gorman, 1985; Lancaster, et aL, 1977). This is in contrast to the 
equine papilloma which has been shown to contain papillomavirus particles 
(Fulton, Doanne and McPherson, 1970; O'Banion, Reichmann and Sundberg, 
1986; Hamada, Oymada, Yoshikawa, Yoshikawa and Itakura, 1990a; 1990b). The 
retrovirus isolated from an equine sarcoid-derived cell line (England et aL, 1973; 
Cheevers et aL, 1982) has since been shown to be endogenous retrovirus present in 
normal equine cells (Cheevers et at., 1986) and it now seems unlikely that the virus 
is of aetiological significance. 
The literature contains many accounts for the extraction of papillomavirus 
from tumours or transformed cells in culture (for example, Crawford, 1965; Favre, 
Breitburd, Croissant and Orth, 1975; O'Banion et at., 1986), most starting with 
large quantities of pooled tumours. The isolation and characterisation of different 
viral types from the various clinical manifestations of bovine papillomavirus 
infection and the pooling of different types of lesion may lead to the isolation of 
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zonal and isopycnic purification. His conclusion was that the purity of virus isolated 
by the former method was of a sufficiently high standard and had the advantage of 
a high yield of intact virions. The following method is an account of his technique 
wherein the tumour homogenate is layered on to a preformed sucrose gradient and 
subjected to centrifugation, separating the particles at a rate determined by their 
density. 
4.2. MATERIALS AND METHODS 
4.2.1. Solutions 
Tris buffer xlO; 116.9g of sodium chloride, 24.2g Tris and 6.7g EDTA were 
dissolved in 1900ml distilled water and adjusted to pH 8.0 with concentrated 
hydrochloric acid. The volume was then made up to 2 litres with distilled water. 
20% sucrose; 216.2g of sucrose were dissolved in 1 litre distilled water and the 
refractive index (RI) and density (D) ascertained to be 0.3638 and 1.0829g/cm3, 
respectively. 
10% sucrose; Equal volumes of the 20% sucrose solution and distilled water were 
mixed and the RI and D ascertained to be 1.3478 and 1.04 g/cm3, respectively. 
Caesium chloride (1.5g/cm3); 6.7183g of caesium chloride were dissolved in lOml 
of Tris buffer such that the RI was 1.3182. 
4.2.2. Source of tumours 
Sarcoid tumours were obtained from clinical cases referred for therapy to the 
Hospital at The Donkey Sanctuary. Sarcoids from two horses referred to the 
University of Glasgow Veterinary School were also examined for the presence of 
papillomavirus. 
100 
CHAPTER IV 
4.2.3. Extraction and purification of virions from sarcoids 
4.23.1. Extraction from superficial scrapings 
A superficial scraping was taken from the epidermis of some of the lesions. The 
scraping was resuspended in 500u1 PBS (pH 7.4) and sonicated for 2 minutes 
before examination for papillomavirus particles by negative staining transmission 
electron microscopy. 
4.23.2 Extraction from sarcoid tumours 
All tumours were stored in PBS (pH 7.4) and glycerol (1:1) for a minimum period 
of 14 days in order to soften the tissue and facilitate homogenisation. The tumours 
were cut up finely with scissors and a scalpel blade before being weighed. The 
tissue was resuspended in Tris buffer containing 0.5 per cent sodium deoxycholate 
and 0.5 per cent Nonidet P40. The final concentration was adjusted to 10 per cent 
weight per volume. The suspension was then homogenised on ice for 20 minutes 
using a Silverson homogeniser. The homogenate was clarified on a bench top 
centrifuge at 2000g for 10 minutes and the supernatant was further clarified in a 
Sorvall om 50 ultracentrifuge at 10000g for 10 minutes at 40 C using an SW-41 
rotor. Sucrose velocity gradients were made in SW-41 ultraclear centrifuge tubes 
(Beckman) by layering 5mls of 10 to 20 per cent sucrose solution on to a bed of 
caesium chloride solution of density 1.5g/ cm3• The clarified supernatant was 
layered carefully on to the gradients and centrifugation was carried out at 40000g 
for 30 minutes at 40 C. The gradients were examined for light scattering viral 
bands by direct illumination and the centrifugate was fractionated by piercing the 
bottom of the centrifuge tube with a 21 gauge needle and collecting five drops per 
fraction into separate tubes. The optical density of each fraction measured and the 
fractions dialysed against three changes of Tris buffer at 40 C, before repeating the 
rate zonal purification. 
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4.2.4. Examination by phosphotungstic acid negative staining transmission 
electron microscopy. 
Each fraction was sonicated for 2 minutes and a 100u1 aliquot placed on a 
parlodion grid for 1 minute. The excess sample was carefully blotted off aI,d a 
100u1 aliquot of phophotungstic acid applied to the grid. The grids were once again 
blotted dry and examined for the presence of virions by transmission electron 
microscopy. In cases where there was a suspicion that virion-like particles were 
present, the corresponding fraction was subjected to ultracentrifugation at 30000g 
for 45 minutes and the resulting pellet resuspended in 200u1 Tris buffer. The 
suspension was then examined for the presence of papillomaviral particles by the 
method described above. 
4.3. RESULTS 
All tumours were confirmed as sarcoids by microscopic examination of formalin-
fixed paraffin-embedded tissue sections stained by haematoxylin and eosin. The 
clinical types of the lesions and the results of the extractions are presented in Table 
23. Forty-nine fractions of tumour homogenate were examined for the presence of 
papillomaviral particles. Of the 49 fractions, 40 were extracted from ten tumours 
from eight donkeys, a further nine fractions from three tumours from two horses. 
Twenty-five of the 49 fractions were re-examined after ultracentrifugation to pellet 
material; 22 were from donkey tumours and three from horse tumours. Superficial 
scrapings were taken from 13 tumours from eight animals (seven donkeys, one 
horse). All four clinical types of tumour (Section 1.4.1.) were represented and two 
of the tumours were badly ulcerated with no intact epidermis. Of the 87 grids that 
were examined, only one grid contained visible particles resembling 
papillomavirus. The grid contained material from a fraction of an early type I or 
tvnP. TV '::Irc.oici with ::In int::lc.t p.nicie h r e. The 
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by negative stain transmission electron microscopy and were approximately 55nm 
in diameter. Both intact and empty particles were present (Figure 14). 
Table 23. Results of the negative staining electron microscopy of tumour homogenates and 
superficial scrapings. 
Sample Tumour Tumour homogenate Superficial Scraping Total no. No. positive 
No. of: 
Identity Type fractions (pelleted) No. of grids of grids for virion 
Do1a IIIU S (-) 1 6 0 
Do1b III 3 (3) 1 7 0 
Dole I (-) 1 1 0 
Do2 I 1 (-) 1 2 0 
Do3a II 2 (2) 4 0 
Do3b I 6 (2) 8 0 
Do4 II 10 (4) 1 11 0 
DoS II 3 (3) 6 0 
Do6 IIU 3 (3) 1 7 0 
Do7 I 3 (3) 6 0 
DoS I 4 (2) 6 0 
Do9a II (-) 1 1 0 
Do9b IV (-) 1 1 0 
DolOa I (-) 1 1 0 
Do10b III (-) 1 1 0 
Do10c II (-) 1 1 0 
Doll II (-) 1 1 0 
Hola IIIV 3 (-) 3 1 
Ho1b II 3 (-) 3 0 
2 1 7 0 
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Figure 14. Transmission electronmicrograph of papillomavirus-like particles extracted from an 
equine sarcoid, purified by rate zonal ultracentrifugation and negatively stained with poatassium 
nhm:nh()tllnlY~tate_ The i~olate contained both intact (closed arrow) and empty (open arrow virions 
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4.4. DISCUSSION 
The identification of papillomavirus-like particles In an extract from a sarcoid 
tumour has been described in this chapter. The particles were of a size, appearance 
and bouyant density similar to that of papillomaviruses although the presence of 
intact and empty capsids in the same fraction may indicate the disturbance of the 
gradient at fractionation. Although papillomaviral virions have been isolated from 
equine papillomas (Fulton, et ai., 1970; O'Banion et ai., 1986), this is the first 
report of a virion being isolated from an equine sarcoid. The tumour from which 
the virus was extracted in this study was a very early lesion (type I/IV) from a 
horse, which was only noticed when the animal was recumbant having been 
anaesthetised for the removal of a much larger periocular sarcoid. The present 
study is largely concerned with sarcoids in the donkey and the fact that the virion 
was found in a horse-derived lesion makes the observation somewhat incidental. 
However, the unique nature of this finding make it worthy of note. 
In contrast to the horse lesion, the tumours which were removed from the 
donkeys at The Donkey Sanctuary were advanced lesions, generally several 
months old. The diagnosis of the disease in the donkey is hindered by the coarse, 
thick hair coat of the animal and by the fact that the animals at The Sanctuary are 
kept under herd management and consequently do not receive detailed clinical 
examinations frequently. It should be noted that the horse from which virus was 
isolated was privately owned, receiving daily grooming, and, even under this 
husbandry, the early sarcoid was not noticed. Whilst it was not possible to estimate 
the age of all the lesions included in this study, it is interesting to speculate that 
intact virus is only present in the very early pathogenesis of the disease, and that 
the well advanced donkey tumours were beyond the stage of viral production. 
Given that papillomaviruses require the terminal differentiation of the maturing 
epidermis to complete the vegetative cycle, it is not surprising that virions were not 
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and Lowy, 1980; Lowy et aL, 1980), but do not release progeny viral particles as the 
late genes are not transcribed in these cells (Heilman, Engel, Lowy and Howley, 
1982). 
The findings in this chapter are not sufficient to conclude that the 
papillomavirus is the cause of the equine sarcoid. In order to establish an agent as 
causative, Koch postulated that: 
1) the agent must be found in all cases of the disease. 
2) the agent must be isolated from a diseased host and grown in pure culture. 
3) the agent must reproduce the disease when introduced to susceptible host. 
4) the agent must be found to be present in the experimental host thus infected. 
The isolation of virions from one lesion satisfies only partially the second postulate 
but the finding is further evidence implicating papillomaviruses in the aetiology of 
the disease. Although papillomaviruses have been detected in all types of cattle 
papillomas in this country (Jarrett, Campo, Moar, McNeil, Laird, O'Neil and 
Murphy, 1980), it has been shown that in the case of BPV-4 induced lesions neither 
virions nor viral nucleic acid were present in 68 of 70 lesions of the upper 
alimentary tract (Campo, Moar, Sartirana, Kennedy and Jarrett, 1985). It should 
also be noted that negative staining electron microscopy will detect virions at a 
minimum concentration of 108 particlesjml and it may be the case that virions 
were present in the tumours examined but at a lower concentration. Thus, the non-
detection of virion in the majority of tumours examined in this chapter is not 
necessarily a reason for excluding the papillomavirus as an aetiological candidate. 
The single isolate of virions described in this chapter provides a very small 
amount of material for future studies. Unfortunately, in order to study the 
biological properties of the virus particles in more detail and carry out 
transmission experiments a greater quantity of virus is required. The propagation 
of the virus remains a major constraint to research In vitro although the 
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Development of this technique and others, such as organotypic (raft) culture 
systems (Meyers and Laimins, 1992) may eventually allow propagation of sufficient 
virus for transmission studies. 
There were several reasons for suspending the virological investigations. 
First, all tumours from donkeys were negative for virus although this may have 
been due to the fact that the majority of the tumours from the donkeys were well 
advanced and had stopped producing virus. Secondly, the time consuming nature 
of the extraction of virions and, in particular, electron microscopic examination 
precluded the study being developed at the molecular level. Finally, the isolation 
of a papillomavirus from both papillomas (Fulton et aL, 1970; Q'Banion et aL, 
1986) and sarcoids does not distinguish between viral types or subtypes. It may be 
the case that the papillomavirus isolates of Q'Banion et aL (1986) and the present 
study are identical, but such a distinction requires analysis at the level of the viral 
nucleic acid. It was for these reasons that the rest of the project was dedicated to 
investigating the molecular biology of the sarcoid in the donkey. 
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CHAPTER V 
MOLECULAR INVESTIGATIONS: 
GENERAL MATERIALS AND METHODS 
CHAPTER V 
CHAPTER V 
MOLECULAR INVESTIGATIONS: 
GENERAL MATERIALS AND METHODS 
5.1. INTRODUCTION 
This chapter summarises the materials and methods used routinely during the 
molecular component of the project. Other, specialised procedures, used 
infrequently, are described in the appropriate sections in subsequent chapters. 
The techniques and procedures employed during the investigation are essentially 
as described by Sambrook, Fritsch and Maniatis (1989) and Davis, Dibner and 
Battey (1986). 
5.2. MATERIALS 
5.2.1. Chemicals 
All chemicals used In the molecular studies were of analaR, ultrapure or 
equivalent purity and were obtained from BDH Chemicals Ltd., Boehringer 
Mannheim Corporation, Gibco BRL, Pharmacia LKG and The Sigma Chemical 
Company except: 
Ampicillin Smithkline Beecham Ltd. 
Ecoscint International Diagnostics Inc. 
5.2.2. Radiochemicals 
[Alpha32P]dCTP for labelling of DNA probes and [alpha35S]dATP for DNA 
sequencing were obtained from Amersham International pIc. 
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5.2.3. Equipment 
Disposable plasticware 
Rybridisation membrane 
Autoradiograph film 
Filter paper 
5.2.4. Bacterial Strains 
Scotlab, Gibco BRL. 
Rybond N +, Amersham International pIc. 
Kodak XAR Omat. 
Whatman International Ltd. 
Cloning vectors were grown in Eschericia coli library efficiency DRS alpha 
competent cells (BRL), genotype F-, endA1, hsdR17 (rk-, mk +), supE44, thi-1, 
lambda-, recA1,mA96, relA1, delta(ru:gF-IacZYA)U169, phi80dlacZdeltaM1S. 
5.2.5. Cloning Vector 
The pIC-20R modification of the pUC plasmid described by Marsh, Erfle and 
Wykes (1984) was utilised during cloning procedures. The vector was kindly 
provided by K T. Smith. 
5.2.6. Restriction endonucleases 
All restriction endonucleases were obtained from Gibco BRL and were used with 
the appropriate reaction buffers. 
5.2.7. Other enzymes 
All enzymes were obtained from Gibco BRL, Boehringer Mannheim Corporation 
or The Sigma Chemical Corporation except: 
Klenow fragment: Amersham International pIc. in their Multiprime DNA 
labelling kit. 
T7 DNA polymerase: United States Biochemical Corporation in their Sequenaser 
version 2 DNA sequencing kit. 
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5.2.8. Antibiotics 
Ampicillin: 19 sodium ampicillin dissolved in 10ml distilled water and sterilised by 
filtration. 
5.2.9. ButTers and solutions 
DNA gel loading buffer (6x): 0.25% bromophenol blue dissolved in a 40% solution 
(w Iv) of sucrose in water. 
EDTA (O.5M, pH 8.0): 186.1g disodium ethylene diamine tetracetate.2H20 
dissolved in 800ml distilled water with addition of approximately 20g NaOH 
pellets until pH 8.0 and adjustment of volume to 11. Sterilised by autoclaving. 
Phenol (Equilibrated, neutral): 250g of redistilled phenol was melted at 680 C and 
extracted several times with equal volumes of 1M Tris HCI (pH 8.0) and then 
O.lM Tris-HCI (pH 8.0) until the aqueous phase was at a pH less than 7.6. Stored 
in aliquots at -200 C, protected from light. 
Phenol (Equilibrated, acid): Same as above, except that 50mM sodium acetate 
(pH 4.0) was used in place of Tris-HCI (pH 8.0). 
Plasmid-prep solution 1: 50 mM glucose, lOmM EDTA, 25mM Tris HCI (pH 8.0). 
Plasmid-prep solution 2: (Freshly prepared) O.2M NaOH, 1% SDS. 
Plasmid-prep solution 3: 60ml 5M potassium acetate, llml glacial acetic acid, 
28.5ml distilled water. This solution is 3M for potassium and 5M for acetate (pH 
4.8). 
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Sodium acetate (3M): 40S.1g sodium acetate.3H20 dissolved in SOO ml distilled 
water and pH adjusted to 5.2 by addition of glacial acetic acid. Volume adjusted 
to 11 and sterilised by autoclaving. 
NaCI (5M): 292.2g NaCI dissolved in SOOml distilled water, adjusted to 11 and 
sterilised by autoclaving. 
NaOH (10M): NaOH pellets disolved in SOOml distilled water adjusted to 11 and 
sterilised by autoclaving. 
SDS (20%): 200g sodium dodecyl sulphate made up to 11 with distilled water and 
sterilised by filtering. 
SSC (2Ox): 175.3g NaCI and SS.2g sodium citrate dissolved in SOOml distilled water, 
pH adjusted to pH 7.0 and volume adjusted to 11. Sterilised by autoclaving. 
TAB (5Ox): 242g Tris base, 57.1ml glacial acetic acid, 100ml 0.5M EDTA (pH S.O) 
made up to 11 with distilled water. 
TEE (lOx): lOSg Tris base, 5Sg boric acid, 40ml O.5M EDTA (pH S.O) made up to 
11 with distilled water and adjusted to pH S.3 and sterilised by autoclaving. 
TE: 10mM Tris HCI, 1mM EDTA and adjusted to appropriate pH. Sterilised by 
autoclaving. 
Tris (1M): 121g Tris base dissolved in SOOml distilled water and adjusted to 
appropriate pH with concentrated HCI. Volume adjusted to 11 and sterilised by 
autoclaving. 
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5.2.10. Bacterial growth media 
L agar: L broth containing 1.5% agarose sterilised by autoc1aving. 
LB medium (L broth): 109 bacto-tryptone, 5g yeast extract and 109 NaCI made up 
to 11 with distilled water and pH adjusted to pH 7.3 with NaOH. Sterilised by 
autoc1aving. Supplemented with ampicillin (50mg/ml), 2 per cent Xgal in DMF 
and O.lM IPTG (filter sterilised) 
SOC medium: 20g bacto-tryptone, 5g yeast extract, O.5g NaCI dissolved in 950ml 
distilled water and lOml of 250mM KCl solution added and pH adjusted to 7.0. 
Sterilised by autoc1aving after volume adjusted to 11. Just before use, 5ml sterile 
2M magnesium chloride solution and 20ml sterile 1M glucose solution were added. 
5.2.11. Hybridisation reagents 
Denhardt's solution (lOOx): 2% bovine serum albumin (fraction V), 2% ficoll, 2% 
polyvinylpyrrolidone in distilled water. Sterilised filtering and stored at -20°C. 
Salmon testes DNA: 19 dessicated salmon testis DNA dissolved in 100ml distilled 
water by stirring for 5 hours at room temperature. DNA was sheared by passage 
through a 20 guage needle 10 times and then by boiling for 10 minutes. Stored in 
1ml aliquots at -20°C. 
Hybridisation buffer (high stringency): For 11 of hybridisation buffer the following 
were combined: 500ml 50% formamide, 50ml 100x Denhardt's solution, 5ml 20% 
SDS, 50ml 1M Tris (pH 7.4), 20ml O.5M EDTA, 150ml 20x SSC, 200ml 50% 
dextran sulphate, 625ul salmon sperm DNA (10mg/ml). 
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5.3. METHODS 
5.3.1. Preparation of plasmid DNA. 
In order to produce large amounts of cloned papillomaviral DNA for restriction 
endonuclease analysis or for the production of bovine papillomaviral DNA probes, 
the pAT153 plasmids, containing BPV-2, 4 and 5 genomes were amplified by the 
two methods outlined below. 
5.3.1.1. Mini-preparation. 
This was a modification of the alkaline lysis method of Birnboim and Doly (1979). 
A single bacterial colony containing the required plasmid was inoculated into 5ml 
of L broth containing ampicillin (100ug/ml) and incubated with shaking at 370 C 
for 12 hours. The bacterial pellet was harvested after centrifugation at 2500g in a 
bench top centrifuge and any remaining supernatant aspirated. The pellet was 
resuspended in 100u1 of Plasmid-prep solution 1 and transferred to a 1.5ml 
micro centrifuge tube, being allowed to stand at room temperature for 5 minutes. 
200u1 of ice cold freshly prepared Plasmid-prep solution 2 was added and the tube 
vortexed briefly and incubated on ice for 5 minutes. 150ul of Plasmid-prep solution 
3 was then added and the tube incubated at 40 C for a further 5 minutes. Cell 
debris and precipitated SDS were pelleted by centrifugation at 14000g in an 
eppendorf centrifuge for 5 minutes and the supernatant transferred to a fresh tube. 
An equal volume of 1:1 v/v equilibrated SS-phenol/chloroform/isoamyl alcohol 
was added and the mixture vortexed and centrifuged as before. If the DNA was to 
be used for nucleotide base sequence analysis, this phenolj chloroform step was 
replaced by the addition of an equal volume of acid phenol and separate 
chloroform extraction. In both cases, the upper aqueous phase was removed and 
one tenth volume 5M sodium chloride solution or 3M sodium acetate solution 
added followed by two volumes of absolute alcohol. After 5 minutes on dry ice the 
precipitated DNA was pelleted by centrifugation at 14000g. The supernatant was 
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pellet was dried at 370 C for 15 minutes and resuspended in 50u1 of TE containing 
50ug/ml DNAase-free pancreatic RNAase. 
5.3.1.2 Large scale preparation 
The use of the large scale preparation was largely superseded by the reliable 
miniprep method described above but in order to produce large amounts of bovine 
papillomaviral DNA probes several large scale preparations were performed in the 
early period of the project. The procedure was a modified version (HettIe, 1985) 
of the alkaline lysis described by Sambrook et at. (1989). A single bacterial colony 
containing the plasmid of interest was inoculated into 200ml L broth containing 
ampicillin (lDOuljml). The bacterial pellet was harvested by centrifugation in a 
250ml polycarbonate flask at 40 C in a Beckman JS-7.5 rotor at 10000g for 15 
minutes. The supernatant was discarded and the pellet resuspended in 10ml 
Plasmid-prep solution 1 and transferred to a polypropylene tube. Twenty ml of 
freshly prepared Plasmid-prep solution 2 were added and the contents of the tube 
mixed gently by inverting several times. After a 15 minute incubation, 15ml of ice-
cold Plasmid-prep solution 3 was added and the tube shaken gently. The bacterial 
debris was then pelleted by centrifugation at 4000g at 40 C for 15 minutes and the 
supernatant filtered through several sterile tissues and 0.6 volumes of isopropanol 
added. The contents of the tube were mixed thoroughly, incubated at room 
temperature for 10 minutes and centrifuged at 5000g for 15 minutes in a Sorvall 
GS3 centrifuge. The pelle ted nucleic acids were air dried, rinsed briefly in 70 per 
cent ethanol and resuspended in 3ml TE (pH 8.0). 
5.3.2. Purification of closed circular DNA by equilibrium centrifugation in 
caesium chloride-ethidium bromide gradient. 
The volume of the DNA solution containing the plasmid DNA was measured and 
1 ml of solid caesium chloride added. For every lDml of the resulting solution. 
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clear pink solution from the centrifugate was transferred to Beckman Quick-Seal 
tubes and the remainder of the tubes filled with light paraffin oil. The gradients 
were then centrifuged at 40000g for 36 hours at 200 e in a Beckman Ti65 rotor 
after which the lower band visible in the body of the gradient was removed using a 
syringe and 21-guage needle. The ethidium bromide was then removed from this 
fraction of closed circular plasmid DNA by several extractions with I-butanol 
saturated with water. The caesium chloride was removed by. the addition of two 
volumes of water and the DNA precipitated by the addition of two volumes of 
ethanol. The DNA was recovered by centrifugation at 10000g for 15 minutes at 
40e in a bench top microcentrifuge. 
5.3.3. Extraction of Genomic DNA from tumour sections 
Approximately 5g of freshly dissected tumour or snap frozen tissue were dissected 
finely with scalpel and forceps. The tissue was then suspended in approximately 
10ml PBS (pH 7.4) to which was added Iml of 10 per cent SDS and llmg 
proteinase K powder. The mixture was then incubated at 370 e for 4 hours after 
which time a further Ilmg proteinase K was added. The mixture was incubated for 
a further 12 hours at 370e with gentle agitation. The solution was clarified by brief 
centrifugation on a bench top centrifuge, the supernatant collected and one tenth 
volume of 3M sodium acetate solution added. The aqueous phase was then 
extracted twice with SS-phenol:chloroform: isoamyl alcohol (10:10:1) and once 
with diethyl ether. The nucleic acids were precipitated by the addition of 2.5 
volumes of absolute ethanol and removed by spooling out on a sealed pasteur 
pipette. Following a brief wash in 70 per cent ethanol, the nucleic acids were 
resuspended in 3ml TE buffer containing 50ugjml DNAase-free pancreatic 
RNAase to remove any residual RNA. 
5.3.4. Agarose gel electrophoresis 
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1x TAE. The running buffer was either Ix TBE or Ix TAE depending upon which 
of the buffers had been used to cast the gel. Each sample of DNA was mixed with 
a 0.2 volumes of gel loading buffer. If genomic DNA was being electrophoresed 
following restriction endonuclease digestion, the sample was heated to 650 C for 10 
minutes in order to to disrupt hydrogen bonds between molecules with compatible 
cohesive termini. Electrophoresis was carried out at approximately 5V / cm, usually 
overnight. Following electrophoresis the DNA was stained by the addition of 
0.5ug/ml ethidium bromide to the gel running buffer for 45 minutes. The gel was 
destained by washing in distilled water for 45 minutes. The stained DNA was 
visualised by viewing the gel under long wave ultraviolet light on a 
transilluminator. (Vilbour Lourmat, 3I2nm wavelength output). The gel was 
photographed using Polaroid type 57 high-speed film on the Polaroid MP-4 
camera system. On all gels the size markers used were the Hindill digest of 
bacteriophage lambda genomic DNA. When a rapid result was required a minigel 
apparatus was used to run the agarose gel, allowing a potential of 20V / em to be 
applied for 30 to 40 minutes. Ethidium bromide was not routinely added to the gel 
at casting as the relative mobilities of supercoiled, circular and linear DNA are 
altered by the intercalation of the dye with the DNA molecules. 
5.3.5. Extraction of DNA from low melting point agarose gels 
Preparation of the LMP agarose gels and DNA samples was carried out as 
described in section 5.3.4. The DNA fragment of interest was visualised by brief 
exposure to ultraviolet light and the section of agarose removed using a scalpel 
and transferred to a micro centrifuge tube. The agarose was then melted by 
incubation at 650 C for 10 minutes and two volumes of TBE added. The diluted 
sample was allowed to cool in a waterbath at 370 C and an equal volume of 
equilibrated phenol was then added. The mixture was vortexed and the aqueous 
phase collected after centrifugation at I4000g for 5 minutes. The sample was 
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5.3.6. Southern blotting 
The alkaline transfer modification of the capillary transfer described by Southern 
(1975) was used for all blotting procedures. This technique allows rapid transfer of 
nucleic acids as the alkaline transfer medium neutralises, hydrolyses and finally 
covalently binds the DNA to the nylon membrane. It has the disadvantage of 
having higher background than other methods during subsequent hybridisation 
experiments. Following agarose gel electrophoresis, staining and photography, the 
gel was washed gently in 0.25M HCI for 20 minutes in order to depurinate the 
DNA. The gel was then transferred briefly to distilled water before being placed 
on a wick of 3MM Whatman paper on a solid support. The wick had been 
previously soaked in O.4M NaOH. A precut piece of positively charged nylon 
membrane the same size as the gel was then laid on top of the gel and was covered 
in turn by a layer of 3MM Whatman paper. Paper towels were then stacked on top 
of the assembly and light pressure applied with a 1kg weight. Approximately 500ml 
O.4M NaOH was then added to the reservoir below the wick and the capillary 
transfer of the nucleic acids allowed to proceed for a maximum time of 5 hours. 
The paper towels were changed after 2 hours. The apparatus was dismantled and 
the nylon membrane washed briefly in 2xSSC and then air dried. 
5.3.7. Pre-hybridisation 
The filter was laid flat in a heat sealable plastic bag and the bag double sealed on 
three sides. A 625ul aliquot of salmon sperm DNA was heated to lOOoC for 5 
minutes, chilled on ice for a further 5 minutes and then added to 25ml of 
hybridisation buffer preheated to 370 C. The mixture was then added to the plastic 
bag and, after excluding all air bubbles, was double-sealed along the remaining 
edge. The bag was then placed in a plastic sandwich box and placed in a rocking 
waterbath at 420 C. Prehybridisation carried out for 4 to 16 hours. 
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5.3.8. Hybridisation 
The prelabelled probe was thawed and the required volume aliquoted into a 
screw-top eppendorf. The volume was calculated by the following formula: 
Volume = 25 x [(No x e-kt)/1()6] 
where No is the counts per minute of luI of the probe 
k is a constant 
t is the number of days since the cpm were measured. 
This formula gives the volume of probe required for addition to 25ml hybridisation 
buffer sufficient to produce an activity of lx106 cpm/ml. The probe was then 
heated to 1000C for 5 minutes, chilled on ice for a further 5 minutes and injected 
into the bag containing the hybridisation buffer using a 1ml syringe and a 1 inch 21 
guage needle. The hole created by the needle was double sealed using a bag 
sealer. Hybridisation was carried out for 16 hours at 420C. 
5.3.9. Washing the filters 
Although the equation regarding stringency of hybridisation (Meinkoth and Wahl, 
1984) which states that, 
Tm= 81.50C + 16.610gM + 0.41(%G+C) - 500/L - 0.61(%formamide) 
Where, T m = melting temperature 
M = molarity of the hybridisation solution 
L= probe length 
was taken into consideration, it was not found to be particularly useful because 
random priming produces probes of varying lengths and the G/C content of the 
target and the degree of homology was unknown at the outset of the project. Two 
different stringencies were used for the washing of the membranes following 
hybridisation. In a low stringency wash, the membranes were washed twice for 20 
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washed twice for ZO minutes at 4Zoe in Zx sse, 0.1 per cent SDS and twice for 30 
minutes at 650 e in O.5x sse, 0.1 per cent SDS. In both cases, the blots were then 
monitored for radioactive emissions with hand-held Geiger-counter and the 
washes repeated until the level of activity was less than Zcpm. The excess fluid was 
then blotted off the membranes which were then wrapped in Saran wrap before 
autoradiography. 
5.3.10. Preparation and purification of synthetic oligonucleotides 
Oligonucleotides 15 nucleotides in length were synthesised using an Applied 
Biosystems 381A DNA synthesiser. The 5' methoxy trityl protecting group was 
removed after the incorporation of the last (5') nucleotide. The oligonucleotides 
were eluted from the synthesis column by the gradual introduction of Zml 30 per 
cent ammonia solution, 0.Z5ml ammonia solution being introduced to the cartridge 
every 30 minutes, passing from one Zml syringe to another. After elution was 
complete the solution was transferred to a screw top micro centrifuge tube and 
incubated at 550 e overnight in order to remove the side-chain protecting groups. 
The oligonucleotide was precipitated as described for other types of DNA and 
quantified by spectrophotometry using the formula: 
O.D.Z60 x Dilution factor x ZO = DNA concentration (ugjml). 
5.3.11. Restriction endonuclease digestions 
A number of different restriction endonucleases (REs) were used in the 
preparation and characterisation of the cloned and genomic DNA. In the case of 
the plasmid DNA, 1 to Zug of plasmid DNA were digested in a total reaction 
volume of ZOuL When digesting genomic DNA, 5 to lOug was incubated with the 
RE in a total volume of SOUl. Restriction enzymes were used at a concentration of 
3 units per lug of substrate DNA. RE digestions were carried out at 370 e for 2 
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5.3.12. 32p radio-labelling of dsDNA. 
This was carried out with the Multiprime labelling kit obtained from Amersham 
International pIc. The method was first described by Feinberg and Vogelstein 
(1983) utilising random sequence hexanucleotides to prime DNA synthesis from a 
denatured DNA template. Synthesis of the DNA was carried out employing 
[alpha32P]dCTP and unlabelled dATP, dGTP, dTIP. The Klenow fragment of E. 
coli DNA polymerase was used to catalyse the reaction and as this enzyme lacks S' 
to 3' exonuclease activity, the product was not degraded once synthesised. Twenty-
five ng of DNA in 2Sul water was heated to 980 C for S minutes and placed on ice. 
Ten ul of Multiprime buffer containing the unlabelled nucleotides, in a buffer of 
Tris HCI (pH 7.8) magnesium chloride and 2-betamercaptoethanol, were added as 
well as Sui of primer, an aqueous solution of random hexanucleotides containing 
nuclease free bovine serum. Eight ul of [alpha32P]dCTP (800Ci/mmol, 1 OuCijul) , 
observing the normal precautions and working in a dedicated area were added 
followed by 2 units of Klenow fragment and the reaction incubated at room 
temperature overnight. The unincorporated label was removed from the labelled 
oligonucleotides by chromatography through a lScm column of Sephadex G-SO. 
This procedure provided approximately SOOuI of probe of activity 1.0 - S.O x 
lOS cpm/ul. The precise activity was measured by adding 2ul of probe to Sml 
Ecoscint and measuring the activity on a Beckman liquid scintillation counter. The 
amount of solution required for anyone hybridisation was calculated as outlined 
in section S.3.8. Probes were heated to 980 C and chilled on ice before being used 
in hybridisation procedures. 
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DETECTION, CLONING AND CHARACTERISATION 
OF PAPILLOMA VIRAL DNA PRESENT 
IN SARCOID TUMOURS 
6.1. INTRODUCTION 
Despite the fact that there have been no previous reports of the isolation of 
papillomavirus virions from equine sarcoids, several groups have detected 
papillomaviral DNA in the tumours (Lancaster et ai., 1977; Lancaster et aL, 1979; 
Amtmann et ai., 1980; Lancaster, 1981; Trenfield et ai., 1985; Angelos, 1990; 
Angelos et ai., 1991). The majority of these studies have been conducted on the 
sarcoids of the horse although there is one report of papillomaviral DNA in a 
sarcoid tumour from a donkey (Amtmann et ai.,1980). The characterisation of the 
DNA detected in the tumours has been carried out to an elementary level by 
restriction endonuclease digestion of tumour genomic DNA, but there has been no 
report of the molecular cloning of any of the papillomaviral elements. The 
evidence from both liquid phase and Southern blotjhybridisation experiments 
points to the fact that the papillomaviral genomes involved are very closely related 
to BPV-1 or 2. Australian workers (Trenfield et ai., 1985) isolated DNA 
homologous at low stringency to BPV-1 and 2 but demonstrated a variety of 
restriction fragment patterns, whilst Angelos (1990) demonstrated BPV-1-like and 
BPV-2-like DNA in sarcoids from Switzerland and the United States. In contrast to 
the work on the sarcoid, Q'Banion et ai. (1986) described the cloning and 
characterisation of a papillomaviral genome extracted from the lesions of a horse 
with juvenile contagious papillomatosis, a disease clinically and pathologically 
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humans and cattle. 
Prior to the advent of the polymerase chain reaction (Chapter VII) the 
molecular cloning of papillomaviral DNA was pre-requisite to the complete 
analysis of the viral genome by restriction endonuclease cleavage and nucleotide 
base sequence determinations. This chapter describes three aspects of the 
molecular biological investigations into sarcoids in the donkey: The detection of 
papillomaviral DNA in the genomic DNA extracted from donkey sarcoids and 
demonstration of a variety of restriction endonuclease cleavage patterns; the 
molecular cloning of a papillomaviral element into plasmid pIC-20H and 
restriction endonuclease analysis of the clone; the determination of the nucleotide 
base sequence of two regions of the cloned papillomaviral DNA 
6.2. MATERIALS AND METHODS 
6.2.1. Probing of sarcoid derived DNA for the presence of papillomaviral DNA 
The genomic DNA was extracted from the snap-frozen sarcoid tumours as 
described in Section 5.3.3 .. Ten ug of this DNA was then digested with Hindm, 
BamHI and KpnI restriction endonucleases as described previously (Section 
5.3.11.). Agarose gel electrophoresis, photography, Southern blotting, hybridisation 
to full-length molecularly cloned BPV-2, BPV-5 and BPV-4 genomes and 
autoradiography were performed exactly as described in the previous chapter. 
6.2.2. Molecular cloning of a papillomaviral element extracted from sarcoid Dolb 
6.221. Dephosphorylation of the plasmid vector 
Five ug of plasmid pIC-20H were digested with HindIII in 20u1 at 370 C for 60 
minutes, linearising the DNA at the unique HindIII site. In order to prevent 
religation of the compatible ends, the 5' phosphate was removed by incubation 
with luI alkaline phosphatase (3U luI) in 24ul water and 5ul alkaline phosphatase 
buffer (O.5M Tris (pH 9.0), 10mM magnesium chloride, 1mM zinc chloride) at 
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6.2.2.2. Isolation and ligation ofinsert 
A HindUI digest of 5ug of the sarcoid-derived genomic DNA from sarcoid Do1b 
of donkey 3590 was electrophoresed through a O.B per cent LMP agarose gel. The 
fragments of approximately Bkbp in size were cut from the gel after visualistion by 
staining with ethidium bromide. The DNA was recovered from the LMP gel as 
described (Section 5.3.5.), precipitated with ethanol and resuspended in TE buffer 
(pH B.O). The concentration of the DNA solution was estimated by measuring the 
OD260/2BO ratio and adjusted to 150ng/ul. Two ul (300ng) of this DNA was then 
combined with luI (lOOng/ul) of the prepared plasmid pIC-20H, luI T4 DNA 
ligase, 2ullOX ligase buffer and 14ul water. The ligation reaction was incubated at 
140 C overnight and the success of the ligation checked by agarose gel 
electrophoresis. 
6.2.2.3. Transfection of competent cells 
Library efficiency DH5alpha cells prepared by BRL's modification of Hanahan's 
procedure were used to produce a library of HindIII digest of sarcoid derived 
DNA. The phi BOlacZdeltaM15 marker provides alpha-complementation of the 
beta-galactosidase gene from pUC derived vectors and was used to produce 
blue/white screening of colonies on bacterial plates containing X-gal. A lOOuI 
volume of competent cells were aliquoted from a purchased stock into a chilled 
polypropylene tube (Falcon 2059). The DNA from the ligation reaction was 
diluted fivefold in TE (pH 7.5) and 1-5ul of the dilution (1-10ng) were added to the 
cells which were then incubated on ice for 30 minutes. The cells were heat shocked 
for 45 seconds at 420 C and returned to ice for a further 2 minutes. After the 
addition of 0.9ml SOC at room temperature the cells were incubated at 370 C and 
shaken at 225rpm for 1 hour. Approximately 150ul of the reaction mixture was 
spread onto L broth/agar plates containing 50mg/ml ampicillin, 2 per cent Xgal in 
DMF and O.lM IPTG. The plates were incubated at 370 C overnight in an inverted 
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6.224. Screening of transfected bacterial colonies 
The efficiency of the transfection was assessed by the number white colonies 
produced after overnight incubation, demonstrating that the plasmids containing 
the inserts were failing to complement the alpha-complementing E. coli. However, 
in order to identify the plasmids containing papillomaviral DNA, the colonies were 
screened by hybridisation to molecularly cloned BPV-2 genome, in a manner 
similar to that outlined in Sections 5.3.7. and 5.3.8.. A circular piece of dry 
nitrocellulose was laid on top of the colonies and marked eccentrically with 
pinholes to facilitate relocation after hybridisation. When wetted, the filter was 
then floated on a solution of O.5M sodium hydroxide, colony side up, for 5 minutes 
followed by flotation on a solution of 1.5M sodium chloride with O.5M Tris (pH 
7.4). Finally, the filter was laid gently on a solution of 105M sodium chloride and 2x 
SSC for 5 minutes before drying at 800 C under vacuum. The pre-hybridisation and 
hybridisation procedures were then identical to those used for any other filter and, 
after autoradiography, the positive colonies were identified by placing the bacterial 
plate over the radiographic film. Positive colonies were picked on a sterile loop 
and grown in L broth as described in Section 5.3.1. prior to RE analysis or 
nucleotide base sequence determination. One ug aliquots of the cloned 
papillomaviral DNA were digested with HindIll, BamHI, EcoRI, KpnI, SmaI, Sst! 
and XbaI in order to characterise the cloned genome. Agarose gel electrophoresis, 
Southern transfer and hybridisation to molecularly cloned BPV-2 were performed 
as described previously in Chapter V. The genomic organisation of the clone was 
then compared to that of BPV-1 and BPV-2 (Lancaster, 1979; Engel, Heilman and 
Howley, 1983) 
6.2.3. Nucleotide sequence analysis of molecularly cloned papillomaviral element 
6.23.1. Introduction 
All nucleotide se uence anal sis was erformed on alkali denatured double-
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obtained from such templates, obviating the need for production of single stranded 
DNA templates. In order to obtain good sequence data, the DNA templates must 
be of high quality. The first sequencing experiments in this project were performed 
on plasmid DNA purified by the equilibrium centrifugation in caesium 
chloridejethidium bromide gradients. The source of template DNA was replaced 
by that purified by acid-phenol minipreparation of plasmid DNA as it was found 
that the results from this source were of equal or better quality than that from the 
caesium chloride gradient purification. In contrast to the acid equilibrated phenol, 
Tris equilibrated phenol was found to be unsuitable for the purification of plasmid 
for use in sequencing reactions. Of the available modern 17 DNA polymerases, the 
genetically engineered Sequenase Version 2.0 (US Biochemical Corporation) was 
used, having a lower 3' to 5' exonuclease activity and higher processivity than the 
native enzyme and, in order to use the high processivity to best advantage, the 
sequencing reaction was divided into two stages. In the first, low concentrations of 
the dNTPs and a low incubation temperature (room temperature) ensured the 
efficient incorporation of the single radiolabelled dNTP at the same time as 
limiting DNA synthesis. In the second stage, the mixture was divided into the four 
standard reactions each containing high concentrations of one of the four dNTPs 
and a single dideoxy NTP in order to terminate the polymerisation. The Sequenase 
Version 2.0 sequencing kit (US Biochemical Corporation) and manufacturers 
protocol were used and the cloning vector was pIC-20H as described in Sections 
5.2.5 .. Two primers were used; one was the Universal M13 primer, the other a 
custom-synthesised 15mer selected from the E5 ORF of BPV-l. 
6.23.2 Production of single stranded template. 
Three to 5ug of pIC-20H DNA containing the papillomaviral element from sarcoid 
Dolb of donkey 3590 and purified by acid-phenol minipreparation were incubated 
with 0.2M NaOH and 2mM EDTA for 30 minutes at 37oC. The mixture was 
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resuspended in 7ul of distilled water. 
6.2.3.3. Annealing template and primer. 
A lOuI reaction volume, comprising luI universal M13 pnmer or custom-
synthesised primer, 2ul reaction buffer and 7ul (lug) of DNA, was heated to 650 e 
for 2 minutes and then cooled slowly to room temperature allowing the primer to 
anneal to the template. The annealed template and primer were placed on ice 
after the temperature had fallen below 30oC. 
6.2.3.4. Labelling reaction 
The labelling mix supplied with the kit containing dGTP, deTP and dTTP was 
diluted five-fold with distilled water and the Sequenase enzyme diluted seven-fold 
with ice-cold enzyme dilution buffer. The annealed template-primer mix was then 
placed on ice and luI O.lM DTI, 2.0u1 diluted labelling mix O.5ul [alpha-35S]dATP 
and 2.0u1 diluted Sequenase enzyme added and the mixture incubated at room 
temperature for 5 minutes. 
6.2.3.5. Termination reaction 
Four 500u1 tubes were labelled G, A, T and e and 2.5ul of the appropriate 
termination mix added to each tube. The ddNTPs contained in these mixes lacked 
the 3'-OH group necessary for DNA chain elongation and thus terminated the 
reaction. The tubes were heated to 370 e for 1 minute after which time 3.5ul of the 
labelling reaction mixture was transferred to the corresponding tube. The mixtures 
were incubated for a further 5 minutes and then 4ul of stop solution added to each 
tube. The reactions were then stored at -200 e for up to one week. 
6.2.3.6. Denaturing gel electrophoresis 
The two glass plates of a customised sequencing rig were cleaned with alcohol and 
then coated on the inner surfaces with 5 per cent dichloromethyl silane in 
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sides with waterproof plastic tape. The denaturing PAGE gel mix containing 23ml 
30 per cent acrylamide, SOg urea, 10ml lOxTEE, distilled water to 100ml, 333ul 10 
per cent ammonium persulphate and 83ul TEMED was then introduced between 
the plates using a SOml syringe and avoiding the introduction of air bubbles. A 
comb was then inserted and the gel left to polymerise for 4 to 12 hours. Once 
polymerised, the tape was removed from the bottom edge of the gel assembly, 
which was then clamped in position between the upper and lower buffer chambers 
of the electrophoresis celL Sufficient O.5x TEE was added to ensure that the 
electrodes were covered and the comb was removed carefully from the geL The 
wells were washed out gently by syringing buffer into them in order to remove any 
unpolymerised acrylamide and bubbles trapped on the bottom edge of the gel 
assembly were dislodged. The apparatus was sealed in a safety cabinet, connected 
to a high voltage power supply and the gel was run at appoximately SOW constant 
power. This setting depended upon the individual gel mixture and buffer strength 
but at no time was the current allowed to exceed 2SmA because the heat generated 
at currents in excess of this cracked the glass plates. The gel was pre-run for 
approximately 30 minutes before flushing the wells and loading the 2ul of each 
sequencing reaction mixture which had been heated to 9SoC immediately prior to 
electrophoresis. The gel was run for two to six hours or until the xylene cyanol had 
migrated approximately 60cm. 
Following electrophoresis the gel assembly was dismantled and the gel 
soaked in 21 of ten per cent acetic acid and 12 per cent methanol in order to 
remove the urea. The gel was transferred to a sheet of 3MM Whatman paper, 
covered in cling film and dried under vacuum at 800 C for 2 hours on a Biorad 853 
gel drier. The dried gel was exposed to Kodak XAR-Omat film at room 
temperature for between 24 and 48 hours. The sequence was analysed and 
compared to the published sequences of characterised papillomaviruses using the 
BESTFIT programme of the GCG sequence analysis software (University of 
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6.3. RESULTS 
6.3.1. Detection and partial characterisation of papillomaviral DNA 
Eighteen sarcoids, one melanoma, one mass of granulation tissue and one sample 
of normal donkey skin were assayed for the presence of papillomaviral DNA by 
Southern blot and hybridisation of HindUI digests of the extracted DNA to 
molecularly cloned full-length genomes of BPV-2, 4 and 5. The identity of each 
tissue sample was confirmed by microscopic examination of formalin-fIxed 
paraffin-embedded tissue sections stained with haematoxylin and eosin and the 
results are summarised in Table 24, together with the results of the further analysis 
of 15 of the sarcoids. All of the sarcoids contained DNA which hybridised to 
molecularly cloned full-length BPV-2, under stringent conditions, and was 
generally present in three forms; linear, open circle and supercoiled DNA (Figure 
15). The DNA in the sarcoid samples did not hybridise to either BPV-4 or BPV-5 
DNA probes at high or low stringency nor was there any DNA which hybridised to 
BPV-2 DNA in that extracted from the melanoma, the granulation tissue or the 
normal donkey skin. 
Fifteen of the DNA samples extracted from the sarcoid tumours were 
subjected to further restriction endonuclease analysis using BamHI and KpnI REs 
and the results of these digests are also summarised in Table 24. Three different 
RE cleavage patterns were obtained: Three of the tumours contained 
papillomaviral DNA identical in size and RE cleavage pattern to BPV-l; three 
tumours contained DNA identical in size and RE cleavage pattern to BPV-2; nine 
tumours contained DNA identical in size to BPV-l and 2 but had a RE cleavage 
pattern similar to both, but identical to neither, BPV -1 or 2. This third isolate was 
approximately 8kbp in length with single HindUI and BamHI sites. The isolate also 
had two KpnI sites yielding two fragments approximately 4250 and 3750bp in size. 
There did not appear to be any correlation between the type of papillomaviral 
DNA and the clinical type and anatomical location of the lesion, nor with the sex 
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Table 24. Summary of the screening of donkey sarcoids for papillomaviral DNA after restriction 
endonuclease digestion, agarose gel electrophoresis, Southern blotting and hybridisation to full-length 
molecularly cloned BPV-2 genome. 
Donkey Sex Sarcoid Sarcoid Anatomical RE digest: No. of fragments DNA 
No. Type Site HindIII Bam HI KpnI Identity 
3590 Male Do1a IIU Penis 1 1 1 BPV-1 
514 Female Do15 IIU Abdomen 1 1 1 BPV-1 
W77 Male 006 IIU Abdomen 1 1 1 BPV-1 
3075 Female 0016 III Nostril 1 2 2 equal BPV-2 
3037 Male Do17 III Brisket 1 2 2 equal BPV-2 
2515 Male 0018 I Periocular 1 2 2 equal BPV-2 
3590 Male Do1d II Prepuce 1 1 2 Novel 
3590 Male Do1b III Stifle 1 1 2 Novel 
W87 Male 0012 II Penis 1 1 2 Novel 
876 Female 0013 II Abdomen 1 1 2 Novel 
R2 Male D03b I Lips (head) 1 1 2 Novel 
R2 Male D03a II Prepuce 1 1 2 Novel 
3459 Male D09a II Prepuce 1 1 2 Novel 
2529 Male Do14a III Prepuce 1 1 2 Novel 
2529 Male Do14b II Abdomen 1 1 2 Novel 
2428 Female Do15 IIIU Periocular 1 N/A N/A PV 
3675 Male Do16 I Lips(head) 1 N/A N/A PV 
1708 Female DolOc II Chin 1 N/A N/A PV 
2529 Male NS2 granulation Abdomen 0 N/A N/A None 
tissue 
3590 Male NS1 nonnal Scrotum 0 N/A N/A None 
skin 
3472 Female D05 melanoma Vulva 0 N/A N/A None 
RE; restriction endonuclease 
U ; Ulcerated 
PV; papillomaviral DNA 
N/A; Not assayed 
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Figure 15. Autoradiograph after Southern blot and hybridisation showing viral DNA detected in 
sarcoid tumours from two donkeys and comparison to cloned BPV-2 genome following restriction 
endonuclease digestion. NR, undigested DNA; B, DNA digested with BamHI, E, DNA digested with 
EcoRI, H, DNA digested with HindIII. Hybridisation was to molecularly cloned BPV-2 DNA. EcoRI 
was found to produce inconsistent results when used to digest high molecular weight DNA and was 
only used in pilot screening hybridisations being replaced by Kpnl. In the majority of samples relaxed 
circle (ll) and linear (ill) forms of the viral DNA were present. The supercoiled (I) form is not 
evident on this autoradiograph. 
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6.3.2. Molecular cloning and characteristion of a papiIlomaviral element from 
tumour Dolb. 
One of the novel isolates, identified by the RE digests of DNA from sarcoid D01b, 
was molecularly cloned into the unique HindIII site in the vector pIC-20H as 
described above. The RE digests using two REs were carried out on mini-
preparations of the resulting plasmid DNA, assigned pDOPVIC20H.' The plasmid 
was digested with HindIII yielding a linearised vector, approximately 2.7kbp in 
size, and the linearised insert, DoPV, approximately 8kbp in size (Figure 16). The 
DoPV insert was then analysed further using BamHI, EcoRI, KpnI, SmaI, SstI and 
XbaI REs. The nature of the DNA visualised after agarose gel electrophoresis was 
confirmed by Southern blotting and hybridisation to full-length molecularly cloned 
BPV-2 genome. The BPV-2 probe did not hybridise to the plasmid DNA as there 
was no 2.7kbp band visible following autoradiography. The results of the RE 
digests are summarised in Tables 25 and 26 and in Figure 16. It appeared that the 
DoPV shared RE sites with both BPV-1 and BPV-2: Like both BPV-1 and 2, 
DoPV had a single HindIII site; like BPV-1, DoPV had single BamHI, EcoRI and 
SmaI sites and lacked an SstI site; like BPV-2, DoPV had two KpnI sites but the 
fragments were of different sizes (4250bp and 3750bp); unlike BPV-1 or 2, DoPV 
had no XbaI site. 
6.3.3. Nucleotide base sequence analysis of DoPV 
The results of the nucleotide base sequence analysis indicated that the DoPV was 
practically identical to BPV-1 in both the L1 ORF and the E5 ORF (Figure 17). 
Comparison of the DoPV genome with BPV-1 by BESTFIT local homology (GCG 
sequence analysis software) indicated that in the L1, the per cent identity, or 
homology, was 95.6 per cent with four gaps and, in the E5 ORF, the homology was 
98.0 per cent, with no gaps. A similar comparison of DoPV with BPV-2 revealed a 
83.9 and 89.8 per cent homology in the L1 and E5 sequences of the two viruses, 
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and 89.8 per cent homology in the Ll and E5, respectively, thus demonstrating that 
the DoPV sequences had greater homology with BPV-l than does BPV-2. 
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Figure 16. Agarose gel after staining with ethidium bromide solution and transillumination with 
UV light (320nm) showing the results of the restriction endonuclease digestion of the cloned 
papillomaviral element, pDoVIC_20H' after electrophoresis. The lanes contained lug of the cloned 
DNA digested with HindIII alone or HindIII followed by the restriction endonuclease ascribed. The 
lane labelled "_- II contained undigested pDoVIC_20H' The molecular weight marker used was a 
Hinclm cliue!':t of lamda hacterionhal!e DNA. The arrow marks the plasmid vector DNA. A fourth 
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Table 25. Characterisation of the papillomaviral element (DoPV), isolated from sarcoid Dolb, by a 
single restriction endonuclease digestion, showing the number of cleavage sites and approximate 
fragment sizes (bp) with the corresponding results from the digestion of BPV -1 and BPV -2 genomes. 
RE DoPV BPV-l BPV-2 
digest No. of Fragment No. of Fragment No. of Fragment 
sites sizes sites sizes sites sizes 
HindIII 1 8000 1 7945 1 7937 
Bam HI 1 8000 1 7945 3 5879,2031,27 
EeoRI 1 8000 1 7945 0 
KpnI 2 4250,3750 1 7945 2 3998,3939 
SmaI 1 8000 1 7945 0 
SstI 0 0 1 7937 
XbaI 0 1 7945 1 7937 
Table 26. Characterisation of the papillomaviral element (DoPV), isolated from sarcoid Dolb, by 
double restriction endonuclease digestion showing the number of cleavage sites and approximate 
fragment sizes (bp) with the corresponding results from the digestion of BPV-l and BPV-2 genomes. 
RE digest DoPV BPV-l BPV-2 
HindIII + No. of Fragment No. of Fragment No. of Fragment 
sites SIZes sites sizes sites SIZeS 
Bam HI 2 5600,2400 2 5437,2508 4 5272,2031,607,27 
EeoRI 2 3300,4700 2 3100,4845 1 7937 
KpnI 3 3750,3550,700 2 4446,3499 3 3939,3633,365 
SmaI 2 6200,1800 2 6011,1934 1 7937 
Sst! 1 8000 1 7945 2 5726,2211 
XhaI 1 MOO 7 
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LIORF 
6970 6980 6990 7000 
DoPV ••• TTCTTTG GACTTAGATC AATTTCCCTT GGAAGAAGA TTTTTAGCAC 
.. ·1111111 1111111111 1111111111 II 111111 1111111111 
BPV' ••• ttctttg gacttagatc aatttccctt gggagaaga tttttagcac 
7010 7020 7030 7040 7050 
DoPV AGCAAGGGGC AGGATGTTCA AC.GTGTAGA AACGAAGAAT TAGCC •• AAA 
1111111111 1111111111 II III I 1111111111 11111 III 
BPV' agcaaggggc aggatgttca actgtgagaa aacgaagaat tagccaaaaa 
7060 7070 7080 
DoPV ACTT •• AGTA AGTCCGCAAA AAA ••• 
1111 1111 II I 11111 III 
BPV1 acttccagta agcctgcaaa aaa ••• 
E50RF 
3910 3920 3930 3940 3950 
DoPV ••••• TTGGG ACTAGTTGCT GCAATGCAAG TGCTGCTGTT ACTGTTCTTA CTCTTGTTTT 
11111 1111111111 111111111 1111111 II 1111111111 1111111111 
BPV1 ••••• ttggg actagttgct gcaatgcaac tgctgctatt actgttctta ctcttgtttt 
3960 3970 3980 3990 4000 
DoPV TTCTTGTATA CTGGGATCAT TTTGAGTGCT CCTGTACAGG TCT ••• 
1111111111 1111111111 1111111111 1111111111 III 
BPV1 ttcttgtata ctgggatcat tttgagtgct cctgtacagg tct ••• 
Figure 17. Nucleotide base sequences of the papillomaviral element DoPV in upper case and 
BPV-l in lower case. The DoPV was extracted from sarcoid Dolb and cloned into pIC-20H at the 
unique HindIII site. Sequencing was carried out utilising the Sequenaser kit (US Biochmeical 
Corporation), with Universal M13 primer for the L1 open reading frame (ORP) segment close to the 
cloning site and custom-synthesised BPV-1 oligonucleotide sequences for the E5 ORF segment. The 
sequencing reactions were the adapted dideoxy method of Chen and Seeberg (1985) on double-
stranded DNA produced by acid-phenol minipreparation. The comparison to BPV-1 illustrated was 
enerated b em 10' the BESTFIT local homolo based on the al orithm of Smith and 
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6.4. DISCUSSION 
The results presented in this chapter have described the detection of full-length 
papillomaviral genomes, identical or very similar to BPV -1 and 2, in donkey 
sarcoids. In the present study, the papillomaviral DNA was demonstrated in all 18 
sarcoids screened which is a higher rate of detection than both the 12/14 of 
Trenfield et aL (1985) and the 29/33 of Angelos (1990). The papillomaviral DNA 
was not detected in the non-sarcoid samples derived from a melanoma, 
granulation tissue and normal skin and these findings suggest that the 
papillomaviral DNA may be involved in the aetiology of the sarcoid in the donkey. 
However, on comparison of the present study with the most recent and 
largest scale screening of sarcoid tumours (Angelos, 1990), it is apparent that there 
are several differences between the two studies that are worthy of note, besides the 
detection rate. First, Angelos (1990) detected papillomaviral DNA in one of two 
pyogranulomatous tissues, a result which is surprising until consideration is given 
to the difficulty in confirming a diagnosis in the case of ulcerated sarcoids. There is 
little doubt that the presentation of a sarcoid biopsy without an epithelial 
component is one of the more troublesome tasks faced by histopathologists, and, as 
a consequence, the diagnosis in the case of equine pyogranulomatous tissue may be 
open to question, especially when papillomaviral DNA is detected. Furthermore, 
of all the suggested modes of transmission of the sarcoid, the most popular is that 
the aetiological agent, whatever it may be, gains entry at a site of injury to the 
integument, and so there would appear to be an argument for a sarcoid developing 
alongside granulation tissue. 
Secondly, Angelos (1990) failed to detect papillomaviral DNA in three 
confirmed sarcoids, a finding which supported the results of Trenfield et al. (1985). 
Although the suggestion was made that a more sensitive method of detection may 
have demonstrated the presence of papillomaviral DNA, or that the diagnosis may 
have been incorrect, a third possibility exists: at some stage in the development (or, 
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and the subsequent clinical development, as well as histopathological assessment 
of development or regression would be essential information. In the present study, 
all sarcoids were positive for papillomaviral DNA and although no estimate was 
made of tumour age, a wide selection of tumour sizes were studied. If the size and 
degree of ulceration is at all indicative of lesion maturity, then it may be fair to 
assume that both reasonably new and long standing tumours were represented. 
Importantly, in no case were the histopathological changes indicative of tumour 
rejection, and it would be interesting to examine sections of those sarcoids negative 
for papillomaviral DNA from Angelos's case series, to ascertain whether or not 
histological changes associated with tumour rejection were evident. 
Thirdly, Angelos (1990) detected partial, as well as full length, 
papillomaviral genomes in two of the sarcoids studied and the deletions of 25 and 
1.9 per cent of the genome were localised to the same region as the 9 per cent 
deletion reported by Amtmann et al. (1980). In the present study all genomes were 
full length, approximately 8kbp in size, results in agreement with the vast majority 
of tumours screened in previous studies, suggesting that the partial genome may be 
the exception to the general finding. 
Having established the presence of papillomaviral DNA in the tumours, 
consideration must be given to the characterisation of the genomes. That the 
papillomaviral DNA is similar to BPV-1 and 2 is without doubt; probing with BPV-
2 under stringent conditions indicated a high degree of homology, results in 
agreement with previous workers (Lancaster et aI., 1977; Lancaster et al., 1979; 
Amtmann et a!., 1980; Lancaster, 1981; Trenfield et al., 1985; Angelos et a!., 1991). 
In the present study, the identities of the genomes detected fell into three classes; 
one identical to BPV-1; one identical to BPV-2; one similar to both BPV-1 and 
BPV-2 but identical to neither. Angelos (1990) and Angelos et al. (1991), detected 
BPV-1-like and BPV-2-like DNA in a study involving sarcoids from Switzerland 
and the USA and Trenfield et al. (1985) detected DNA identical to neither BPV-1 
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and cloned papillomaviruses from equine papillomas, demonstrating different RE 
fragment patterns in viral DNA isolated from different anatomical sites, as well as 
varying degrees of homology to BPV-1 and HPV-l. None of the RE fragment 
patterns observed by O'Banion et aL, (1986) resembled the results of the present 
study. It is unfortunate that the results from previous studies are not exactly 
comparable as there was no standardised choice of either REs or stringency of 
hybridisation but, despite the fact that some of the data presented by Angelos 
(1990) were complicated by partial digestion of some of the DNA samples, it was 
apparent that the sarcoids screened contained DNA practically identical to BPV-1 
and BPV-2, as well as DNA similar to BPV-1 and BPV-2, results broadly similar to 
the findings outlined in this chapter. However, care is required when interpreting 
these results as the variation from BPV -1 was slight, a limited number of REs were 
used in the analysis of the fifteen genomic samples and no multiple-cutters were 
employed in the study. The novel isolate differed from BPV-1 only in the absence 
of the XbaI site and the presence of an additional KpnI site, the latter being found 
in BPV-2. Although a complete mapping using multiple double digests was not 
performed, there was great similarity in the fragment sizes of DoPV and BPV-1 
following HindIII/RE digestion and it is a possibility that there may be several 
wild-type BPV-1 papillomaviruses: Angelos (1990) pointed out the limitations of 
comparing RE digests alone by the demonstration of an RE digest pattern of DNA 
from a BPV-2 induced lesion different to that previously published. 
The similarity of the DoPV to BPV -1 is further emphasised by the 
nucleotide base sequence of the cloned element. In both instances there was a high 
degree of homology with over 95 per cent similarity in the L1, 98 per cent 
similarity in the E5 and 96.5 per cent similarity combined. However, it should be 
remembered that only 212 of the 8000bp were involved in the analysis and it may 
be the case that other parts of the genome are less similar; sequencing of the 
URR, a region known to show variation between closely related papillomaviruses 
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E5 ORF is well conserved and there is complete identity of the amino acid 
sequence in BPV-1 and BPV-2 (Pfister, Krube, Dietrich, Iftner and Fuchs, 1986). 
However, the comparison of the DoPV sequences with BPV-1 and 2 becomes 
more significant when the nucleotide base similarity of the two bovine viruses is 
considered. The results of the limited sequence analysis indicate that there is 
greater homology between DoPV and BPV-1 than there is between BPV-1 and 
BPV-2, viruses that are known to be very closely related. The extremely high 
homology thus supports the similarity of the RE digests and it seems most likely 
that DoPV is in fact a subtype of BPV-1, in agreement with the conclusions of 
Trenfield et al. (1985) and Angelos et al. (1991). The detection of specific E5 
sequences confirms the presence in the DoPV of at least one of the ORFs known 
to have a transforming function in the biology of BPV -1, suggesting that cellular 
transformation in sarcoids may be associated with this viral oncogene. The 
presence of other ORFs, such as the E6, requires confirmation by further 
sequencing or probing with subgenomic fragments, but although similar genomic 
organistion is suggestive of a uniformity of function, expression and transfection 
experiments would still be required. 
In the case of the L1 fragment, there is also great homology between the 
DoPV and BPV-1 sequences and although the L1 is relatively well conserved 
amongst the subgroup A bovine papillomaviruses, minor differences in the L1 may 
lead to altered structure of the major capsid protein which is coded for by the L1 
ORF (Pfister, 1984). It is interesting to speculate that the differences, although 
minor, may include codon alterations and perhaps frame-shifts, resulting in an 
immunological epitope that possesses the interspecific antigenic properties of 
BPV-1 and BPV-2 but has an altered neutralising antibody binding site, one 
possible explanation for the detection of non-neutralising antibody to 
papillomaviral antigen in Chapter III. 
The great similarity between DoPV and BPV -1 could be confirmed by 
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An alternative method of confirmation by heteroduplex comparison of BPV-1 and 
DoPV (Campo and Coggins, 1982) is currently being undertaken with the DoPV 
recloned into pBR322, and preliminary results have failed to demonstrate any 
significant areas of reduced homology. 
Further work is necessary to investigate the state of papillomaviral DNA in 
the sarcoid and the consideration of future strategies highlights the deficiencies of 
this, and previous investigations. In the present study, it was not possible to obtain 
control healthy skin samples from each of the donkeys with sarcoids, and it may be 
the case that latent papillomaviral genomes may exist in healthy tissue, awaiting 
activation by some insult to the integument, as in Mastomys natalensis (Amtmann, 
Volm and Wayss, 1984). In addition, precise mapping in order to localise the RE 
cleavage sites in the DoPV genome involving, double digests with all possible 
combinations of the REs used in the present study, a wider range of REs as well as 
those with multiple cleavage sites, would provide further information about the 
genomic organisation in relation to the bovine viruses. In this respect, it is 
unfortunate that the REs used in this study were different to those employed by 
Angelos (1990) and other workers, thus precluding direct comparison, and an 
important initiative would be the establishment of standardised protocols in any 
collaborative multicentre prospective study. 
The screening methods outlined at the beginning of this chapter in the 
detection of papillomaviral genomes in sarcoid tumour cells were time consuming 
and involved the use of radioactive isotopes, the latter being a hazard to researcher 
and environment. In addition, substantial biopsies are required from clinical cases 
in order to provide adequate amounts of DNA for RE analysis and the provision of 
such biopsies usually requires invasive surgery and was the limiting factor in the 
failure to obtain control healthy tissue. The following chapter describes the 
methodology adopted to overcome these drawbacks, allowing rapid non-
radioactive screening and RE mapping of DNA extracted from smaller tissue 
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CHAPTER VII 
DETECTION OF PAPILLOMAVIRAL DNA SEQUENCES 
IN SARCOID TUMOURS USING 
THE POLYMERASE CHAIN REACTION 
7.1. INTRODUCTION 
In order to carry out the analyses described in Chapter VI, tumour biopsy, DNA 
extraction, restriction endonuclease digestion, Southern blotting and hybridisation 
were performed. This was a labour intensive process and required the use of 
radioactive isotopes. The Polymerase Chain Reaction (PCR) is a rapid, sensitive, 
primer directed method for DNA amplification (Saiki, Gelfand, Stoffel, Scharf, 
Higuchi, Horn, Mullis and Erlich,1987), involving the use of a thermostable DNA 
polymerase and the repeated dissociation and annealing of selected 
oligonucleotide primers to a DNA template, in the presence of substrate. Using 
either specific or consensus primers, this technique has been used extensively in 
human papillomaviral research as a means of detecting papillomaviral DNA from 
very small tumour biopsies (Levi, Delcelo, Alberti, Torloni and Villa, 1989; 
Melchers, van der Brule, Walboomers, de Bruin, Burger, Herbrink, Meijer, 
Lindeman and Quint, 1989). The quantities of DNA generated are typically 
sufficient for restriction endonuclease analysis, the results of which can be 
visualised on an ethidium stained agarose gel, without the need for Southern 
blotting and hybridisation. The papillomavirus genome contains a number of 
interspecies conserved sequences (Law, Lancaster and Howley, 1979; Danos et al., 
1984; Baker, 1987) and the use of such sequences in primer design for use in a 
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Figure 18. Schematic representaion of the polymerase chain reaction showing the use of consensus 
.. .. . etween two conserved regions of the 
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As outlined in the previous chapter, papillomaviral DNA has been detected in 
DNA derived from sarcoid tumour cells (Lancaster et a!., 1977; Lancaster et 
aI.,1979; Amtmann et a!., 1980, Lancaster, 1981; Trenfield et a!., 1985, Angelos et 
at., 1991) but not in every case. Trenfield et al. (1985) demonstrated the presence 
of episomal papillomaviral DNA that co-migrated with bovine papillomavirus 
types 1 and 2 (BPV-l and 2) in 12 out of 14 cases and Angelos et al., (1991) in 29 of 
33 sarcoids. The presence of the papillomaviral sequences did not appear to be 
related to either the clinical type of the lesion or the presence or absence of the 
epidermis. Restriction endonuclease analysis of the DNA extracted from the 
sarcoid has been shown to differ from that of BPV -1 and 2 but only at subtype level 
(Trenfield et al. 1985), findings confirmed by Angelos et a!. (1991). 
The aims of this part of the project were to use consensus primers and the 
polymerase chain reaction to test for the presence of papillomaviral sequences in 
the DNA extracted from sarcoid tumours; to confirm the identity of the amplified 
products by Southern blotting and hybridisation; to analyse the PCR products by 
restriction endonuclease digestion; to confirm the results obtained by Southern 
hybridisation of genomic digests presented in the previous chapter. 
7.2. MATERIALS AND METHODS. 
7.2.1. Source of tumours 
Sarcoid tumour biopsies were obtained from 18 sarcoid-affected donkeys at the 
Donkey Sanctuary, Sidmouth, Devon. Biopsies were snap frozen in liquid nitrogen 
and stored at -70°C until required for DNA extraction. 
7.2.2. Preparation of genomic DNA 
Extraction of genomic DNA was performed essentially as described in Section 
5.3.3., with minor modifications. Briefly, tumours were macerated with a scalpel 
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SDS to a final concentration of 0.5 per cent w Iv. The mixture was then incubated 
at 37°C overnight. The aqueous phase was then extracted three times with SS-
phenol/chloroform and once with diethyl ether. The DNA was precipitated by the 
addition of two volumes of absolute ethanol and removed by spooling out with a 
sealed pasteur pipette. Following a brief wash in 70 per cent ethanol, the DNA was 
dried briefly under vacuum and resuspended in TE (pH 8.0). 
7.2.3. Design of consensus oligonucleotide primers 
Oligonucleotides 15 bases in length were selected from the interspecies conserved 
regions in the El, 12 and Ll open reading frames (ORFs) of BPV-l, BPV-2, 
Human PV-6 and the European Elk PV (Table 27.). The oligonucleotides were 
synthesised on an Applied Biosystems 380A DNA Synthesiser using the 
beta-cyanoethyl phosphoramidite method and purified as described in Section 
5.3.10 .. 
Table 27. Nucleotide base sequence of the six oligonucleotide primers and open reading frame 
(ORF) in which the sequences were identified. The strand to which the primers were compilmentary 
is also shown. The primers were used in pairs, i.e., 1 and 2; 3 and 4; 5 and 6. 
Primer No. 
1 
2 
3 
4 
5 
6 
Sequence 
TIC GGA TCC ATG GTG 
CCf GAA TIC CAA GTC 
TIC GAA TIC CfA TGA 
CAG AAG CIT GCA GGA 
CTG AAG CIT TAG GTA 
AAG CIT AGG ATC ATA 
ORF 
El (5') 
12 (3') 
12 (5') 
Ll (3') 
12 (5') 
El (3') 
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7.2.4. The Polymerase Chain Reaction 
The PCR was performed as described by Saiki et aL (1987) using the GeneAmp 
PCR Reagent Kit (Perkin Elmer Cetus). Ten ul of 100ng/ul template DNA from 
the sarcoid tumours was added to a 40u1 reaction mixture containing, 200uM of 
dATP, dCTP, dGTP, dTTP, 5Opmol of both primers from the pairs described 
above, 1 unit of Amplitaq DNA Polymerase and 5ul of reaction buffer. The 
reaction buffer contained 100mM Tris HCI, 500mM potassium chloride, 0.01 per 
cent (w/v) gelatin and either 5, 10, 15,20,25 or 30mM magnesium chloride. Ten ul 
aliquots of ultrapure water, TE (pH 8.0), ovine lymphocyte DNA (l00ng/ul) and 
lymphocyte DNA from a clinically healthy donkey were used as negative controls. 
The positive control was 10ul of BPV-l virion DNA (5ng/ul). The solution was 
overlaid with two drops of mineral oil to prevent evaporation. Forty cycles of 
amplification were performed using a Perkin Elmer Cetus thermal cycler. Each 
cycle consisted of I minute at 940 C to denature the DNA, I minute at 55°C to 
anneal the primers to the template and 3.5 minutes at 720 C for primer extension. 
Mter the last cycle, a further incubation for 7 minutes at 72°C was performed to 
allow extension of any partially completed product. 
7.2.S. Analysis of PCR products 
On completion of the amplification, lOuI of the reaction mixture was 
electrophoresed through a 1.5 per cent LMP agarose geL The DNA was visualised 
by staining with ethidium bromide and exposure to ultraviolet light (312nm). 
Amplified products were recovered from the gel as described in Section 5.3.5., 
phenolj chloroform extracted, ethanol precipitated and resusupended in TE (pH 
8.0). One ug of each fragment was then incubated with 3 units of Hindm, BamHl 
and KpnI restriction endonucleases in the appropriate reaction buffer for I hour at 
370 C. Agarose gel electrophoresis was performed as described above. The agarose 
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blotting in 0.4 M sodium hydroxide. The blots were air dried. Prehybridisation and 
hybridisation were carried out at 420 e for 8 and 16 hours respectively in a solution 
containing 5x sse, 5x Denhardt, 0.5 per cent SDS, 75mM EDTA and 0.1mgjml 
denatured salmon sperm DNA The probe was full length molecularly doned 
BPV -2 genome labelled with [alpha-32p] dCfP, using the Multiprime DNA 
labelling system (Amersham International pIc). The blots were washed twice for 20 
minutes at 420 e in 2x sse, 0.1 per cent SDS and twice for 30 minutes at 650 C in 
0.5x SSC, 0.1 per cent SDS. The blots were exposed for 4 hours to Kodak XAR 
Omat film at -700 C. 
7.3. RESULTS 
Amplified products were generated in all 18 cases using the three primer sets. The 
fragments generated were approximately 2450 (E1-12), 2650 (12-L1) and 2900 
(L1-E1) base pairs in length (Figure 19). All fragments hybridised with full length 
molecularly cloned BPV-2 under stringent conditions (Figures 19 and 20). The 
negative controls yielded no detectable products. Restriction endonuclease analysis 
revealed the absence of a KpnI restriction site in the L1-E1 fragment in three of 
the samples (Figure 20). An additional BamHI site in the 12-L1 fragment was 
present in four of the 18 samples, one of which also lacked the KpnI site in the L1-
E1 fragment. In all cases the DNA fragments could be seen on the ethidium 
stained agarose gel (Figure 21) and it was found that the assay was of optimal 
sensitivity with fewest artefactual bands when the concentration of Mg2+ was 
1.5mM. 
7.4. DISCUSSION 
In this chapter the polymerase chain reaction has been used to detect 
papillomaviral DNA in cryo-preserved biopsies from equine sarcoids. The PCR is 
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contamination of genomic samples with cloned papillomaviral plasmids or peR 
products. In order to eliminate this possibility, extraction of genomic DNA, 
preparation of the peR reaction mixtures, amplification and analysis of the 
products were carried out in different laboratories. In addition, all peR products 
were aliquoted prior to the study. Where possible, screw-top microcentrifuge tubes 
were used in order to avoid the aerosolisation of peR products. In the present 
study, papillomaviral DNA was detected in all cases of histologically confirmed 
sarcoids. The amplified products were visible on agarose gels stained with 
ethidium bromide and viewed under ultraviolet light without the need for 
hybridisation, although Southern blotting and hybridisation with radiolabelled 
BPV-2 was used to confirm the identity of the products. This is an improved rate of 
detection compared with the findings of Trenfield et at. (1985), Angelos (1990) and 
Angelos et at. (1991), and is in agreement with the rate of detection demonstrated 
by Teifke and Weiss (1991). The data agree with the findings of the previous 
chapter that papillomaviruses are implicated in the aetiology of sarcoids in the 
donkey and although the detection rate was 100 per cent by Southern blot, much 
smaller amounts of tumour DNA were required for a positive result using peR, 
typically lug in the case of peR versus 10-15ug for Southern blot an hybridisation. 
The use of consensus primers from conserved regions of the papillomaviral 
genome thus provides a rapid, sensitive method of screening a large number of 
tumours for the presence of papillomaviral DNA. 
It has been shown that in the region between L1 and E1 a Kpnl restriction 
site was absent in four of the 18 samples assayed thus localising the additional 
Kpnl site in DoPV described in the previous chapter to the region between the 
HindU site and the origin, a site approximately in the same region as in BPV-2. 
The presence of an additional BamHI site provides more evidence that several 
subtypes of papillomavirus may be involved in the aetiology of the disease, adding 
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to the results of Teifk:e and Weiss (1991). In the latter study, primers from the E5 
ORF of BPV-1/2 were used to amplify a region of the viral genome that in 
general exhibits a high degree of variability between papillomaviral types but is 
relatively well conserved amongst the fibropapillomas. Restriction endonuclease 
digests of the products using BstI, showed all amplification products to be 
indistinguishable from BPV -1, a result which supports the high nucleotide base 
sequence homology described in the preceding chapter. The results of the present 
study have demonstrated minor differences from the restriction pattern of BPV-1, 
but, as a limited number of restriction enzyme cleavage sites were utilised, more 
extensive mapping using a larger number of restriction enzymes and multicutting 
enzymes may distinguish the DNA into further subtypes. In addition, type specific 
primers may be used to screen for different subtypes (Nuovo, Darfier, Impraim 
and Bromley, 1991) and PCR products may now be sequenced directly 
(Gyllensten, 1989), thus removing the need for many of the procedures described 
in the previous chapter. 
The involvement of papillomaviral DNA in sarcoids using PCR may be 
investigated further by relating the subtype of viral DNA to tumour type, 
anatomical site and geographical location. PCR has also been applied by several 
workers to the detection of papillomaviral DNA in formalin fixed 
paraffin-embedded tissue sections (Claas, Melchers, van der Linden, Lindeman 
and Quint, 1989; Shibata, Gupta, Shah, Amheim, and Martin, 1988). This will 
allow extensive archival studies to be carried out, work currently being undertaken 
as an extension of the current project. In the present study, one of the major 
limitations was that the majority of samples assayed were from clinically diseased 
animals and undoubtedly, other tissues, healthy and diseased, should also be 
screened for the presence of papillomaviral DNA This can now be carried out 
without the need for large skin biopsies from normal donkeys due to the sensitivity 
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at The Donkey Sanctuary. 
Although the peR is undoubtedly a powerful investigative tool, 
interpretation of data resulting from such studies cannot be divorced from either 
clinical or epidemiological studies. Wikstrom, Lidbrink, Johansson and von Krogh 
(1991) employed peR in screening males attending a sexually-transmitted 
diseases clinic, for the presence of HPV 6 or 16. Using both dot blot and agarose 
gel methods of analysis these authors demonstrated a detection rate of 76 and 43 
per cent for HPV-6 and 16, respectively, in men with no previous history or 
evidence of condylomata. Furthermore, a study of clinically normal women 
undertaken by Tidy, Vousden and Farrell (1989) demonstrated HPV 16 DNA in 
over 80 per cent of individual. These studies suggest that the frequency of occult 
papillomaviral infections, as demonstrated by peR, is extremely high, but in the 
case of HPV 16, the over representation of the viral type in comparison to the 
prevalence in clinical lesions, suggests that extreme caution is required before 
making any definitive conclusion, far less clinical decision or diagnosis, based on 
peR data alone. 
The drawbacks of peR diagnosis are well documented (Stanley, 1990) but 
III HPV research the technique is rapidly becoming the preferred method of 
identification (Guerrero and Shah, 1991). However, with the introduction of 
standardised reagents, protocols designed to avoid contamination and the 
development of quality controls (Guerrero and Shah, 1991) peR is a valuable 
component in the diagnostic armamentarium of a mutidisciplinary approach to 
disease investigation (Wright and Winford-Thomas, 1990). 
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Figure 19. Autoradiograph of a Southern blot after hybridisation showing the amplified products of 
the three fragments of the papillomaviral genome as detected in all tumour samples. a, Normal 
equine skin DNA template with primers for EI-L2; b,c and d, sarcoid DNA template with primers for 
EI-L2, L2-Ll and LI-El, respectively. Hybridisation was to molecularly cloned BPV-2 DNA. 
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Figure 20. Autoradiograph of a Southern blot showing KpnI restriction endonuclease digestion of 
two subtypes of papillomaviral DNA amplified by peR. A, undigested Ll-El fragment; Band e, 
KpnI digested LI-El fragment showing absence of KpnI site in sample C. D, undigested EI-L2 
fragment; E and F, KpnI digested EI-L2 fragment showing presence of Kpnl site in both fragments.B 
and E were products from the same sarcoid DNA template, e and F were both products from a 
different sarcoid DNA template. Hybridisation was to molecularly cloned BPV-2 DNA. 
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Figure 21. PCR products after electrophoresis through a 0.8 per cent agarose gel showing effect of 
MgZ + concentration. Each lane was loaded with 10m of peR products following a 40 cycle 
amplification of lug DNA extracted from a sarcoid, employing oligonucleotide primers from the E1 
and L2 open reading frames of BPV-l.. The magnesium ion concentrations used were (a-e) 1.0, 1.5, 
2.0, 2.5 and 3.0mM with 1.5mM Mg2+ judged to provide clearest bands with fewest artefacts. The 
2.5kbp product was visible without the need for Southern blot, hybridisation and autoradiography. 
Lane f contained the negative control assyed at l.5mM Mg2 +. The gel was stained with ethidium 
bromide solution and photographed when transilluminated with UV light (312nm). 
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CHAPTER VIII 
GENERAL DISCUSSION AND SUMMARY 
The aim of this research project was to investigate aspects of the equine 
sarcoid of the donkey, with the long term objective of assessing the feasibility of 
adopting a vaccination programme against the disease at The Donkey Sanctuary. 
The first stage in the investigation was into the epidemiology of the disease, 
identifying animals with sarcoids and those most at risk of developing the disease. 
The results of Chapter II are a major advance in this respect and have provided the 
basis for management changes at The Sanctuary. Based on the investigation into 
the epidemiology of the disease at The Sanctuary, a disease model has been 
developed and, en route to this model it has been demonstrated that several 
variables affect the likelihood of individual donkeys having sarcoids. Sex, age at 
entry and exposure have all been shown to have individual effects as well as 
interaction of sex and exposure effects and this has highlighted the young castrated 
males as being the group of animals most likely to have sarcoids. 
Any procedures requiring surgical intervention and general anaesthesia 
carry a risk of death or sequelae detrimental to the health of the animal and, in 
order to minimize the suffering of the donkey, removal of tumours should be 
performed as soon as possible after diagnosis, reducing stress and physical trauma. 
Furthermore, as all the Case animals are treated by a variety of modalities and in 
most instances require a general anaesthetic, the disease is of economic 
significance to The Sanctuary's financial budget. In general terms, the duration of 
the operation and the financial cost to the charity is related to the size and number 
of tumours. Thus, minimising trauma and expense may best be achieved by the 
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have been identified and changes in management implemented, ensuring regular 
inspection of the young male donkeys by the paraclinical staff at The Sanctuary. 
The high risk groups at The Sanctuary are now being examined monthly whilst 
those less at risk are examined less frequently, identifying those animals with 
sarcoids at an earlier stage and allowing the therapeutic measures currently being 
employed by the clinicians at The Donkey Sanctuary to be implemented sooner in 
the disease process. As surgical procedures are now carried out sooner, earlier 
lesions are being submitted for histological examination which, whilst improving 
the welfare of the donkeys, also provides valuable material for further 
investigation, not available previously. This will lead to a fuller understanding of 
the development of the tumours and the role of aetiological agents in the 
pathogenesis of the disease. 
Other specific managemental changes have arisen from the observation that 
a possibility exists, suggested by the sex, age and exposure of the animals most 
affected by sarcoids, that a potential pathogen may be disseminated at, or around, 
the time of castration. It has been recommended that strict attention should be 
paid to complete sterilisation of surgical instruments between operations, including 
cryoprobes and cautery blades, and that insecticidal sprays and insect repellents 
should be used to minimise the possibility of fly-borne transmission of an 
aetiological agent, either on the same animal or to a close in-contact which may 
share a box immediately post-operatively. It may also be advisable to keep all 
scrotal wounds covered with surgical dressings until healing has occurred, but this 
may prove to be impracticaL 
The epidemiological study described has underlined the immense potential 
for developing the database management of animal disease in the population of 
donkeys at The Donkey Sanctuary. The construction of disease-risk models for 
other diseases, using carefully structured databases and the interrogative software 
tools employed during the current project, will lead to the identification of major 
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Having identified a diseased population and animals at risk from the 
disease, the success of a vaccine development requires the identification of an 
aetiological agent. The demonstration of papillomaviral DNA in the sarcoid 
material collected from the animals at The Sanctuary is strongly suggestive of the 
involvement of this known pathogen in the aetiopathogenesis of the disease, results 
in agreement with the conclusions of other workers. The findings of Jarrett et al. 
(1990a; 1990b; 1991) in vaccination studies against BPV-induced neoplasms in 
bovidae, indicate that there is a place for both therapeutic and prophylactic 
vaccination strategies against papillomaviral infection. However, assuming the 
involvement of a papillomavirus in the donkey sarcoid, the differences between the 
disease process in the two species must be highlighted. First, the apparent absence 
of a productive papillomaviral infection in the donkey is in contrast to the 
production of infectious viral particles in the bovine cutaneous lesions. Secondly, 
infection of cattle by BPV -1 and 2 results in an humoral immune response with the 
production of neutralising antibody. In the donkey this does not appear to be the 
case, although the results of the Western blot assays in Chapter II demonstrate an 
antibody response to a 64 and 55kDa antigen similar in size to the 12 and L1 viral 
proteins of BPV -1 and 2. The absence of neutralising antibody is in agreement with 
the findings of Ragland and Spencer (1968) but is in contrast to the presence of 
neutralising antibody in horses inoculated intradermally and subcutaneously with 
BPV (Segre et aL, 1955; Olson and Cook, 1951). Thirdly, in cattle the tumours are 
usually rejected in 4-12 months, whereas in the donkey the lesions persist. There 
are no clinical records at The Sanctuary that suggest any of the donkeys have 
rejected the tumours. 
The apparent lack of viral production must be considered in more detaiL 
Viral extractions performed on the donkey tumours were usually carried out on 
mature lesions larger than 1cm3 in size. A very early horse sarcoid did yield 
papillomavirus-like particles and it may be the case that virus is produced in the 
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production has ceased. In order to investigate whether or not viral production 
occurs at any stage in the development of the sarcoid, more vigilant attention must 
be paid to the animals in the high risk categories, identified in Chapter II, in the 
hope of observing, biopsying and assaying earlier lesions for the presence of 
virions. It is also important that any attempt at viral extraction should be from a 
field case, as it is known that the biology and pathology of the disease produced by 
experimental infection of equine skin with BPV -1 and 2 differs from the natural 
disease. 
The need to isolate an infectious particle and fulfil Koch's postulates 
remain and Ragland et aL (1970b) stated that the understanding of the equine 
sarcoid is unlikely to be advanced until suspected virus ( es) have been isolated and 
characterised. The cloning and partial characterisation of a papillomaviral genome 
described in Chapter VI and the isolation of a viral particle in Chapter IV (albeit 
from a horse sarcoid) provide the basis for more detailed molecular biological and 
viral investigations. In the face of the accumulating evidence demonstrating 
papillomaviral DNA in sarcoid tumours throughout the world, (Lancaster et 
aL,1979; Amtmann et aL, 1980; Trenfield et aL, 1985; Angelos et aL, 1991) it 
seems increasingly unlikely that the virus does not play a role in the 
aetiopathogenesis of the tumour. Futhermore, the evidence presented in Chapters 
VI and VII confirms previous reports that although the viral DNA isolated is very 
similar to BPV -1 and 2, subtypes of the viruses may be involved in the disease 
process. 
The development of an assay for papillomaviral DNA using PCR 
technology (Chapter VII) allows equine tissue samples to be screened rapidly and 
without the need for Southern blotting or the use of radioactive isotopes. This 
technology is currently being applied to other equine tissues such as PBLs and 
formalin-fixed paraffin-embedded tissue sections and information from these 
studies may provide insight into latency of infection involving PBLs as suggested by 
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The development of a peR assay is another major step towards improved 
welfare of affected donkeys as it is now possible to take small amounts of tissue 
and screen for papillomaviral DNA During the course of the present study, 
histopathological confirmation of sarcoid tissue was carried out by examining 
formalin-fixed paraffin embedded tumour sections stained with haematoxylin and 
eosin. It was noticed that in distinction to bovine cutaneous lesions the hair follicle 
was very frequently involved in the tumour of the donkey, with marked 
proliferation of the epidermis around the hair follicle. Thus, plucking a few hairs 
from the tumours may provide enough material for PCR analysis and it may now 
be possible to provide control tissue for screening without the need for surgical 
biopsy of healthy skin, a procedure precluded by the constraints of the current 
project. Another interesting application of the exquisite sensitivity of PCR would 
be to assay DNA from insect vectors trapped at The Sanctuary in order to 
ascertain whether papillomaviral DNA was present and thus go some way to 
confirming fly-borne transmission as one route of inoculation of a putative 
aetiological agent. 
Ultimately, any future research must be based on a multidisciplinary 
approach to the disease involving concurrent investigation into both aetiological 
and host factors. The early transmission and serological studies were carried out 
before the existence of different types and sub-types of BPV was known. However, 
it is most likely that the viruses involved were either BPV -1 or 2 and although a 
case could be made for the repetition of the experiments with known amounts of 
typed virus, it is unlikely that the results would be radically different from those 
published. In contrast, the need to consider the host in the response to 
experimental inoculation of either homogenised tumour or BPV should be given 
priority. Genetic predispostion to sarcoids, evidenced by the association of specific 
ELAs (MHC types) to risk of the tumour in the horse, may well explain the 
inconsistent results of the various workers who have tried to re roduce the disease 
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Unfortunately, the small amount of familial information available concerning the 
animals involved in this study was too sparse and unreliable to make any definitive 
statements with regard to the genetic effect of the disease in donkeys. In view of 
this, a logical development of the research programme at The Donkey Sanctuary 
would be to look for disease-risk association with the donkey MHC. This 
programme of work has recently started using commercially available murine and 
human class II DNA probes on digests of genomic DNA from the Case population 
and on a population of paired controls, matching each case for sex and age. 
Ragland and Spencer (1969) stated that transmission attempts with nucleic 
acid rather than tumour extract may provide further information regarding the 
aetiology of the disease and this may now be carried out comparing whole virus, 
viral DNA or molecularly cloned viral DNA Angelos (1990) proposed three 
models upon which the significance of papillomaviral DNA and host factors could 
be assessed. In the first, only the fibroblasts of genetically susceptible animals 
become infected by an ubiquitous papillomavirus; in the second, all fibroblasts of 
donkeys are infected if they encounter a papillomavirus, but only those fibroblasts 
of genetically susceptible animals are permissive for papillomaviral replication; in 
the third model, all fibroblasts of donkeys are infected if the cells encounter a 
papillomavirus and replication occurs but in resistant animals the transcription of 
papillomaviral genes is inhibited. All three of these models could be tested in vitro 
on horse-derived fibroblasts for which the host genotype has been characterised, 
unlike the situation in the donkey. 
There are some aspects of the results that require further consideration. If 
the donkeys are infected with a papillomavirus similar to BPV -1 and 2, why is the 
antibody produced unable to neutralise the virus in the same manner that horses 
inoculated with BPV develop neutralising antibody? As suggested in Chapter VI 
there may be slight differences in the virus that is infecting the donkeys, perhaps 
traceable to nucleotide base se uences in that art of the viral enome which 
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likelihood that major immunological differences exist between the two viruses 
seems remote but cannot, at this stage, be ruled out. 
Another possibility lies in the amount of virus required to cause clinical 
disease. If the infecting dose is very small, it may be insufficient to trigger a 
response by the immune system, thus allowing the viral DNA to effect 
transformation and, as there does not appear to be production of viral particles in 
the donkey tumours examined, no further stimulation of the immune system by the 
Ll. If this explanation is adopted then it must be assumed that the antibody 
detected in Chapter III is not related to the viral infection causing the disease, but 
may be due to exposure to another papillomaviral antigen. 
Given the similarity of the isolated genomes to BPV -1 and 2 it is surprising 
that it has not been possible to reproduce the disease experimentally. This may be 
due to the other factors such as the size of inoculum; in experimental infection it is 
likely to be many fold larger than a naturally-occurring infection and may 
consequently interact with the host immune system in a different manner. This 
would certainly be one explanation for the development of neutralising antibody to 
BPV -1 in some experimental studies but not in others, nor in animals with sarcoids. 
However, regardless of whether the development of an humoral immune response 
is nonexistent, non-neutralising or unpredictable, the economics and ethical 
considerations of vaccinating prophylactically may be of more importance in the 
assessment of the feasibility of such an approach: although the sarcoid is among 
the most common of skin tumours affecting equidae, the disease does not appear 
to be a risk to all animals equally nor life-threatening to the majority of the general 
population, and, in view of this, a therapeutic vaccine would seem to be more 
appropriate to the clinical situation. The work reported by Jarrett et aL, (1991) 
Meneguzzi et aL, (1991) and Campo (1991) would indicate that the L2, and 
transforming early proteins offer possibilities for vaccines that stimulate cell 
mediated immunity (CM!) resulting in tumour regression and rejection. Campo 
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During the current project, an attempt was made to demonstrate viral 
structural proteins in sarcoid tissue sections using anti-BPV-2 peroxidase-
antiperoxidase immunocytochemistry, without success, a result that may be 
expected in view of the failure to isolate virions in the vast majority of tumours. 
However, as all the tumours in this study were found to contain DNA similar to 
BPV -lor 2, one future strategy may be to screen the tissue sections using 
monoclonal antibodies to BPV-1/2 L1, L2, E5 and E6 proteins. If the virus 
undergoes only the early part of the replicative cycle, sufficient to produce only the 
early transforming proteins (E5 and E6), vaccination against these proteins may 
prevent or halt transformation and stimulate a CMI response leading to tumour 
rejection. 
Other avenues remain to be investigated; the expression of papillomaviral 
antigens on the cell membrane of transformed fibroblasts in vitro and in vivo; more 
complete mapping of the cloned genome; the use of the PCR to screen for specific 
subtypes; relation of subtype to clinical type, anatomical site or geographical 
location; localisation of the viral DNA within the tumour either by dissection and 
extraction of the nucleic acid or by in-situ probing of tumour sections with BPV 
DNA probes; extraction and characterisation of mRNA may provide an insight 
into the viral biology within the tumour. In conclusion, despite all the suggested 
scope for future research, there is still a lack of basic knowledge about sarcoids 
that stems from the inability to reproduce the disease and study it from infection 
through lesion development to (rarely) rejection. Although clinically-based case-
control trials, employing the molecularly cloned proteins developed for the 
successful vaccination studies in cattle, may provide one area for development, 
there is still a case for transmission and infection studies both in vitro and in vivo. 
Although this work can be performed in the horse, where MHC type has been 
defined, the same is not true of the donkey and the characterisation of the donkey 
MHC is an essential development in the research programme. This investigation 
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animal welfare by identifying donkeys susceptible to the sarcoid. 
APPENDIX I 
APPENDIX I 
CONTROL POPULATION DATA 
Key: Sex 1; male (gelding) 
Sex 2; female (jenny) 
*; Dead donkey (See Appendix IV) 
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Number Sex Date of Birth Date of Entry 
1 2* 01/01/63 02/28/73 
2 2 01/01/65 02/28/73 
3 2* 01/01/69 03/13/73 4 2 01/01/64 03/13/73 6 2* 01/01/63 03/13/73 
7 2 01/01/69 03/13/73 
8 2* 01/01/60 03/13/73 9 2* 01/01/53 05/05/73 
10 2* 01/01/53 05/07/73 
11 2* 01/01/69 03/13/73 
12 2 01/01/68 05/09/73 
13 1 01/01/72 05/07/73 
14 2 01/01/55 05/08/73 
15 2* 01/01/69 05/07/73 
16 1* 01/01/66 06/06/73 
18 1* 01/01/68 06/19/73 
19 2 01/01/63 06/19/73 
22 1* 05/01/72 06/19/73 
25 1* 01/01/63 06/19/73 
27 2 01/01/46 06/19/73 
28 2* 01/01/70 06/19/73 
30 2 01/01/72 06/19/73 
33 1 01/01/68 06/19/73 
34 1* 01/01/70 06/19/73 
35 2* 01/01/70 08/22/73 
36 2 01/01/69 08/22/73 
38 2 01/01/63 08/22/73 
39 2* 01/01/63 08/22/73 
41 2 01/01/70 08/22/73 
42 2* 01/01/47 10/11/73 
43 2* 01/01/40 09/11/73 
44 2* 01/01/59 08/11/73 
45 2 01/01/65 09/11/73 
47 2* 01/01/38 01/01/68 
48 1* 01/01/71 12/12/73 
50 2* 01/01/73 12/11/74 
52 1* 01/01/58 12/12/73 
53 2* 01/01/63 12/12/73 
55 1 09/01/73 09/30/73 
58 1* 02/01/74 02/24/74 
59 2 03/01/74 03/27/74 
60 2* 01/01/62 03/27/74 
61 2 01/01/74 03/27/74 
63 1* 01/01/67 03/27/74 
64 2* 01/01/60 03/27/74 
65 2* 01/01/59 03/27/74 
66 1* 04/01/73 04/21/73 
67 2* 01/01/66 04/04/74 
69 1* 01/01/53 04/10/74 
73 2* 01/01/69 04/10/74 
74 2* 01/01/71 04/10/74 
78 1* 01 01 65 05 09 74 
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Number Sex Date of Birth Date of Entry 
87 2 01/01/71 05/01/74 
88 2 01/01/71 OS/29/79 
89 1* 01/01/70 OS/29/74 
90 2* 01/01/60 OS/29/74 92 1 05/01/74 05/14/74 93 1* 01/01/70 07/24/74 94 2* 01/01/65 07/24/74 
95 2* 01/01/54 07/24/74 
96 2* 01/01/73 07/24/74 
97 2* 01/01/70 07/24/74 
99 2* 01/01/67 07/24/74 
100 1* 01/01/69 04/27/74 
101 2* 01/01/44 07/24/74 
102 2* 01/01/54 07/24/74 
103 1* 01/01/60 07/24/74 
105 2* 01/01/58 07/24/74 
106 2* 01/01/73 07/24/74 
107 2* 01/01/70 07/24/74 
108 2 01/01/70 07/24/74 
109 2 01/01/70 07/24/74 
110 1* 01/01/60 07/24/74 
112 1* 01/01/54 07/27/74 
113 1* 01/01/70 07/24/74 
114 1* 01/01/70 07/24/74 
115 1 01/01/70 07/24/74 
116 2 01/01/66 07/24/74 
117 1 01/01/68 07/24/74 
120 1* 01/01/68 07/24/74 
121 1* 01/01/40 07/24/74 
122 1* 01/01/66 07/24/74 
124 1 01/01/68 07/24/74 
129 1 01/01/70 07/24/74 
134 2* 01/01/65 07/24/74 
135 1 01/01/59 07/24/74 
136 1* 01/01/57 07/27/74 
138 1* 01/01/60 07/24/74 
139 1 01/01/44 07/24/74 
141 1 01/01/68 07/24/74 
143 1 01/01/62 07/24/74 
144 2* 01/01/60 07/24/74 
145 1* 01/01/69 07/24/74 
148 1* 01/01/64 09/04/74 
150 1 01/01/70 09/10/74 
151 2 01/01/70 09/10/74 
152 2* 01/01/69 09/10/74 
153 1* 01/01/54 09/10/74 
154 1 01/01/69 09/10/74 
155 1* 01/01/68 09/10/74 
156 2* 01/01/49 09/10/74 
157 1* 01/01/40 09/10/74 
159 2 01/01/73 09/10/74 
161 1* 1 1 1 4 
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Number Sex Date of Birth Date of Entry 
168 1 01/01/68 09/10/74 
169 1* 01/01/60 09/11/74 
170 1 01/01/72 09/11/74 
171 1* 01/01/67 09/11/74 
172 1 01/01/68 09/11/74 
173 1 01/01/69 09/11/74 
174 1* 01/01/68 09/11/74 
175 1 01/01/70 09/11/74 
176 1 01/01/70 09/11/74 
177 1* 01/01/60 09/11/74 
178 1* 01/01/67 09/11/74 
179 1 01/01/54 09/11/74 
181 2* 01/01/71 10/19/74 
182 1 01/01/70 11/05/74 
183 2* 01/01/25 11/05/74 
186 1* 11/01/74 11/01/74 
187 2* 01/01/64 12/03/74 
188 2* 01/01/62 12/02/74 
189 1* 01/01/70 12/12/74 
190 2* 01/01/60 12/12/74 
192 1 01/01/72 01/07/75 
193 1* 01/01/54 12/01/74 
194 1* 01/01/55 01/30/75 
195 1* 01/01/64 01/30/75 
196 1* 01/01/64 04/24/74 
198 1* 01/01/67 01/01/74 
201 2 01/01/57 06/20/77 
202 1* 01/01/70 01/01/74 
203 1 01/01/60 07/29/85 
204 1* 01/01/68 11/01/74 
205 1* 01/01/72 07/29/85 
206 1 01/01/63 03/12/80 
207 1* 01/01/71 02/01/75 
208 1* 01/01/70 02/01/75 
209 2* 01/01/55 02/01/75 
210 2* 01/01/70 02/01/75 
211 1* 01/01/73 02/03/75 
212 1* 01/01/70 02/05/75 
214 2 01/01/67 02/04/75 
216 2 01/01/71 02/04/75 
217 2* 01/01/74 02/04/75 
220 2 01/01/72 02/04/75 
221 2 01/01/66 03/04/75 
223 2* 01/01/72 08/01/77 
226 1* 01/01/70 03/01/75 
228 2* 05/01/63 03/05/75 
229 1* 01/01/50 03/19/75 
230 2* 01/01/68 03/25/75 
231 2 01/01/74 03/25/75 
232 2* 01/01/63 03/25/75 
234 1* 01/01/74 03/25/75 
235 2 01 01 66 04 02 75 
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241 1* 08/01/73 08/15/73 242 2* 01/01/63 01/01/75 244 2 01/01/68 05/01/75 245 2 11/01/71 05/01/75 246 2* 01/01/69 06/20/74 249 2 01/01/67 01/01/75 250 2* 01/01/75 01/01/75 251 1* 01/01/65 12/06/79 252 2 07/01/70 07/07/70 
255 1* 01/01/70 04/01/75 257 2 01/01/73 05/01/75 258 2 01/01/74 05/02/75 259 2 01/01/68 05/01/75 
260 2* 01/01/70 05/01/75 261 1 01/01/71 05/01/75 
262 2* 01/01/68 05/01/75 264 2 01/01/71 05/01/75 
265 2 01/01/73 05/01/75 
266 2 01/01/68 05/03/75 268 1 04/01/75 04/29/75 
269 2 05/01/75 05/10/75 
271 2 05/01/75 05/02/75 
272 2* 01/01/70 04/20/75 
276 2* 01/01/45 06/10/75 
277 2* 01/01/55 06/09/75 
279 2* 01/01/65 06/22/75 
281 2* 01/01/55 06/09/75 
282 2* 01/01/45 07/01/75 
283 1* 07/01/75 07/07/75 
286 2* 01/01/55 07/25/75 
287 1* 01/01/74 07/30/75 
288 1* 01/01/69 07/31/75 
289 2 01/01/65 07/31/75 
290 2* 01/01/60 07/31/75 
291 1 01/01/75 07/29/75 
292 2 01/01/72 07/29/75 
296 1 01/01/70 08/19/75 
297 1* 01/01/71 08/03/75 
298 2* 01/01/55 09/17/75 
299 1* 01/01/45 09/17 /75 
301 2 10/01/75 10/23/75 
302 2* 01/01/63 10/01/75 
304 2* 01/01/70 07/24/74 
305 1 10/01/75 10/31/75 
306 1* 01/01/59 10/30/74 
307 1* 01/01/61 11/24/75 
308 2 01/01/74 11/25/75 
309 2 01/01/72 11/25/75 
311 2* 01/01/66 11/25/75 
312 2* 01/01/57 11/25/75 
314 1* 01/01/70 12/12/75 
315 1 01 01 72 12 12 75 
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328 2 01/01/76 01/25/76 329 1* 01/01/73 09/14/75 331 2 01/01/68 02/12/76 333 2 01/01/71 02/28/76 
335 2* 01/01/60 03/06/76 
336 1 01/01/70 03/08/76 339 2 01/01/65 03/12/76 340 2 01/01/73 03/12/76 341 2 01/01/72 03/15/76 342 2 01/01/73 03/15/76 
343 1* 01/01/50 03/18/76 
345 1* 01/01/70 03/21/76 346 2 01/01/64 03/21/76 
349 2 01/01/67 04/05/76 
350 2* 01/01/70 04/05/76 
351 2* 01/01/66 04/26/76 
352 2 01/01/68 04/26/76 
354 1 01/01/62 OS/22/76 
356 2 01/01/76 OS/25/76 
359 2 01/01/66 06/14/76 
360 1 01/01/72 06/19/76 
361 2 01/01/74 06/19/76 
362 2 01/01/75 06/01/76 
364 1 01/01/56 06/01/76 
365 1 01/01/51 07/05/76 
366 1 01/01/50 08/01/76 
367 2 01/01/68 08/16/76 
368 2* 01/01/60 08/18/76 
369 1* 01/01/74 09/02/76 
370 1 01/01/68 09/06/76 
372 2 01/01/75 09/09/76 
376 2* 01/01/56 10/01/76 
377 1* 01/01/73 10/07/76 
378 2* 01/01/69 10/07/76 
379 1 01/01/72 10/07/76 
380 2 01/01/71 10/11/76 
381 1* 01/01/69 10/21/76 
382 1* 01/01/56 11/02/76 
383 2* 01/01/70 11/02/76 
384 2 01/01/65 11/02/76 
385 2 01/01/73 11/02/76 
386 1* 01/01/56 11/02/76 
387 1* 01/01/46 11/02/76 
388 1* 01/01/66 11/14/76 
389 1* 01/01/72 11/25/76 
391 2 01/01/68 11/30/76 
392 1 01/01/65 11/30/76 
393 2* 01/01/57 11/30/76 
394 1 01/01/66 12/06/76 
395 2 01/01/69 12/06/76 
397 2* 01/01/65 12/14/76 
399 2 01/01/64 12 21 76 
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404 2 01/01/71 12/21/76 405 2 01/01/70 01/05/77 407 1* 02/01/77 02/14/77 410 2 01/01/64 03/01/77 
411 1* 01/01/72 03/01/77 412 1 01/01/72 03/04/77 413 2 01/01/74 03/04/77 414 2* 01/01/37 03/17/77 415 1 01/01/61 03/23/77 416 1 01/01/76 03/23/77 
417 2 01/01/71 03/13/77 418 2* 01/01/60 04/13/77 419 2 01/01/74 04/13/77 
423 2 01/01/71 04/21/77 
426 2* 01/01/47 04/21/77 
427 1 01/01/73 04/26/77 
428 2 01/01/71 05/08/77 
432 1 01/01/73 05/16/77 
434 2 01/01/74 05/16/77 
435 1* 01/01/65 05/30/77 
436 2 01/01/69 05/30/77 438 2* 01/01/48 06/20/77 
439 2* 01/01/62 06/20/77 441 2* 01/01/59 07/03/77 
443 1* 01/01/63 07/17/77 
444 2* 04/01/75 10/10/76 445 1 01/01/70 01/25/74 
446 2* 07/01/77 07/22/77 
447 1* 01/01/67 08/01/77 
448 1 01/01/67 08/01/77 
449 2* 01/01/50 02/18/75 
450 1 01/01/72 08/09/77 
451 2* 01/01/71 08/09/77 
452 2 01/01/64 08/09/77 
453 1 01/01/71 08/19/77 
454 2* 01/01/42 08/23/77 
455 1* 01/01/59 08/23/77 
456 1* 01/01/47 09/02/77 
458 1* 01/01/52 09/02/77 
459 1* 01/01/55 09/02/77 
460 1* 01/01/57 09/06/77 
461 1* 01/01/67 09/06/77 
463 1 01/01/57 09/21/77 
464 2 01/01/66 09/26/77 
465 2* 01/01/75 09/26/77 
468 2 01/01/74 10/10/77 
469 2 01/01/64 10/14/77 
470 1 01/01/71 10/14/77 
473 2 10/01/77 10/22/77 
474 2 01/01/67 11/04/77 
475 1 01/01/67 11/04/77 
477 1* 01 01 63 11 04 77 
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486 2 01/01/70 01/10/78 
489 2 01/01/72 01/20/78 492 1* 01/01/66 01/25/78 493 1* 01/01/58 02/03/78 
494 1* 01/01/53 02/14/78 
495 2 01/01/66 03/01/78 
496 2 01/01/68 03/01/78 
497 1* 01/01/68 03/01/78 
498 2* 01/01/76 03/07/78 
499 2 01/01/64 03/08/78 500 2 01/01/75 03/15/78 501 1 01/01/63 03/17/78 502 2* 01/01/64 03/17/78 503 2 01/01/58 03/28/78 504 1 01/01/63 03/31/78 505 2* 01/01/72 03/31/78 
507 2* 01/01/62 04/03/78 508 2 01/01/56 04/09/78 511 1 01/01/65 04/16/78 512 1* 01/01/65 04/19/78 
513 2 01/01/74 04/28/74 515 2 05/01/78 05/06/78 517 1* 01/01/52 05/08/78 518 1* 01/01/47 05/08/78 519 1* 01/01/43 05/10/78 
520 2* 01/01/43 05/10/78 522 1* 01/01/48 05/15/78 
524 2* 01/01/51 05/15/78 
527 2* 01/01/48 05/16/78 
529 1 01/01/77 OS/23/78 
530 2 01/01/62 OS/23/78 
532 2* 01/01/63 06/08/78 
533 2 01/01/72 06/12/72 
534 1* 01/01/73 . 06/12/78 
535 2 01/01/66 06/12/78 
535 2 01/01/66 06/12/78 
536 2 01/01/67 06/12/78 
538 2* 01/01/58 06/21/78 
539 2* 01/01/58 06/21/78 
542 2 01/01/58 06/28/78 
544 1 01/01/62 07/27/78 
546 1* 01/01/68 08/01/78 
547 2* 01/01/48 08/04/78 
548 1* 01/01/72 08/08/78 
550 1 01/01/63 08/18/78 
551 2 01/01/75 08/21/78 
552 2* 01/01/62 08/21/78 
553 1* 01/01/72 08/21/78 
555 2* 01/01/73 09/05/78 
557 1 01/01/74 09/09/78 
558 2 01/01/69 09/09/78 
559 2 01 01 73 09 14 78 
APPENDIX I 173 
Number Sex Date of Birth Date of Entry 
565 2 01/01/56 09/27/78 566 1 01/01/67 09/27/78 
567 1 01/01/77 09/27/78 568 1 01/01/77 09/27/78 570 2 01/01/67 10/02/78 571 2 01/01/48 10/02/78 572 2* 01/01/63 10/15/78 
573 2* 01/01/71 10/15/78 574 1 01/01/70 10/22/78 
575 1 01/01/66 10/22/78 
577 2* 01/01/62 10/22/78 
578 2 01/01/68 10/22/78 
581 1 01/01/74 10/25/78 
582 1 04/01/78 11/01/78 
583 2 01/01/70 11/01/78 584 2 01/01/66 11/01/78 585 2* 01/01/65 11/01/78 
586 2 01/01/69 11/06/78 
587 1* 01/01/72 11/06/78 
588 2 01/01/69 11/06/78 
589 1* 01/01/65 11/07/78 
594 1 05/01/78 11/22/78 
595 2 01/01/72 11/29/78 
596 2* 01/01/58 11/21/78 
597 1 01/01/76 11/21/78 
598 2* 01/01/73 12/10/78 
599 2 01/01/74 12/10/78 
600 2 01/01/75 12/10/78 
602 1* 01/01/66 12/10/78 
603 2 01/01/66 12/10/78 
604 1* 01/01/58 12/10/78 
606 2* 01/01/70 01/12/79 
607 2 01/13/79 01/13/79 
608 1* 01/01/77 01/16/79 
609 1* 01/01/69 01/22/79 
610 2* 01/01/56 02/09/79 
611 1 01/01/74 02/09/79 
612 1 01/01/62 02/09/79 
613 2* 01/01/59 02/09/79 
615 2* 01/01/62 02/09/79 
616 2 01/01/69 02/15/69 
617 2* 01/01/49 02/15/79 
619 2 01/01/59 02/20/79 
620 1 01/01/61 02/21/79 
622 1 01/01/72 02/25/79 
623 2 01/01/70 03/03/79 
624 1* 01/01/69 03/03/79 
625 1* 01/01/69 03/03/79 
626 2* 03/01/79 03/02/79 
627 2* 01/01/62 03/18/79 
629 2 01/01/69 03/19/79 
630 2 01 01 68 03 19 79 
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636 2 01/01/69 04/02/79 
638 2 01/01/76 04/05/79 
639 2* 01/01/71 04/05/79 640 2 01/01/65 04/05/79 642 2 05/01/77 04/18/79 644 2* 01/01/49 04/18/79 645 2* 01/01/73 04/18/79 646 2 01/01/64 04/20/79 
648 1 01/01/65 05/02/79 649 2 01/01/63 05/02/79 
650 1 05/01/79 05/10/79 
651 1* 05/01/79 05/12/79 654 2* 01/01/39 05/17/79 655 2 05/01/79 05/19/79 659 1* 01/01/65 06/06/79 661 2 01/01/72 06/15/79 
662 2 01/01/74 06/15/79 
664 2* 01/01/61 06/15/79 
667 2 01/01/69 06/22/79 
668 2 01/01/75 06/22/79 
669 2 01/01/54 06/22/79 
670 1* 01/01/70 06/22/79 
673 1* 01/01/59 06/27/79 
675 2* 01/01/49 07/17 /79 
679 1 01/01/59 07/19/79 
682 1* 01/01/63 07/31/79 
684 2 01/01/72 08/20/79 
685 2* 01/01/72 08/21/79 
688 2* 01/01/49 09/11/79 
689 2* 01/01/61 09/11/79 
690 2* 05/01/76 09/11/79 
692 1 01/01/69 09/14/79 
693 2* 01/01/68 09/14/79 
694 1 01/01/76 09/14/79 
696 1 01/01/77 09/21/79 
698 1 01/01/75 09/21/79 
699 2 01/01/63 09/25/79 
700 1 01/01/70 09/25/79 
704 2* 01/01/74 09/26/79 
705 1* 01/01/59 09/26/79 
706 2 01/01/61 09/26/79 
707 1* 01/01/39 09/28/79 
708 1* 01/01/63 09/28/79 
709 1 03/01/79 10/12/79 
711 1* 01/01/64 11/06/79 
712 2* 01/01/69 11/06/79 
713 2 01/01/74 11/27/79 
714 2 01/01/63 12/11/79 
716 1 01/01/67 12/11/79 
718 2* 01/01/65 12/11/79 
719 2 01/01/65 12/11/79 
720 2* 1 01 49 12 11 79 
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726 1 01/01/60 01/08/80 
727 1 01/01/75 01/10/80 
728 2 01/01/70 01/24/80 
729 2 01/01/79 01/24/80 
731 1 01/01/75 01/24/80 
732 1* 01/01/77 01/24/80 
737 2* 01/01/69 02/07/80 
738 2 01/01/75 02/07/80 
739 2 01/01/76 02/07/76 
740 2 01/01/72 02/07/80 
741 2 01/01/71 02/07/80 
742 1* 01/01/72 02/07/80 
743 1* 01/01/58 02/07/80 
744 2 01/01/76 02/11/80 
745 1* 01/01/63 02/11/80 
746 2 01/01/60 02/12/80 
750 2* 01/01/45 02/29/80 
751 2 01/01/72 02/29/80 
753 1* 01/01/50 03/04/80 
754 2 01/01/76 03/04/80 
755 2* 01/01/66 03/04/80 
756 2 01/01/74 03/11/80 
758 2* 01/01/62 03/11/80 
761 2 01/01/70 03/10/80 
762 2 01/01/73 03/18/80 
763 2 01/01/74 03/18/80 
765 2* 01/01/50 03/27/80 
766 2 01/01/65 03/27/80 
767 2* 01/01/55 03/27/80 
768 2 03/01/80 03/29/80 
769 2 01/01/73 04/08/80 
770 2 01/01/70 04/08/80 
773 2 01/01/71 04/17/80 
775 2* 01/01/68 04/18/80 
777 2* 01/01/78 04/23/80 
780 2 01/01/77 04/24/80 
781 2 01/01/69 04/24/80 
783 2* 01/01/70 04/24/80 
784 2 01/01/69 04/25/80 
785 2 01/01/73 04/25/80 
786 2 01/01/74 04/25/80 
787 2 01/01/55 04/28/80 
788 2 01/01/76 04/28/80 
791 2 01/01/76 04/30/80 
792 2 01/01/75 05/09/80 
793 2 01/01/73 05/09/80 
794 1* 01/01/73 05/30/80 
797 1 01/01/71 06/04/80 
798 1* 01/01/72 06/07/80 
801 1 01/01/66 06/17/80 
802 2 05/01/69 06/17/80 
807 2 1 7 2 
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811 1 01/01/73 07/03/80 812 1 01/01/60 07/03/80 
813 1* 01/01/65 07/03/80 814 2* 01/01/76 07/08/80 
816 1 01/01/68 07/11/80 818 1* 01/01/70 07/14/80 819 1 01/01/62 07/25/80 
822 2* 01/01/73 08/01/80 823 2* 01/01/55 08/01/80 
825 2 01/01/70 08/05/80 827 1* 01/01/60 08/20/80 
828 1 01/01/75 08/21/80 829 1 01/01/72 09/02/80 
830 2 01/01/76 09/06/80 
832 2 01/01/76 09/06/80 
833 1* 01/01/70 09/06/80 
834 2* 09/01/80 09/08/80 
836 2* 01/01/70 09/17/80 
838 2 01/01/77 09/17/80 
839 2 01/01/78 09/17/80 
840 2 01/01/71 09/19/80 
842 1 01/01/77 09/24/80 
843 2 01/01/69 09/24/80 
844 2* 01/01/55 09/24/80 
846 2 01/01/68 10/01/80 
847 1* 01/01/55 10/01/80 
848 2 01/01/75 10/01/80 
849 2 01/01/75 10/01/80 
850 1* 01/01/56 10/01/80 
851 2 01/01/65 10/03/80 
852 2* 01/01/62 10/03/80 
857 1* 01/01/73 10/08/80 
858 2 01/01/75 10/08/80 
864 1 06/01/69 10/12/80 
865 2 01/01/70 10/12/80 
866 2 01/01/62 10/13/80 
867 2 01/01/73 10/13/80 
869 2 01/01/73 10/29/80 
870 2 01/01/64 10/31/80 
871 2* 01/01/60 10/31/80 
872 1 01/01/65 10/31/80 
873 2 01/01/78 11/04/80 
875 1 01/01/65 11/06/80 
877 1 01/01/72 11/06/80 
878 2 01/01/70 11/06/80 
879 2 01/01/73 11/07/80 
880 2 01/01/73 11/07/80 
881 1 05/01/77 11/07/80 
882 2* 01/01/68 11/18/80 
884 2 01/01/74 11/18/80 
887 1 01/01/73 11/19/80 
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897 2 01/01/72 11/29/80 
898 2 01/01/75 11/28/80 
901 2 01/01/68 12/01/80 
904 1 01/01/71 12/04/80 
905 1 01/01/72 12/04/80 
906 1* 01/01/63 12/04/80 
907 2* 01/01/50 12/04/80 
909 1* 01/01/74 12/09/80 
910 1 01/01/60 12/10/80 
911 1 01/01/70 12/10/80 
913 2 01/01/77 12/12/80 
916 1 01/01/73 12/16/80 
917 1 01/01/77 12/15/80 
918 2 01/01/73 12/15/80 
920 1* 01/01/65 12/18/80 
925 2 01/01/79 01/03/81 
926 1 01/01/66 01/14/81 
930 1 01/01/70 01/16/81 
931 2* 01/01/72 01/20/81 
932 2 01/01/76 01/20/81 
933 1* 01/01/71 01/22/81 
935 1 01/01/69 02/04/81 
936 2 06/01/75 02/04/81 
938 2* 01/01/79 02/14/81 
939 2 01/01/63 02/14/81 
940 2 09/01/80 02/14/81 
943 2* 01/01/77 03/03/81 
944 1 01/01/56 03/10/81 
947 1 01/01/74 03/11/81 
948 2 01/01/64 03/11/81 
949 2 01/01/74 03/11/81 
950 1 01/01/73 03/11/81 
951 2 01/01/76 03/16/81 
952 2 01/01/72 03/16/81 
953 2 01/01/58 03/20/81 
954 1 01/01/73 03/20/81 
955 2* 01/01/60 03/20/81 
956 1* 01/01/73 03/20/81 
959 2 01/01/66 03/24/81 
960 2* 01/01/41 03/24/81 
964 2 01/01/76 03/30/81 
965 1 01/01/50 03/31/81 
966 2 01/01/70 04/03/81 
967 1 01/01/75 04/03/81 
968 2* 01/01/65 04/03/81 
969 1 01/01/73 04/03/81 
970 1* 01/01/73 04/06/81 
971 1* 01/01/71 04/06/81 
972 2* 01/01/73 04/06/81 
973 2 01/01/71 04/06/81 
974 1 01/01/72 04/07/81 
975 
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982 1* 01/01/50 04/16/81 984 2 01/01/61 04/22/81 985 2* 01/01/64 04/22/81 
986 2* 01/01/56 04/24/81 
987 2 06/01/76 04/24/81 
988 2 01/01/63 04/24/81 
989 2 01/01/60 04/24/81 
990 2 01/01/61 04/24/81 
994 2 01/01/64 04/30/81 
995 2 01/01/76 04/30/81 
996 2 01/01/79 04/30/81 
997 2 01/01/63 04/30/81 
998 2 01/01/62 04/30/81 
999 2 01/01/76 05/01/81 
1000 2* 01/01/70 05/01/81 
1001 2* 01/01/70 05/05/81 
1002 2 04/01/72 05/07/81 
1003 1 01/01/65 05/07/81 
1004 2 08/01/67 05/12/81 
1005 1 04/01/68 05/12/81 
1006 2 01/01/75 05/12/81 
1007 2* 01/01/61 05/12/81 
1008 2* 01/01/59 05/15/81 
1009 2* 01/01/56 05/15/81 
1010 2 01/01/75 05/14/81 
1011 2 01/01/78 05/14/81 
1012 1 01/01/67 05/14/81 
1015 2* 01/01/71 OS/20/81 
1016 2 01/01/76 OS/20/81 
1019 2* 05/01/81 OS/23/81 
1020 1* 01/01/60 OS/26/81 
1021 2* 01/01/60 OS/26/81 
1023 2* 01/01/71 OS/29/81 
1024 2 01/01/72 OS/29/81 
1027 2 01/01/74 06/08/81 
1029 2 01/01/74 06/09/81 
1030 1 05/01/67 06/10/81 
1031 2 01/01/66 06/16/81 
1033 1 01/01/66 06/30/81 
1034 2 01/01/76 06/30/81 
1036 1* 08/01/79 06/30/81 
1037 1 07/01/78 06/30/81 
1038 2 01/01/68 06/30/81 
1039 2 01/01/70 07/07/81 
1040 2 01/01/69 07/07/81 
1041 2 01/01/69 07/09/81 
1042 2 01/01/71 07/09/81 
1043 2 01/01/72 07/09/81 
1044 2 01/01/70 07/09/81 
1045 2* 01/01/72 07/09/81 
1046 2 01/01/76 07/09/81 
1047 2 1 
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1051 1* 01/01/75 07/10/81 1053 1 01/01/62 07/14/81 1054 2 01/01/65 07/14/81 
1055 2 01/01/81 07/14/81 
1057 2 01/01/76 07/16/81 
1058 2 01/01/75 07/17/81 1059 2* 01/01/71 07/17 /81 1060 1 01/01/71 07/20/81 
1061 2* 01/01/71 07/20/81 1062 2 01/01/71 07/28/81 
1063 1 01/01/70 07/28/81 
1065 1* 01/01/74 08/10/81 
1068 1* 01/01/47 08/25/81 
1069 1* 01/01/75 08/27/81 
1071 2 01/01/68 08/27/81 
1072 1 01/01/71 08/27/81 
1073 2 01/01/73 09/04/81 1074 2 01/01/54 09/04/81 
1076 2* 01/01/66 09/15/81 
1077 1* 01/01/72 09/15/81 
1078 2* 01/01/75 09/15/81 
1079 1* 01/01/72 09/15/81 
1080 2 01/01/65 09/22/81 
1081 1 01/01/65 09/22/81 
1082 2* 01/01/56 09/22/81 
1083 2* 01/01/60 09/22/81 
1085 1 08/01/72 09/22/81 
1088 2* 01/01/69 09/25/81 
1089 1* 01/01/56 09/25/81 
1090 2* 01/01/56 10/08/81 
1091 2 01/01/76 10/08/81 
1094 2 01/01/79 10/13/81 
1097 2 01/01/70 10/14/81 
1100 2 01/01/75 10/14/81 
1101 2 01/01/76 10/14/81 
1102 2 01/01/72 10/14/81 
1104 2 01/01/62 10/14/82 
1105 2 01/01/76 10/14/81 
1106 2* 01/01/51 10/16/81 
1107 1 02/01/80 10/20/81 
1108 2 01/01/56 10/20/81 
1109 1 01/01/71 10/20/81 
1111 1* 01/01/69 10/23/81 
1112 1 01/01/69 10/23/81 
1113 1 01/01/71 10/23/81 
1115 2 01/01/72 10/27/81 
1116 2 01/01/62 10/27/81 
1118 1 01/01/76 10/30/81 
1121 2 01/01/67 11/05/81 
1122 2 05/01/79 11/04/81 
1123 2 01/01/70 11/06/81 
1124 2* 01 01 62 11 06 81 
APPENDIX I 180 
Number Sex Date of Birth Date of Entry 
1129 1* 06/01/75 11/17/81 
1131 1 06/01/79 11/24/81 
1132 2 01/01/73 11/25/81 
1133 2 01/01/79 11/25/81 
1135 2* 01/01/65 11/30/81 
1136 1* 01/01/71 12/04/81 
1137 1 01/01/78 12/04/81 
1138 1 01/01/77 12/22/81 
1141 2* 01/01/50 12/16/81 
1142 1* 01/01/61 12/30/81 
1145 2* 01/01/71 01/06/82 
1148 1* 01/01/57 01/07/82 
1149 2 01/01/68 01/07/82 
1150 2 01/01/75 01/07/82 
1151 2* 01/01/72 01/07/82 
1153 1 01/01/75 01/20/82 
1154 2 01/01/79 01/20/82 
1155 2 01/01/77 01/20/82 
1156 1 01/01/77 01/20/82 
1158 1 01/01/80 01/20/82 
1159 2 01/01/77 01/21/82 
1160 1 01/01/77 01/21/82 
1161 2* 01/01/81 01/26/81 
1162 2* 01/01/78 02/26/82 
1163 2 01/01/67 01/21/82 
1164 2 01/01/62 02/21/82 
1165 1 01/01/64 01/21/82 
1168 2 01/01/74 01/28/82 
1169 1 01/01/79 01/28/82 
1175 1 01/01/75 02/05/82 
1176 2 01/01/77 02/05/82 
1177 1 01/01/64 02/08/82 
1178 2* 01/01/65 12/08/82 
1179 2 01/01/62 02/08/82 
1180 1 01/01/81 02/15/82 
1181 1* 01/01/57 02/16/82 
1182 2* 01/01/55 02/19/82 
1183 1 01/01/52 02/19/82 
1184 1 02/01/82 02/01/82 
1185 2* 01/01/66 02/23/82 
1186 1 01/01/75 02/23/82 
1187 2 01/01/74 02/23/82 
1188 2 01/01/71 02/25/82 
1191 2* 01/01/75 03/04/82 
1195 2 01/01/74 03/08/82 
1196 2* 01/01/73 03/08/82 
1197 2 01/01/72 03/08/82 
1198 2* 01/01/70 03/08/82 
1199 2 01/01/72 03/08/82 
1200 1 01/01/72 03/10/82 
1201 2 01/01/62 03/12/82 
1202 2* 03/12/82 
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1218 2* 01/01/60 03/24/82 1225 2 01/01/72 04/02/82 1226 2 01/01/78 04/02/82 1227 2 01/01/77 04/02/82 
1229 1 01/01/81 04/02/82 
1230 2 01/01/72 04/02/82 
1231 1 04/01/82 04/02/82 
1232 2* 04/01/82 04/02/82 
1234 2* 01/01/67 04/06/82 
1238 1 01/01/75 04/22/82 
1239 2 01/01/73 04/22/82 
1240 1* 01/01/48 04/22/82 
1241 2 01/01/74 04/22/82 
1243 2* 01/01/76 04/26/82 1245 2 01/01/77 04/27/82 
1246 2 01/01/78 04/27/82 
1247 1 06/01/80 04/27/82 
1248 1 01/01/72 04/27/82 
1249 2 01/01/75 04/27/82 
1251 2* 01/01/53 05/07/82 
1252 2 01/01/60 05/07/82 
1256 2 01/01/75 05/18/82 
1258 1 01/01/77 05/18/82 
1259 1 01/01/58 OS/21/82 
1260 2* 01/01/65 OS/21/82 
1262 2 01/01/68 OS/25/82 
1263 1 01/01/68 OS/25/82 
1264 2 01/01/57 OS/27/82 
1265 1 01/01/62 OS/27/82 
1266 2 01/01/67 OS/28/82 
1270 1* 01/01/57 06/01/82 
1271 2 01/01/62 06/01/82 
1272 2* 01/01/75 06/01/82 
1274 1 01/01/62 06/09/82 
1275 1 01/01/79 06/11/82 
1276 2 01/01/67 06/11/82 
1279 2 01/01/75 06/16/82 
1280 2 01/01/57 06/16/82 
1281 2 01/01/66 06/18/82 
1282 2 05/01/71 06/18/82 
1283 2 08/01/71 06/18/82 
1284 2 11/01/72 06/18/82 
1285 2 04/01/76 06/18/82 
1286 1 10/01/73 06/18/82 
1287 1* 09/01/74 06/18/82 
1288 1 06/01/75 06/18/82 
1290 1* 01/01/57 06/25/82 
1293 2 01/01/50 07/07/82 
1295 2* 01/01/79 07/07/82 
1297 2* 05/01/82 07/07/82 
1298 2 01/01/78 07/07/82 
1299 2* 01 01 40 07 07 82 
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Number Sex Date of Birth Date of Entry 
1308 2* 06/01/72 07/21/82 
1309 2 05/01/77 07/21/82 
1311 1 01/01/75 07/22/82 
1319 2 01/01/70 08/02/82 
1320 1 01/01/68 08/03/82 1321 2* 01/01/63 08/03/82 1322 1 01/01/60 08/03/82 
1323 1 01/01/60 08/03/82 1324 2 01/01/70 08/06/82 
1326 2 01/01/72 08/06/82 
1331 1 01/01/72 08/12/82 
1333 1 01/01/76 09/02/82 1334 2 01/01/76 09/02/82 
1341 1 01/01/72 09/17/82 
1342 1* 01/01/68 09/17/82 
1344 1* 01/01/81 09/17 /82 
1345 1 01/01/65 09/17/82 
1346 1* 01/01/69 09/21/82 
1347 1 01/01/79 09/21/82 
1349 1 01/01/80 10/05/82 
1350 1 01/01/64 10/08/82 
1353 2* 01/01/68 10/08/82 
1360 1* 01/01/70 10/27/82 
1361 1 01/01/72 10/27/82 
1371 1 01/01/70 11/10/82 
1372 1 01/01/45 11/12/82 
1376 1 01/01/74 11/17/82 
1377 2 01/01/80 11/17/82 
1378 2 01/01/76 11/17/82 
1385 1* 01/01/72 11/18/82 
1388 1 01/01/72 11/18/82 
1390 1 01/01/72 11/19/82 
1391 1* 01/01/70 11/19/82 
1397 2* 01/01/69 12/08/82 
1398 2* 01/01/68 12/09/82 
1399 2* 01/01/69 12/09/82 
1400 2* 01/01/42 12/09/82 
1401 2* 01/01/68 12/09/82 
1402 2 01/01/70 12/11/82 
1403 2 01/01/76 12/11/82 
1404 1 01/01/81 12/11/82 
1411 2 01/01/62 12/21/82 
1412 1 01/01/72 12/21/82 
1413 2 01/01/70 12/21/82 
1414 2* 01/01/69 12/21/82 
1416 1 01/01/77 12/21/82 
1419 2 01/01/75 01/07/83 
1422 1* 01/01/63 01/10/83 
1424 1 01/01/53 01/11/83 
1426 2 01/01/58 01/19/83 
1427 1 01/01/50 01/19/83 
1428 2 01 01 80 01 18 83 
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1438 2 01/01/70 02/04/83 
1441 2* 01/01/63 02/09/83 
1442 2* 01/01/74 02/09/83 
1443 2 01/01/64 02/09/83 
1444 2 01/01/64 02/09/83 
1445 2 01/01/67 02/15/83 
1447 1* 01/01/68 02/15/83 
1448 2* 01/01/63 02/15/83 
1449 2 01/01/61 02/15/83 
1450 1 01/01/67 02/16/83 
1451 2 01/01/63 02/18/83 
1452 2 01/01/68 02/21/83 
1453 2 01/01/74 02/21/83 
1454 2* 01/01/71 02/21/83 
1455 2 01/01/72 02/22/83 
1456 1 01/01/77 02/22/83 
1457 1 01/01/76 02/22/83 
1458 1 10/01/81 02/22/83 
1461 2* 01/01/63 02/24/83 
1465 1 01/01/55 03/10/83 
1466 1 01/01/63 03/10/83 
1467 2* 01/01/70 03/10/83 
1470 2 01/01/63 03/13/83 
1471 2* 01/01/53 03/13/83 
1472 2 01/01/53 03/13/83 
1473 2 01/01/76 03/16/83 
1475 1* 01/01/79 03/16/83 
1476 2 01/01/59 03/16/83 
1480 1* 06/30/82 04/01/83 
1483 1* 01/01/53 04/06/83 
1487 1 01/01/71 04/12/83 
1488 2 01/01/69 04/12/83 
1490 2 01/01/80 04/12/83 
1492 2 01/01/76 04/12/83 
1494 2 01/01/53 04/12/83 
1496 2 01/01/72 04/15/83 
1497 2 01/01/78 04/15/83 
1498 1 01/01/80 04/15/83 
1499 1 11/01/81 04/15/83 
1500 2 01/01/72 04/19/83 
1501 2* 01/01/67 04/19/83 
1502 1 01/01/73 04/19/83 
1503 1 01/01/66 04/20/83 
1504 2* 01/01/63 04/20/83 
1505 2 01/01/68 04/20/83 
1506 2 01/01/70 04/25/83 
1507 2* 01/01/73 04/25/83 
1511 2* 01/01/73 04/28/83 
1514 1* 01/01/58 05/05/83 
1515 2 01/01/58 05/05/83 
1516 2 01/01/58 05/05/83 
1518 2 1 1 1 1 
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1528 1 01/01/70 05/13/83 
1529 2* 01/01/63 05/13/83 
1530 2 01/01/59 05/13/83 
1533 2 01/01/72 05/18/83 
1536 2* 01/01/48 OS/25/83 
1537 2 01/01/74 OS/25/83 
1538 1 01/01/63 OS/25/83 
1539 2* 01/01/43 OS/25/83 
1540 2 01/01/68 OS/25/83 
1541 1* 01/01/60 OS/25/83 
1546 2* 01/01/63 06/10/83 
1547 2* 01/01/73 06/10/83 
1548 2 06/11/83 06/11/83 
1552 2 01/01/63 06/22/83 
1554 2 01/01/50 06/30/83 
1555 2* 01/01/66 06/30/83 
1557 1 01/01/58 06/30/83 
1562 1 01/01/50 07/11/83 
1564 2* 01/01/63 07/12/83 
1565 1 01/01/63 07/12/83 
1566 2 01/01/75 07/12/83 
1568 1* 01/01/79 07/12/83 
1569 2 01/01/78 07/12/83 
1571 2 01/01/81 07/12/83 
1572 1 01/01/72 07/15/83 
1573 2 01/01/73 07/15/83 
1574 2* 01/01/58 07/15/83 
1576 2 01/01/78 07/15/83 
1579 2 01/01/75 07/19/83 
1580 2 01/01/71 07/19/83 
1581 2 01/01/76 07/21/83 
1584 2 06/01/74 07/21/83 
1585 2 05/01/73 07/21/83 
1586 2 01/01/67 07/21/83 
1587 1 01/01/73 07/27/83 
1588 2 01/01/76 07/27/83 
1590 2 01/01/73 08/01/83 
1591 1* 01/01/68 08/01/83 
1592 2 01/01/63 08/01/83 
1593 1 01/01/57 08/08/83 
1594 1 01/01/68 08/08/83 
1595 2 04/01/77 08/11/83 
1596 2 01/01/70 08/16/83 
1597 1 01/01/77 08/16/83 
1598 2 01/01/78 08/16/83 
1600 2 01/01/79 08/19/83 
1603 1 01/01/72 08/19/83 
1604 2 01/01/70 08/19/83 
1608 2 01/01/63 08/24/83 
1609 2 01/01/71 08/24/83 
1612 1 01/01/73 08/26/83 
1613 
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1622 2* 01/01/79 09/08/83 1623 2 01/01/75 09/08/83 1628 1 01/01/70 09/16/83 1629 1 01/01/65 09/16/83 1631 2 01/01/70 09/21/83 1632 1 01/01/74 09/21/83 
1633 1 01/01/73 09/23/83 
1634 2 01/01/75 10/03/83 
1638 1 01/01/60 10/07/83 
1639 2 01/01/67 10/07/83 
1640 1 01/01/67 10/07/83 
1649 1 02/01/76 10/17/83 
1650 1 02/01/78 01/17/83 
1651 2 07/01/69 01/17/83 
1658 2 01/01/70 10/21/83 
1659 2* 01/01/78 10/21/83 
1660 2* 01/01/70 10/25/83 
1661 2 06/01/74 10/25/83 
1664 1 01/01/58 10/27/83 
1665 1* 01/01/53 10/28/83 
1666 1 01/01/58 10/28/83 
1668 2* 01/01/63 11/01/83 
1671 2* 01/01/70 11/01/83 
1672 1 01/01/76 11/01/83 
1674 1 01/01/67 11/04/83 
1675 1 01/01/60 11/04/83 
1676 2 01/01/58 11/04/83 
1677 1 01/01/75 11/04/83 
1680 2* 01/01/43 11/10/83 
1681 1 01/01/66 11/10/83 
1682 1 01/01/66 11/10/83 
1684 1 01/01/63 11/17/83 
1688 2 01/01/63 11/21/83 
1689 1 01/01/71 11/21/83 
1690 1 01/01/76 11/23/83 
1691 1* 01/01/70 11/28/83 
1694 2* 01/01/71 12/01/83 
1696 2 06/01/82 12/01/83 
1697 2 01/01/72 12/01/83 
1699 2 01/01/75 12/01/83 
1700 1 01/01/75 12/01/83 
1703 2* 01/01/72 12/09/83 
1707 1 01/01/80 12/09/83 
1709 1 01/01/73 12/09/83 
1712 1 01/01/81 12/16/83 
1714 2 01/01/79 12/19/83 
1716 1 01/01/76 12/22/83 
1717 2 01/01/71 12/22/83 
1718 1* 01/01/68 01/06/84 
1721 2 01/01/79 01/10/84 
1723 2 01/01/64 01/13/84 
1724 2 08 01 71 01 13 84 
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1733 1 01/01/79 01/21/84 
1736 2 01/01/72 02/08/84 
1738 1 01/01/72 02/16/84 
1739 1 01/01/61 02/16/84 
1740 2 01/01/74 02/16/84 
1741 2 01/01/77 02/16/84 
1742 2 01/01/58 02/16/84 
1743 2 01/01/72 02/03/84 
1744 2 01/01/80 02/03/84 
1745 2 01/01/78 02/03/84 
1746 1 01/01/83 02/06/84 
1747 2* 01/01/82 02/10/84 
1749 1 01/01/73 02/10/84 
1753 2 01/01/70 02/21/84 
1754 1 01/01/73 02/21/84 
1758 2* 01/01/54 02/28/84 
1759 2 01/01/64 02/28/84 
1760 2 01/01/79 02/28/84 
1763 2 01/01/80 03/09/84 
1764 2 01/01/78 03/13/84 
1766 2 01/01/72 03/13/84 
1767 2 01/01/77 03/13/84 
1768 1* 01/01/71 03/14/84 
1772 2 04/01/70 03/20/84 
1773 2 01/01/59 03/20/84 
1774 2 01/01/62 03/20/84 
1776 2* 01/01/68 03/20/84 
1782 2 01/01/75 03/23/84 
1783 1 01/01/70 03/29/84 
1784 1* 01/01/71 03/29/84 
1785 2 01/01/75 04/05/84 
1786 2 01/01/73 04/05/84 
1788 2 01/01/66 04/05/84 
1790 1 04/01/73 04/05/84 
1791 2 04/01/84 04/07/84 
1793 1 01/01/83 04/12/84 
1794 1 01/01/83 04/12/84 
1795 2 01/01/83 04/12/84 
1797 2 01/01/74 04/12/84 
1799 2 04/01/84 04/18/84 
1806 2* 07/01/71 04/25/84 
1807 1 06/01/72 04/25/84 
1808 2 08/01/74 04/25/84 
1810 1* 01/01/50 04/27/84 
1811 1 01/01/68 04/27/84 
1814 2 05/01/84 05/02/84 
1818 2* 01/01/78 05/09/84 
1822 1* 01/01/39 05/11/84 
1823 2 01/01/76 05/11/84 
1824 1 01/01/64 05/11/84 
1825 2 01/01/70 05/11/84 
1828 2 01 01 77 05 16 84 
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1832 2 01/01/60 05/18/84 
1833 1 01/01/60 OS/23/84 
1834 1 01/01/60 OS/23/84 
1835 1* 01/01/79 OS/23/84 
1836 2* 01/01/79 OS/23/84 
1837 1 01/01/60 OS/25/84 
1840 2 01/01/59 OS/25/84 
1841 1 01/01/73 OS/25/84 
1843 1 01/01/60 05/30/84 
1844 2 01/01/69 05/30/84 
1845 2 01/01/80 06/07/84 
1846 1 01/01/80 06/07/84 
1847 2 01/01/67 06/09/84 
1848 2 01/01/59 06/12/84 
1849 1 01/01/78 06/12/84 
1850 2 01/01/79 06/12/84 
1851 2* 01/01/49 06/14/84 
1854 1 01/01/80 06/22/84 
1857 1 01/01/54 06/22/84 
1858 1 01/01/77 06/22/84 
1859 2 01/01/68 06/22/84 
1860 2 01/01/69 06/26/84 
1861 2 01/01/69 06/26/84 
1865 1 01/01/79 07/03/84 
1866 1 01/01/79 07/03/84 
1867 1 01/01/78 07/03/84 
1868 1 01/01/76 07/03/84 
1869 2 01/01/77 07/03/84 
1870 2 01/01/74 07/03/84 
1872 1* 01/01/77 07/06/84 
1873 2* 01/01/70 07/06/84 
1874 2 01/01/70 07/06/84 
1875 2 01/01/80 07/06/84 
1876 1 01/01/50 07/06/84 
1877 1 01/01/65 07/14/84 
1878 1 01/01/66 07/09/84 
1879 1 01/01/72 07/11/84 
1880 2 01/01/78 07/11/84 
1881 2 01/01/72 07/11/84 
1884 2 01/01/69 07/17 /84 
1885 1 01/01/76 07/17 /84 
1886 1 01/01/76 07/20/84 
1887 1 01/01/76 07/20/84 
1888 1 01/01/65 07/20/84 
1889 2 01/01/71 07/20/84 
1890 1 01/01/76 07/20/84 
1891 2* 01/01/70 07/20/84 
1904 1 01/01/72 08/03/84 
1906 2 01/01/68 08/15/84 
1907 2 06/01/74 08/15/84 
1908 2 06/01/75 08/15/84 
1909 2 01 01 64 08/15/84 
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1915 2* 01/01/64 08/30/84 
1916 1 01/01/54 08/30/84 
1917 2 01/01/78 09/05/84 
1921 2 01/01/75 09/06/84 
1922 2* 01/01/80 09/06/84 
1923 1 01/01/73 09/06/84 
1925 2 01/01/69 09/11/84 
1926 1 07/01/82 09/14/84 
1927 2* 01/01/50 09/14/84 
1928 2* 01/01/64 09/14/84 
1936 1 01/01/60 09/19/84 
1937 2 01/01/54 09/19/84 
1938 1* 01/01/69 09/19/84 
1939 2 01/01/60 09/21/84 
1945 1* 01/01/60 10/03/84 
1946 1 01/01/60 10/03/84 
1948 2 01/01/54 10/05/84 
1949 2 01/01/64 10/05/84 
1952 2 01/01/79 10/12/84 
1959 2 01/01/63 10/19/84 
1960 2 01/01/59 10/19/84 
1961 1 01/01/64 10/19/84 
1963 1 01/01/60 10/29/84 
1965 1 01/01/44 10/25/84 
1966 2* 01/01/59 10/25/84 
1967 1* 01/01/60 10/25/84 
1968 2 01/01/80 10/25/84 
1969 2 01/01/59 10/25/84 
1973 1 01/01/59 10/29/84 
1976 2 01/01/62 11/06/84 
1977 2 01/01/62 11/06/84 
1979 1* 01/01/68 11/06/84 
1981 1* 01/01/70 11/09/84 
1982 2* 01/01/70 11/09/84 
1983 2 01/01/75 11/09/84 
1984 1 01/01/60 11/09/84 
1985 1* 01/01/71 11/09/84 
1986 2 11/01/81 11/07/84 
1987 2* 01/01/64 11/13/84 
1989 1 01/01/73 11/21/84 
1990 1 01/01/79 11/21/84 
1991 2 01/01/76 11/21/84 
1992 2 01/01/73 11/21/84 
1993 2* 01/01/67 11/21/84 
1995 2* 01/01/70 11/21/84 
1997 2 01/01/74 11/27/84 
1999 1 01/01/75 11/30/84 
2003 2* 01/01/74 12/07/84 
2004 1 01/01/79 12/07/84 
2005 2* 01/01/69 12/12/84 
2007 1 01/01/81 12/12/84 
2010 2* 01 01/61 12/14/84 
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2014 1 01/01/72 12/14/84 2015 1 01/01/72 12/14/84 
2016 2 01/01/69 12/14/84 
2017 2* 01/01/70 12/11/84 
2025 2* 01/01/70 12/18/84 
2027 2* 01/01/64 12/21/84 
2031 1* 01/01/81 01/10/85 
2042 2 01/01/45 01/22/85 
2043 2* 01/01/60 01/22/85 
2044 2* 01/01/82 01/24/85 
2047 2 01/01/70 01/29/85 
2048 1 07/01/75 01/29/85 
2050 2* 01/01/81 02/01/85 
2054 1* 05/01/72 02/05/85 
2055 2* 06/01/69 02/05/85 
2056 2 01/01/62 02/05/85 
2059 2* 01/01/57 02/07/85 
2060 2 01/01/50 02/07/85 
2061 1* 01/01/67 02/07/85 
2063 2* 01/01/60 02/07/85 
2066 1 01/01/70 02/08/85 
2067 1* 01/01/70 02/08/85 
2068 2 01/01/70 02/08/85 
2069 1 01/01/68 02/13/85 
2073 2 01/01/74 02/18/85 
2074 1 01/01/76 02/18/85 
2075 1 01/01/78 02/18/85 
2076 1 01/01/79 02/18/85 
2081 2 01/01/70 02/21/85 
2082 1 01/01/75 02/21/85 
2085 1 01/01/83 02/28/85 
2086 1* 01/01/65 03/06/85 
2093 2* 01/01/62 03/08/85 
2099 2 01/01/73 03/08/85 
2100 1 01/01/71 03/08/85 
2101 2 01/01/73 03/13/85 
2102 2 01/01/79 03/13/85 
2104 2 01/01/67 03/15/85 
2105 2 01/01/65 03/15/85 
2106 2 01/01/78 03/15/85 
2107 2 01/01/74 03/15/85 
2108 2 01/01/72 03/15/85 
2114 2 01/01/55 03/19/85 
2115 2* 01/01/70 03/19/85 
2116 1 01/01/66 03/19/85 
2117 2 01/01/75 03/21/85 
2118 2 09/01/83 03/21/85 
2119 1 09/01/82 03/21/85 
2124 1 01/01/70 03/22/85 
2125 2 01/01/65 03/22/85 
2126 2* 01/01/75 03/22/85 
2129 2 01 01 76 03 22 85 
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2134 2 05/01/82 03/28/85 2135 2 06/01/83 03/28/85 
2138 1 01/01/70 03/28/85 
2141 2 01/01/67 04/02/85 
2142 2 01/01/80 04/02/85 
2143 1 01/01/76 04/02/85 
2144 2 01/01/65 OS/21/85 
2145 2 01/01/65 OS/21/85 
2147 2 01/01/79 04/04/85 
2149 2 01/01/65 04/04/85 
2150 2 01/01/65 04/04/85 
2151 2 01/01/72 04/10/85 
2152 2 01/01/64 04/10/85 
2153 1 01/01/64 04/10/85 
2155 2 01/01/45 04/10/85 
2156 1* 01/01/72 04/10/85 
2157 2 01/01/72 04/10/85 
2158 1 01/01/72 04/10/85 
2161 1 01/01/80 04/17/85 
2164 2 01/01/76 04/17/85 
2166 1 01/01/70 04/24/85 
2167 1 01/01/75 04/24/85 
2168 2 01/01/71 04/24/85 
2169 1 01/01/75 04/24/85 
2170 1 01/01/69 04/24/85 
2171 1 01/01/73 04/24/85 
2172 2 01/01/65 04/24/85 
2173 1 01/01/71 04/24/85 
2174 2* 01/01/65 04/24/85 
2176 1 01/01/69 04/25/85 
2177 2 01/01/79 04/25/85 
2178 2 01/01/77 04/25/85 
2179 2 01/01/71 04/25/85 
2180 2 01/01/73 04/25/85 
2181 2 01/01/80 04/25/85 
2182 2* 01/01/71 04/25/85 
2183 1 01/01/83 04/25/85 
2185 2 01/01/69 04/30/85 
2186 2 01/01/74 04/30/85 
2187 2* 01/01/73 04/30/85 
2188 1 01/01/69 05/02/85 
2190 2 01/01/65 05/02/85 
2195 1 01/01/75 05/03/85 
2198 1* 01/01/61 05/07/85 
2201 2 01/01/81 05/10/85 
2203 1 01/01/67 05/10/85 
2205 2* 01/01/70 05/10/85 
2206 2 01/01/60 05/10/85 
2210 1 01/01/75 05/14/85 
2211 2 01/01/73 05/14/85 
2215 2 05/01/85 05/10/85 
2221 1 01 01 79 05 17 85 
APPENDIX I 191 
Number Sex Date of Birth Date of Entry 
2228 1 01/01/75 OS/23/85 
2229 2 01/01/80 OS/23/85 
2232 2* 01/01/73 OS/29/85 
2234 2 01/01/55 OS/29/85 
2235 1 01/01/75 OS/29/85 
2236 2 01/01/70 OS/29/85 
2237 1 01/01/60 OS/29/85 
2244 1 01/01/70 06/12/85 
2247 1 01/01/73 06/14/85 
2248 2 01/01/78 06/14/85 
2249 1 01/01/72 06/14/85 
2251 2 01/01/74 06/21/85 
2252 2* 01/01/76 06/21/85 
2253 2 01/01/78 06/21/85 
2251 2 01/01/74 06/21/85 
2252 2* 01/01/76 06/21/85 
2253 2 01/01/78 06/21/85 
2254 1 01/01/72 06/26/85 
2258 1 01/01/71 06/26/85 
2259 1 01/01/74 06/26/85 
2265 2 01/01/69 06/28/85 
2266 1 01/01/73 07/05/85 
2267 1 01/01/69 07/05/85 
2268 1 01/01/79 07/05/85 
2277 1 01/01/77 07/10/85 
2278 2 01/01/79 07/10/85 
2280 1 01/01/80 07/12/85 
2281 1 01/01/80 07/12/85 
2283 2 01/01/74 07/17/85 
2284 2* 01/01/67 07/17/85 
2285 2 01/01/69 07/17/85 
2287 1 01/01/70 07/18/85 
2288 1 07/01/75 07/18/85 
2290 1 01/01/80 07/23/85 
2294 1 01/01/60 07/23/85 
2295 2 01/01/77 07/25/85 
2296 1 01/01/65 07/25/85 
2297 1 01/01/57 07/29/85 
2298 1 01/01/71 07/29/85 
2299 1 01/01/71 07/29/85 
2300 1 01/01/65 08/02/85 
2301 1 01/01/80 08/02/85 
2302 2 01/01/73 08/02/85 
2303 1* 01/01/67 08/02/85 
2306 2* 01/01/65 08/14/85 
2307 1* 01/01/70 08/14/85 
2311 2* 01/01/69 08/30/85 
2314 1 01/01/65 08/30/85 
2315 1* 01/01/64 07/08/85 
2317 2 01/01/72 09/03/85 
2318 2 01/01/74 09/03/85 
2324 2 01 01 68 09 06 85 
APPENDIX I 192 
Number Sex Date of Birth Date of Entry 
2328 1 01/01/65 09/11/85 2329 1 01/01/72 09/11/85 2330 1* 01/01/82 09/11/85 
2333 1 01/01/60 09/11/85 
2335 1 01/01/62 09/13/85 
2336 2* 09/01/65 09/13/85 
2337 2* 09/01/60 09/13/85 2339 1 01/01/65 09/13/85 2341 2 01/01/77 09/19/85 
2342 2* 01/01/65 09/19/85 
2343 2 01/01/68 09/19/85 
2347 1 01/01/65 09/25/85 
2348 2 01/01/55 09/25/85 
2351 1 01/01/58 09/27/85 
2352 1* 01/01/45 09/27/85 
2354 1* 01/01/55 09/27/85 
2355 1 01/01/80 09/27/85 
2356 1 01/01/63 10/04/85 
2357 1 01/01/67 10/04/85 
2358 2* 01/01/74 11/15/85 
2362 2* 01/01/55 11/20/85 
2363 2 01/01/72 11/20/85 
2368 2* 01/01/50 10/09/85 
2370 2 10/01/60 10/16/85 
2373 1 01/01/69 10/16/85 
2376 1 01/01/57 10/16/85 
2383 1 01/01/67 10/22/85 
2384 1 01/01/67 10/22/85 
2386 2* 01/01/74 10/22/85 
2391 2 01/01/66 10/22/85 
2392 2* 01/01/77 10/22/85 
2393 1 01/01/79 10/22/85 
2394 2 01/01/72 10/22/85 
2395 2 01/01/79 10/22/85 
2396 1 01/01/81 10/22/85 
2397 2 01/01/50 10/22/85 
2398 1 01/01/76 10/24/85 
2399 1 01/01/74 10/24/85 
2401 2 01/01/75 10/24/85 
2402 1 01/01/65 10/24/85 
2403 2 01/01/65 10/24/85 
2404 2 01/01/58 10/24/85 
2405 1 01/01/65 10/24/85 
2410 1 01/01/79 10/31/85 
2411 2 01/01/60 10/31/85 
2412 1 01/01/60 10/31/85 
2413 2 01/01/66 10/31/85 
2414 1 01/01/65 10/31/85 
2416 2 01/01/72 11/06/85 
2417 2 01/01/60 11/06/85 
2418 2 01/01/72 11/06/85 
2420 2 01 01/77 11 06 85 
APPENDIX I 193 
Number Sex Date of Birth Date of Entry 
2433 2 01/01/68 11/12/85 
2434 1 01/01/60 11/12/85 
2436 2 05/01/82 11/14/85 
2438 1 07/01/85 11/14/85 
2440 2 01/01/70 11/14/85 
2442 2* 01/01/73 11/14/85 
2443 1 09/01/85 11/14/85 
2444 2* 01/01/73 11/15/85 
2445 2* 01/01/62 11/15/85 
2449 1 01/01/55 11/18/85 
2450 1 01/01/65 11/18/85 
2451 1 01/01/72 11/20/85 
2452 2 01/01/55 11/22/85 
2453 2* 01/01/60 11/22/85 
2455 2 01/01/65 11/20/85 
2459 1 01/01/80 04/17/85 
2462 2 01/01/70 10/04/85 
2467 1* 01/01/69 11/08/85 
2468 1 01/01/72 11/29/85 
2469 1 01/01/72 11/29/85 
2478 1 01/01/65 12/10/85 
2480 1 01/01/78 12/10/85 
2481 2 01/01/67 12/10/85 
2483 2* 01/01/60 12/12/85 
2487 1 01/01/66 11/29/85 
2488 1 01/01/66 11/29/85 
2489 1 01/01/76 12/13/85 
2490 2 01/01/70 12/13/85 
2491 2 01/01/82 12/19/85 
2492 1 01/01/60 12/19/85 
2503 2 01/01/69 01/07/86 
2504 1 01/01/80 01/07/86 
2505 1 01/01/71 01/07/86 
2508 1 01/01/73 01/08/86 
2509 1 01/01/81 01/08/86 
2516 2 01/01/78 01/13/86 
2517 2 01/01/74 01/13/86 
2518 2 01/01/72 01/13/86 
2525 2 01/01/68 01/21/86 
2526 1 01/01/76 01/21/86 
2530 2 01/01/77 01/23/86 
2531 1 01/01/76 01/20/86 
2532 2* 01/01/46 01/30/86 
2533 1 01/01/69 01/31/86 
2534 2 01/01/84 01/31/86 
2536 2 01/01/72 01/31/86 
2537 2 01/01/81 01/31/86 
2538 1 01/01/73 01/10/86 
2547 2* 01/01/66 02/07/86 
2548 2 01/01/51 02/07/86 
2551 1 01/01/78 02/12/86 
2552 2 01 01 74 02 12/86 
APPENDIX I 194 
Number Sex Date of Birth Date of Entry 
2556 2* 01/01/68 02/13/86 
2557 2 01/01/68 02/13/86 
2558 1 01/01/70 02/19/86 
2559 2 01/01/71 02/19/86 
2563 2 01/01/74 02/21/86 2564 2 01/01/76 02/21/86 
2565 2* 01/01/58 02/21/86 
2566 1 01/01/78 02/26/86 
2567 2 06/01/84 02/26/86 
2568 1 01/01/80 02/26/86 
2571 1 01/01/68 03/27/86 
2573 2 01/01/67 02/04/86 
2575 1 01/01/60 03/05/86 
2576 2 01/01/56 03/12/86 
2577 2 01/01/78 03/12/86 
2578 1 06/01/81 03/12/86 
2579 1 01/01/76 03/12/86 
2580 1 01/01/75 03/12/86 
2585 1 01/01/75 03/21/86 
2586 2 01/01/72 03/21/86 
2588 1 01/01/62 03/21/86 
2593 1* 01/01/58 03/21/86 
2594 2 01/01/76 03/24/86 
2595 1 01/01/73 03/24/86 
2596 1 01/01/70 03/24/86 
2597 1 01/01/72 03/25/86 
2600 1 01/01/80 03/25/86 
2601 2 01/01/70 03/25/86 
2602 1 01/01/56 03/24/86 
2603 2 08/01/83 03/24/86 
2604 1 01/01/66 03/27/86 
2605 2 01/01/73 03/27/86 
2606 2 01/01/56 03/27/86 
2608 2 01/01/78 04/02/86 
2609 1 03/01/85 04/02/86 
2610 1 04/01/85 04/02/86 
2611 2 01/01/70 04/02/86 
2612 2 01/01/60 04/02/86 
2613 2 01/01/71 04/02/86 
2614 1 01/01/61 04/02/86 
2615 2 01/01/78 04/02/86 
2616 1 01/01/56 04/02/86 
2617 1 01/01/77 04/02/86 
2618 1 01/01/56 04/02/86 
2619 1 01/01/56 04/02/86 
2620 2 01/01/82 04/02/86 
2621 2 01/01/56 04/02/86 
2622 1 01/01/77 03/13/86 
2623 1 01/01/78 03/13/86 
2624 2 01/01/60 04/09/86 
2628 1 05/01/69 04/08/86 
2629 2 05 01 69 04 08/86 
APPENDIX I 195 
Number Sex Date of Birth Date of Entry 
2633 1 01/01/48 04/20/86 
2636 1* 01/01/69 04/20/86 
2639 1 01/01/73 04/16/86 
2640 1* 01/01/60 04/16/86 
2643 1 01/01/74 04/23/86 
2644 2 01/01/68 04/23/86 
2645 2 01/01/83 04/23/86 
2646 2 01/01/80 04/23/86 
2647 1 10/01/85 04/23/86 
2650 2 01/01/66 04/24/86 
2651 1 01/01/75 04/24/86 
2655 1 04/01/86 04/21/86 
2656 2 01/01/66 04/25/86 
2661 1 01/01/60 04/29/86 
2662 1 01/01/65 04/29/86 
2663 1 01/01/81 05/13/86 
2668 2 01/01/83 05/16/86 
2669 2 01/01/72 05/16/86 
2670 1 01/01/61 05/16/86 
2671 2* 01/01/46 05/16/86 
2672 2* 01/01/66 05/16/86 
2674 2 01/01/84 05/19/86 
2675 2 01/01/61 05/19/86 
2676 1 01/01/80 05/19/86 
2677 2 01/01/69 05/16/86 
2679 2 07/01/85 OS/22/86 
2680 2 04/01/83 OS/22/86 
2682 1 01/01/61 OS/22/86 
2686 1 01/01/70 05/19/86 
2691 2 01/01/56 06/03/86 
2694 1 05/01/86 05/31/86 
2695 2* 01/01/71 06/12/86 
2698 2 01/01/71 06/12/86 
2699 1 01/01/59 06/13/86 
2702 1 01/01/78 06/18/86 
2703 2 01/01/82 06/18/86 
2704 1 01/01/61 06/18/86 
2708 1 01/01/66 06/25/86 
2713 2 05/01/86 06/25/86 
2714 1 01/01/79 06/30/86 
2721 2* 01/01/46 07/08/86 
2722 1* 01/01/46 07/08/86 
2726 2 01/01/74 07/11/86 
2727 2 01/01/81 07/11/86 
2728 1 01/01/76 07/11/86 
2731 2* 01/01/60 07/15/86 
2733 2 01/01/81 07/18/86 
2736 1 01/01/85 07/18/86 
2737 2 01/01/84 07/18/86 
2738 2 01/01/58 06/06/86 
2739 2 01/01/53 06/06/86 
2744 2 01 01 74 07 22 86 
APPENDIX I 196 
Number Sex Date of Birth Date of Entry 
2750 1 01/01/78 07/29/86 2751 2 01/01/77 07/31/86 2755 1 01/01/68 08/08/86 
2756 2 01/01/68 08/08/86 
2757 2 01/01/73 08/08/86 2758 2 01/01/73 08/08/86 2761 2* 01/01/49 08/12/86 
2763 2 01/01/73 08/13/86 
2764 1 01/01/84 08/13/86 
2765 1 01/01/82 08/13/86 2768 2 01/01/60 08/18/86 2769 1 01/01/77 08/18/86 
2770 1 01/01/60 08/18/86 2772 1 01/01/56 08/22/86 
2773 1 01/01/61 08/22/86 
2774 1 01/01/67 08/22/86 
2775 2 01/01/77 08/22/86 
2776 1 01/01/68 08/22/86 
2777 1 01/01/77 08/14/86 
2778 1 01/01/77 08/14/86 
2779 1 01/01/62 08/21/86 
2780 2 01/01/65 08/21/86 
2782 2 01/01/71 08/27/86 
2783 1 01/01/67 08/27/86 
2785 1 01/01/75 09/02/86 
2786 2* 01/01/61 09/05/86 
2787 2 01/01/68 09/05/86 
2788 2 01/01/76 09/05/86 
2789 1 01/01/73 09/05/86 
2790 2 01/01/82 09/05/86 
2792 2 01/01/61 09/11/86 
2793 2 01/01/61 09/11/86 
2794 2 01/01/70 09/11/86 
2798 1 01/01/76 09/19/86 
2803 1 01/01/61 09/23/86 
2804 1 01/01/86 09/23/86 
2805 1 01/01/61 09/23/86 
2815 2 01/01/56 10/01/86 
2816 1 01/01/66 10/01/86 
2821 1 05/01/80 09/04/86 
2822 2 01/01/82 09/04/86 
2824 1 01/01/67 10/09/86 
2825 1* 01/01/62 10/09/86 
2827 2 01/01/78 09/04/86 
2828 1 01/01/74 10/07/86 
2829 1 01/01/75 10/07/86 
2830 1 01/01/76 10/07/86 
2831 1 01/01/82 10/07/86 
2834 1 01/01/74 10/09/86 
2836 1 01/01/66 10/09/86 
2838 2* 10/01/66 10/17/86 
2841 1* 01/01/82 10/01/86 
APPENDIX I 197 
Number Sex Date of Birth Date of Entry 
2854 1 01/01/79 09/24/86 
2856 2 07/01/76 11/04/86 
2857 2 04/01/72 11/04/86 
2860 2 01/01/78 11/04/86 
2861 2 01/01/78 11/04/86 
2862 1 01/01/73 11/04/86 
2867 2 01/01/51 11/06/86 
2868 1* 01/01/51 11/06/86 
2869 1 01/01/51 11/11/86 
2871 1* 01/01/61 11/14/86 
2875 1 01/01/74 11/21/86 
2882 1 01/01/61 11/26/86 
2884 1* 01/01/61 11/26/86 
2885 2 01/01/68 11/26/86 
2886 1 01/01/75 11/26/86 
2887 2 06/01/85 11/26/86 
2888 1* 01/01/70 12/02/86 
2889 2 01/01/79 12/04/86 
2892 2* 01/01/71 12/05/86 
2893 2* 01/01/56 12/05/86 
2896 1 01/01/70 12/02/86 
2900 2* 01/01/61 12/10/86 
2901 2 01/01/71 12/16/86 
2902 2 01/01/66 12/16/86 
2903 2 01/01/79 12/16/86 
2904 1 01/01/69 12/16/86 
2908 2* 01/01/61 12/11/86 
2909 1 01/01/68 12/16/86 
2910 1 01/01/82 12/16/86 
2911 2 01/01/74 12/16/86 
2912 2 01/01/68 12/16/86 
2914 1 01/01/51 12/19/86 
2915 1* 01/01/59 12/19/86 
2916 2* 01/01/61 12/19/86 
2919 1 01/01/82 12/19/86 
2920 2 01/01/82 12/19/86 
2921 1* 01/01/61 12/19/86 
2922 1* 01/01/61 12/23/86 
2923 1* 01/01/59 12/23/86 
2924 2* 01/01/47 12/23/86 
2925 1* 01/01/51 12/23/86 
2927 2 01/01/60 12/31/86 
2933 2 01/01/85 01/21/87 
2934 2 01/01/82 01/21/87 
2935 2 01/01/84 01/21/87 
2936 2 01/01/64 01/21/87 
2937 1 01/01/63 01/21/87 
2938 2* 01/01/60 01/23/87 
2941 1 01/01/68 01/23/87 
2942 1 01/01/61 01/28/87 
2943 1 01/01/71 01/28/87 
2944 1* 01 01 52 01 28 87 
APPENDIX I 198 
Number Sex Date of Birth Date of Entry 
2951 1 01/01/69 02/03/87 
2952 1 01/01/75 02/03/87 
2954 1 05/01/86 02/06/87 
2955 2 01/01/64 02/06/87 
2960 1 01/01/61 02/13/87 
2961 1 01/01/81 02/17/87 
2962 2* 01/01/47 02/17/87 
2963 2* 01/01/47 02/17/87 
2964 2 06/01/69 02/20/87 
2965 1 01/01/63 02/20/87 
2966 2 01/01/78 02/27/87 
2967 1 03/01/85 02/27/87 
2970 1* 01/01/52 02/27/87 
2971 1 01/01/59 02/27/87 
2973 2 01/01/50 02/27/87 
2974 2 01/01/68 02/27/87 
2976 1 01/01/62 03/03/87 
2977 1 01/01/75 03/03/87 
2978 1 01/01/62 03/11/87 
2979 1 01/01/66 03/12/87 
2980 1 01/01/71 12/10/86 
2984 1 01/01/58 03/17/87 
2988 1 04/01/74 03/20/87 
2989 1 07/01/86 03/17/87 
2991 2 01/01/57 03/27/87 
2992 2 01/01/62 03/27/87 
2993 2 01/01/50 03/27/87 
2995 2 01/01/73 04/02/87 
2996 2 01/01/83 04/02/87 
2997 1 01/01/77 03/24/87 
3000 1 04/01/87 04/05/87 
3001 2 01/01/58 04/08/87 
3003 2 01/01/77 04/08/87 
3004 2 01/01/83 04/08/87 
3005 1 01/01/70 04/14/87 
3009 2 01/01/69 04/14/87 
3010 1 01/01/76 04/15/87 
3016 1 01/01/70 04/28/87 
3019 1 01/01/73 04/21/87 
3020 2 01/01/73 05/12/87 
3021 2 01/01/65 05/12/87 
3022 2 01/01/62 05/12/87 
3023 2 01/01/81 05/12/87 
3024 1 01/01/75 04/24/87 
3026 2 01/01/66 04/21/87 
3027 2 01/01/77 04/21/87 
3028 1 01/01/86 04/21/87 
3034 2 01/01/84 05/12/87 
3035 1 01/01/81 05/06/87 
3036 1 01/01/54 05/06/87 
3038 2 01/01/57 05/07/87 
3039 2 01 01 72 05 07 87 
APPENDIX I 199 
Number Sex Date of Birth Date of Entry 
3047 1 01/01/75 05/05/87 3049 2 05/19/87 05/19/87 
3050 2 01/01/81 OS/22/87 3052 1 01/01/52 OS/27/87 
3053 2 01/01/52 OS/27/87 3054 1 01/01/77 OS/27/87 3055 1 01/01/64 OS/20/87 3057 2 01/01/71 OS/29/87 
3058 1 01/01/71 OS/29/87 3060 2 01/01/83 OS/29/87 
3061 2 01/01/72 OS/29/87 3063 2 01/01/52 OS/29/87 
3064 2* 01/01/50 OS/29/87 
3065 1 01/01/62 06/05/87 
3066 1 04/01/85 06/05/87 3071 2* 01/01/76 06/05/87 
3072 2 01/01/67 06/05/87 3076 1 01/01/62 06/12/87 
3077 1 01/01/58 06/12/87 
3080 2* 01/01/67 06/12/87 
3081 2 01/01/81 06/12/87 
3082 2 01/01/52 06/19/87 
3083 2* 01/01/52 06/19/87 
3084 2 01/01/79 06/18/87 
3085 1* 01/01/67 06/18/87 
3086 2 01/01/62 06/18/87 
3087 2 01/01/65 06/18/87 
3088 2 01/01/70 06/24/87 
3089 2 01/01/62 06/24/87 
3090 2 01/01/85 06/24/87 
3091 2* 01/01/67 06/24/87 
3092 1 01/01/74 06/24/87 
3093 2* 01/01/51 06/24/87 
3097 2* 01/01/62 06/26/87 
3098 1 09/01/67 06/29/87 
3099 2 01/01/70 07/02/87 
3100 1 01/01/60 07/02/87 
3102 2 01/01/57 06/29/87 
3107 2* 01/01/80 07/03/87 
3108 2 06/01/87 07/03/87 
3109 2 01/01/85 07/03/87 
3111 2* 01/01/70 07/03/87 
3113 2* 01/01/85 07/03/87 
3115 1 01/01/60 07/06/87 
3116 1 01/01/65 07/09/87 
3120 1 01/01/52 07/14/87 
3121 1 01/01/55 07/14/87 
3122 1 01/01/82 07/14/87 
3123 1 01/01/85 07/14/87 
3124 1 01/01/84 07/14/87 
3129 2 01/01/72 07/17/87 
3130 2 01 01 81 07/21/87 
APPENDIX I 200 
Number Sex Date of Birth Date of Entry 
3134 1 01/01/80 07/23/87 3135 2 01/01/83 07/23/87 3136 1 01/01/81 07/23/87 3137 2 01/01/60 07/23/87 
3138 1 01/01/84 07/24/87 
3139 1 01/01/72 07/24/87 3140 1 01/01/69 07/28/87 3141 1 01/01/65 07/28/87 3143 2 01/01/52 07/24/87 3144 2 01/01/62 07/24/87 
3145 2 07/01/87 07/25/87 3147 1 01/01/75 07/28/87 3148 2 01/01/84 07/22/87 3149 2 01/01/83 07/22/87 3150 2 01/01/72 07/22/87 3152 2 01/01/83 07/22/87 3153 2 01/01/83 07/22/87 3154 2 01/01/80 07/22/87 
3155 2 01/01/75 07/22/87 
3156 2 01/01/82 07/22/87 
3157 1* 01/01/60 07/24/87 
3158 1 01/01/69 07/24/87 
3159 1 01/01/73 07/29/87 
3162 1 10/01/68 08/07/87 
3163 1 01/01/72 08/07/87 
3164 2 01/01/72 08/12/87 
3166 2 01/01/52 08/15/87 
3167 1 01/01/76 08/21/87 
3168 2 01/01/71 08/26/87 
3169 1 01/01/72 08/26/87 
3170 2 09/01/82 08/26/87 
3166 2 01/01/52 08/15/87 
3167 1 01/01/76 08/21/87 
3168 2 01/01/71 08/26/87 
3169 1 01/01/72 08/26/87 
3170 2 09/01/82 08/26/87 
3172 1 01/01/57 09/02/87 
3185 2 01/01/73 09/10/87 
3186 1 01/01/75 09/10/87 
3187 2 01/01/69 09/10/87 
3188 1 01/01/78 09/11/87 
3191 2 01/01/72 09/11/87 
3192 2 01/01/72 09/11/87 
3193 2 01/01/76 09/16/87 
3194 1 01/01/82 09/18/87 
3195 1 01/01/75 09/18/87 
3196 2 01/01/75 09/18/87 
3197 1 01/01/62 09/18/87 
3198 2 01/01/72 09/18/87 
3199 1 01/01/57 09/18/87 
3200 2 01/01/79 09/18/87 
3201 1 01 01 87 09 18 87 
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3206 2 01/01/78 09/01/87 3207 2 01/01/78 09/25/87 3208 2 01/01/77 09/25/87 
3211 2 01/01/61 09/29/87 
3217 2 01/01/74 10/06/87 3218 2 01/01/72 10/06/87 3220 2 01/01/77 10/06/87 3221 2 01/01/62 10/06/87 3223 1 01/01/57 10/13/87 3228 2 01/01/59 10/16/87 3229 1 01/01/72 10/16/87 3232 2 01/01/83 10/16/87 3234 1 10/01/87 10/19/87 
3238 1 01/01/67 10/28/87 3239 2 01/01/70 10/28/87 
3240 2 01/01/76 10/28/87 3241 2* 01/01/57 10/28/87 3243 1 01/01/80 10/29/87 3244 2 01/01/62 10/31/87 
3245 1 01/01/74 10/31/87 
3246 1 01/01/75 10/31/87 3247 2 01/01/67 10/31/87 3248 1 01/01/62 10/31/87 3250 1 01/01/83 09/14/87 
3252 1 01/01/62 11/03/87 
3253 1 01/01/60 11/06/87 
3254 2 01/01/74 11/13/87 3255 2 01/01/83 11/13/87 
3257 1* 01/01/65 11/13/87 
3258 2 01/01/62 11/13/87 
3264 2 01/01/79 10/27/87 
3265 1 01/01/62 11/18/87 
3268 2 01/01/80 11/07/87 
3269 1* 01/01/77 11/17/87 
3270 2* 01/01/62 11/17 /87 
3272 2 01/01/57 11/17/87 
3278 2* 01/01/47 11/20/87 
3279 1 01/01/66 11/20/87 
3283 2 01/01/57 11/25/87 
3284 1 01/01/72 11/25/87 
3285 1* 01/01/52 11/25/87 
3286 2 01/01/63 12/01/87 
3287 1 01/01/68 12/01/87 
3288 1 01/01/61 12/01/87 
3289 1 01/01/73 12/01/87 
3294 1 01/01/84 12/04/87 
3295 1 01/01/85 12/04/87 
3296 1 01/01/82 12/04/87 
3298 1 01/01/47 12/08/87 
3299 1 01/01/49 12/08/87 
3301 2 01/01/57 12/11/87 
3309 2 01/01/80 12 13 87 
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3323 2 07/01/74 12/30/87 3324 2 01/01/58 12/29/87 
3325 1 01/01/58 12/29/87 
3326 1 07/01/69 01/06/88 
3327 2 Oi/Oi/76 01/06/88 3330 2 01/01/74 01/06/88 
3331 2 01/01/63 01/03/88 3332 1 01/01/77 01/09/88 
3333 1 01/01/72 01/12/88 
3334 2 01/01/60 01/12/88 
3335 1 01/01/59 01/14/88 
3336 2 01/01/63 01/19/88 3338 2 01/01/68 01/22/88 
3340 1 01/01/60 01/22/88 
3341 2 01/01/58 01/22/88 
3342 1 01/01/76 01/22/88 
3343 2 01/01/61 01/26/88 
3344 2 01/01/68 01/26/88 
3347 2 01/01/60 01/29/88 
3350 1 01/01/84 01/29/88 
3351 2 01/01/83 02/02/88 
3352 1 06/01/87 02/02/88 
3353 2 01/01/84 02/02/88 
3354 2 06/01/87 02/02/88 
3355 2 01/01/63 02/05/88 
3356 1 01/01/70 02/05/88 
3357 1 01/01/47 02/05/88 
3358 1 01/01/78 02/05/88 
3359 1 01/01/69 02/05/88 
3360 1 01/01/78 02/02/88 
3362 1 01/01/53 02/05/88 
3363 2 01/01/61 02/09/88 
3364 1 01/01/87 02/09/88 
3366 2 01/01/53 02/12/88 
3367 1 01/01/69 02/09/88 
3368 1 01/01/67 02/09/88 
3369 2* 01/01/53 02/15/88 
3370 1 01/01/73 02/17/88 
3372 1 01/01/63 02/25/88 
3373 1* 01/01/48 02/25/88 
3374 2 01/01/53 02/25/88 
3375 2 01/01/55 02/25/88 
3380 2 01/01/68 03/02/88 
3381 1 01/01/57 03/02/88 
3382 1 01/01/78 03/01/88 
3383 1 01/01/63 03/04/88 
3385 1 01/01/60 03/04/88 
3386 1 01/01/68 03/04/88 
3388 2 01/01/58 03/09/88 
3389 2 01/01/68 03/09/88 
3390 2 01/01/77 03/09/88 
3391 1 01 01 78 03 10 88 
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3397 1 01/01/63 03/18/88 
3398 1 01/01/63 03/18/88 
3403 2 01/01/71 03/23/88 
3404 2 01/01/63 03/23/88 
3405 2 01/01/60 03/23/88 
3410 2 01/01/63 03/25/88 3411 2 01/01/58 03/25/88 
3412 2 01/01/53 03/25/88 
3413 1 01/01/63 03/25/88 
3414 2 01/01/58 03/25/88 
3415 1 01/01/84 03/25/88 
3416 1 01/01/80 03/24/88 
3417 1 01/01/84 03/24/88 
3418 1 01/01/61 03/30/88 
3420 1 01/01/87 04/08/88 
3421 2 01/01/68 04/08/88 
3422 1 01/01/63 04/12/88 
3425 1 01/01/74 04/12/88 
3427 2 01/01/60 04/15/88 
3430 2 01/01/78 04/15/88 
3434 1 01/01/82 04/15/88 
3435 1 01/01/84 04/15/88 
3436 1 01/01/77 04/15/88 
3437 1 01/01/70 04/20/88 
3439 1 01/01/68 04/26/88 
3440 1 01/01/63 04/26/88 
3441 1 01/01/58 04/26/88 
3443 2 01/01/73 04/29/88 
3445 1 01/01/80 05/03/88 
3448 1 01/01/70 04/18/88 
3449 1 01/01/72 05/13/88 
3450 1 01/01/63 05/09/88 
3451 1 01/01/71 05/18/88 
3452 1 01/01/63 05/18/88 
3453 2 01/01/62 05/18/88 
3454 1* 01/01/48 05/18/88 
3455 1 01/01/50 05/18/88 
3456 1 01/01/83 05/18/88 
3457 2 01/01/76 05/18/88 
3460 1 01/01/46 05/19/88 
3461 1 01/01/85 05/18/88 
3462 1 01/01/62 05/18/88 
3463 2 01/01/87 05/18/88 
3464 2 01/01/53 05/18/88 
3465 2 01/01/61 OS/25/88 
3466 2 01/01/58 OS/25/88 
3467 2 01/01/63 OS/25/88 
3469 2 01/01/58 OS/25/88 
3471 2 01/01/60 OS/25/88 
3472 2 01/01/64 OS/25/88 
3473 2 01/01/63 OS/20/88 
3474 2 01/01/63 05 20 88 
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3479 1 01/01/72 06/02/88 3480 2* 01/01/56 06/03/88 3481 1 10/01/60 06/07/88 3483 1 01/01/85 06/10/88 3484 2 01/01/83 06/10/88 3485 1 01/01/83 06/24/88 
3486 1 01/01/80 06/24/88 3487 2 01/01/75 06/24/88 
3488 1 01/01/79 06/24/88 3490 2 06/01/88 06/08/88 3491 2 06/01/88 06/09/88 3492 1* 01/01/58 06/15/88 3493 2 01/01/58 06/15/88 3494 2 01/01/73 06/15/88 
3495 1 01/01/58 06/15/88 3497 1 01/01/75 06/21/88 3498 2 01/01/70 06/21/88 
3500 2 01/01/63 06/24/88 
3501 2 01/01/68 06/24/88 
3502 1 01/01/83 06/24/88 
3503 2 01/01/63 06/22/88 
3504 1 01/01/76 06/22/88 
3505 1* 01/01/76 06/22/88 
3506 2 01/01/63 07/01/88 
3508 2 01/01/60 06/29/88 
3510 2 01/01/71 07/01/88 
3511 1 01/01/78 07/05/88 
3512 1 01/01/83 07/05/88 
3518 1 01/01/58 07/07/88 
3519 2* 01/01/76 07/07/88 
3520 2 01/01/82 07/07/88 
3523 2 01/01/78 07/14/88 
3527 2 01/01/68 07/22/88 
3528 1 01/01/70 07/22/88 
3529 2 01/01/63 09/23/88 
3530 1 01/01/76 09/23/88 
3531 2 01/01/58 07/22/88 
3532 2 01/01/69 07/21/88 
3533 2 01/01/86 07/22/88 
3534 2 01/01/63 07/21/88 
3535 1 01/01/74 07/21/88 
3536 2 01/01/76 07/21/88 
3537 1 01/01/70 07/21/88 
3539 1 01/01/68 07/21/88 
3540 1 01/01/58 07/28/88 
3541 1 01/01/63 07/28/88 
3542 2* 01/01/63 07/28/88 
3543 1 01/01/70 07/28/88 
3544 2 01/01/84 07/28/88 
3545 2 01/01/87 07/28/88 
3546 2 01/01/73 07/28/88 
3547 2 01/01/86 07/28/88 
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3559 2 01/01/74 08/05/88 3566 1 01/01/73 08/09/88 3568 1 01/01/53 08/12/88 3569 2 01/01/76 08/12/88 3572 1 01/01/70 08/17/88 3575 1 01/01/75 08/19/88 3576 1 01/01/58 08/19/88 3577 2 01/01/64 08/19/88 3578 2 01/01/70 08/19/88 3580 2 01/01/80 08/08/88 3581 1* 01/01/61 08/19/88 3582 1 01/01/74 08/25/88 3583 1 01/01/63 08/25/88 3584 1 01/01/70 08/25/88 3586 1 01/01/76 08/25/88 3592 1 01/01/80 09/02/88 
3593 2 01/01/48 09/02/88 3594 2 01/01/68 09/02/88 
3597 1 01/01/76 09/07/88 
3599 2 01/01/76 09/09/88 
3600 2 01/01/74 09/09/88 
3601 2 01/01/48 09/13/88 
3605 2 01/01/78 09/13/88 3606 1 01/01/66 09/13/88 
3607 1 01/01/58 09/09/88 3609 1 01/01/68 09/13/88 3610 2 01/01/79 09/15/88 3611 2 01/01/79 09/15/88 3612 1 01/01/69 09/15/88 
3613 2 01/01/73 09/15/88 
3614 1 01/01/73 09/15/88 
3615 2 01/01/74 09/15/88 
3620 2 01/01/75 09/22/88 
3621 1 01/01/78 09/23/88 
3622 2 01/01/63 09/27/88 
3623 1 01/01/67 09/27/88 
3624 2* 01/01/48 09/27/88 
3625 1 01/01/63 09/29/88 
3627 1 01/01/85 09/29/88 
3630 2 01/01/82 10/04/88 
3631 2 01/01/48 10/04/88 
3632 1 01/01/73 10/04/88 
3633 2 01/01/63 10/06/88 
3634 1* 01/01/63 10/07/88 
3635 1 01/01/68 10/07/88 
3636 1 01/01/60 10/07/88 
3637 1 01/01/58 10/07/88 
3638 2* 01/01/80 10/07/88 
3639 2* 01/01/48 10/07/88 
3643 2 01/01/61 10/11/88 
3644 1 01/01/78 10/11/88 
3645 2* 01 01 48 10 20 88 
APPENDIX I 206 
Number Sex Date of Birth Date of Entry 
3649 1* 01/01/82 10/20/88 3650 2 01/01/64 10/20/88 3651 1 08/01/88 10/20/88 3652 2 01/01/84 10/20/88 3653 1 04/01/88 10/20/88 3654 2 01/01/79 10/20/88 3655 2 09/01/88 10/20/88 3656 2 01/01/77 10/20/88 3657 1 08/01/88 10/20/88 3658 1 01/01/79 10/19/88 3659 2 01/01/81 11/04/88 3662 2 01/01/82 11/09/88 3663 2* 01/01/63 11/09/88 3664 2 01/01/79 11/09/88 3665 1 01/01/77 11/09/88 3666 2 01/01/63 11/09/88 3670 2 01/01/78 11/11/88 3671 2 01/01/65 11/09/88 3672 2 01/01/73 11/09/88 
3673 1 01/01/63 11/09/88 3674 1 09/01/79 11/09/88 3676 2 01/01/73 11/15/88 3677 1 01/01/68 11/09/88 
3678 1 01/01/53 11/16/88 
3679 2 01/01/68 11/16/88 
3680 2 01/01/72 11/16/88 3681 1 01/01/48 11/16/88 
3682 2 01/01/68 11/15/88 
3683 1 01/01/63 11/15/88 
3684 2 01/01/58 11/15/88 
3685 1 01/01/53 11/18/88 
3686 1 01/01/52 11/22/88 
3687 1 01/01/74 11/23/88 
3688 2 01/01/58 11/23/88 
3689 1* 01/01/76 11/23/88 
3690 1* 01/01/62 11/28/88 
3691 2 01/01/81 11/24/88 
3692 1 01/01/76 11/24/88 
3693 2* 01/01/48 12/01/88 
3694 2 01/01/84 12/01/88 
3695 2 01/01/78 12/01/88 
3697 2 01/01/85 12/01/88 
3698 2 01/01/87 12/01/88 
3699 2 01/01/76 12/01/88 
3701 2 01/01/79 12/01/88 
3702 2 01/01/87 12/01/88 
3703 2 01/01/76 12/01/88 
3704 2 01/01/87 12/01/88 
3705 2 01/01/48 12/01/88 
3706 2 01/01/64 12/01/88 
3708 1 01/01/63 12/01/88 
3709 2 09/01/71 12/06/88 
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3715 2 01/01/74 12/06/88 
3716 1 01/01/69 12/03/88 
3720 2 01/01/54 12/13/88 
3721 2 01/01/69 12/13/88 
3722 2 01/01/70 12/13/88 
3723 2 01/01/54 12/13/88 
3724 2 01/01/53 12/20/88 
3725 2 01/01/69 12/19/88 
3726 2 01/01/68 12/19/88 
3728 1 01/01/84 12/13/88 
3731 1 01/01/79 12/14/88 
3732 1 01/01/74 12/19/88 
3733 1 01/01/59 12/19/88 
3734 2 01/01/70 12/19/88 
3735 2 01/01/71 12/19/88 
3736 1 01/01/82 12/14/88 
3738 1 01/01/73 12/12/88 
3740 2 01/01/81 01/05/89 
3741 1 07/01/88 01/05/89 
3742 2 01/01/87 01/05/89 
3743 2 01/01/49 01/05/89 
3744 2 01/01/85 01/05/89 
3750 1 01/01/67 01/31/89 
3751 2 01/01/49 01/31/89 
3752 2 01/01/62 01/12/89 
3754 2 12/01/88 12/25/88 
3755 2 01/01/51 01/10/89 
3756 1 10/01/88 01/10/89 
3757 1 01/01/84 01/16/89 
3758 1 01/01/79 01/12/89 
3759 2 01/01/65 01/12/89 
3761 2 01/01/54 01/12/89 
3762 1 01/01/69 01/16/89 
3763 1 01/01/69 01/16/89 
3764 2 01/01/84 01/16/89 
3765 1 01/01/88 01/16/89 
3766 2 01/01/75 01/16/89 
3767 2 01/01/54 01/20/89 
3768 1 01/01/81 01/24/89 
3769 2 01/14/89 01/14/89 
3770 1 01/01/88 01/23/89 
3773 2 01/01/85 01/23/89 
3774 2 01/01/75 01/23/89 
3776 2 01/01/86 02/01/89 
3778 2 01/01/88 03/30/89 
3779 1 01/01/52 03/29/89 
3780 2 01/01/64 01/31/89 
3781 2 01/01/64 01/31/89 
3782 2 01/01/73 01/31/89 
3783 2 01/01/82 01/31/89 
3784 2 01/01/71 02/02/89 
3785 2 01/01/71 02/03/89 
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3792 2 01/01/85 02/09/89 
3793 1 01/01/73 02/08/89 
3794 2 01/01/54 02/10/89 
3795 2 01/01/69 02/16/89 
3796 2 01/01/86 02/16/89 
3797 2 01/01/74 02/16/89 
3798 2 01/01/74 02/16/89 
3799 2 01/01/77 02/16/89 
3800 2 01/01/74 02/16/89 
3801 2 01/01/74 02/16/89 
3802 2 01/01/79 02/16/89 
3803 2 01/01/67 02/16/89 
3804 1 01/01/88 02/16/89 
3805 2 01/01/52 02/16/89 
3806 2 01/01/61 02/16/89 
3807 1 01/01/88 02/16/89 
3808 2 01/01/88 02/16/89 
3809 2 01/01/88 02/16/89 
3810 1 01/01/67 02/16/89 
3812 2 01/01/65 03/17 /89 
3815 2 01/01/79 02/21/89 
3816 2 01/01/85 02/21/89 
3817 1 06/01/88 02/21/89 
3818 1 01/01/86 02/21/89 
3819 2 01/01/59 02/21/89 
3820 1 01/01/81 02/21/89 
3822 1 01/01/85 02/24/89 
3823 2 01/01/72 02/28/89 
3824 1 01/01/74 03/07/89 
3825 1 01/01/73 02/28/89 
3828 1 01/01/82 03/01/89 
3829 1 01/01/61 03/01/89 
3830 1 01/01/84 03/01/89 
3834 2 01/01/59 03/08/89 
3836 2 01/01/73 03/08/89 
3837 2 01/01/66 03/08/89 
3838 2 01/01/77 03/08/89 
3840 2 01/01/74 03/15/89 
3841 1 01/01/79 03/15/89 
3842 2 01/01/80 03/15/89 
3844 1 01/01/71 03/16/89 
3845 2 01/01/77 03/14/89 
3846 1 01/01/80 03/17/89 
3847 1 01/01/69 03/17/89 
3849 2 01/01/54 03/21/89 
3850 1 01/01/69 03/21/89 
3851 1 01/01/79 03/21/89 
3854 1 01/01/75 03/30/89 
3855 1 01/01/59 03/30/89 
3857 2 01/01/64 04/04/89 
3860 1 01/01/80 04/06/89 
3861 1 01 01 64 04 06 89 
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3866 2 01/01/84 04/13/89 
3867 1* 03/01/89 04/13/89 
3869 2 01/01/49 04/12/89 
3870 2 01/01/83 04/10/89 
3871 2 01/01/85 04/13/89 
3872 2 01/01/83 04/13/89 
3873 2 01/01/49 04/13/89 
3874 2 01/01/49 04/13/89 
3876 2 01/01/54 04/17/89 
3877 1 01/01/84 04/17/89 
3878 1 01/01/64 04/21/89 
3879 1 01/01/79 04/13/89 
3881 1 01/01/69 04/28/89 
3882 2 01/01/77 04/27/89 
3884 1 01/01/77 04/21/89 
3886 1 01/01/88 05/03/89 
3887 1 01/01/59 05/03/89 
3888 1 01/01/62 05/03/89 
3889 1 01/01/64 05/03/89 
3891 2 01/01/67 05/02/89 
3892 1 01/01/82 05/04/89 
3898 2 09/01/79 08/16/89 
3899 2 01/01/44 05/16/89 
3900 2 01/01/49 05/17/89 
3907 2 01/01/68 05/15/89 
3910 1 01/01/85 OS/24/89 
3911 1 01/01/69 OS/24/89 
3916 1 01/01/85 06/02/89 
3917 2 01/01/88 06/02/89 
3918 2 01/01/54 06/02/89 
3919 2 01/01/77 06/02/89 
3920 2 01/01/59 05/30/89 
3921 1 01/01/72 05/30/89 
3922 1 01/01/75 05/30/89 
3923 1 01/01/86 06/01/89 
3924 1 01/01/85 06/01/89 
3926 2 10/01/72 06/06/89 
3927 1 01/01/65 06/06/89 
3928 2 01/01/77 06/06/89 
3929 2 01/01/67 06/07/89 
3937 1 04/01/70 06/12/89 
3938 1 01/01/71 06/12/89 
3939 1 01/01/74 06/15/89 
3940 1 01/01/69 06/12/89 
3941 2 04/01/69 06/12/89 
3942 2 01/01/63 06/12/89 
3943 2 02/15/80 06/12/89 
3944 2 01/01/73 06/12/89 
3911 1 01/01/69 OS/24/89 
3916 1 01/01/85 06/02/89 
3917 2 01/01/88 06/02/89 
3918 2 1 4 2 89 
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3953 2 01/01/51 06/13/89 3954 2 01/01/73 06/22/89 3955 2 01/01/79 06/22/89 3956 2 01/01/52 06/22/89 3957 2 01/01/79 06/22/89 3958 2 01/01/64 06/22/89 3959 2 01/01/67 06/22/89 3960 1 01/01/79 06/22/89 3962 1 01/01/61 06/22/89 3963 1 01/01/57 06/23/89 3965 1 01/01/84 06/23/89 3967 2 01/01/67 06/23/89 3968 1 01/01/63 06/29/89 3969 1 01/01/77 06/29/89 3970 1 01/01/86 06/29/89 
3971 1 01/01/81 06/29/89 3972 1 01/01/81 06/29/89 3973 1 01/01/80 06/29/89 3974 1 01/01/69 06/29/89 
3975 1 01/01/79 06/29/89 
3976 1 01/01/72 06/28/89 
3977 1 01/01/85 07/03/89 
3979 1 01/01/75 07/06/89 
3984 1 01/01/64 07/06/89 
3985 2 01/01/76 07/06/89 
3987 2 07/02/89 07/02/89 
3988 2 01/01/54 07/07/89 
3989 1 01/01/64 07/07/89 
3990 1 01/01/74 07/13/89 
3991 2 01/01/74 07/13/89 
3993 1 01/01/79 07/14/89 
3994 1 01/01/72 07/13/89 
4000 1 07/13/89 07/13/89 
4001 2 01/01/69 07/12/89 
4002 1 01/01/74 07/19/89 
4003 2 01/01/72 07/19/89 
4005 1 01/01/83 07/21/89 
4006 1 03/01/87 07/24/89 
4007 1 01/01/75 07/25/89 
4008 1 01/01/77 07/25/89 
3972 1 01/01/81 06/29/89 
3973 1 01/01/80 06/29/89 
3974 1 01/01/69 06/29/89 
3975 1 01/01/79 06/29/89 
3976 1 01/01/72 06/28/89 
3977 1 01/01/85 07/03/89 
3979 1 01/01/75 07/06/89 
3984 1 01/01/64 07/06/89 
3985 2 01/01/76 07/06/89 
3987 2 07/02/89 07/02/89 
3988 2 01/01/54 07/07/89 
3989 1 01 01 64 07 07 89 
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3994 1 01/01/72 07/13/89 
4000 1 07/13/89 07/13/89 
4001 2 01/01/69 07/12/89 
4002 1 01/01/74 07/19/89 
4003 2 01/01/72 07/19/89 
4005 1 01/01/83 07/21/89 
4006 1 03/01/87 07/24/89 
4007 1 01/01/75 07/25/89 
4008 1 01/01/77 07/25/89 
4015 1 07/31/70 07/27/89 
4020 2 01/01/74 08/02/89 
4021 1 01/01/81 08/02/89 
4023 1 01/01/74 08/01/89 
4024 1 01/01/77 08/01/89 
4027 1 01/01/74 08/10/89 
4028 2 01/01/85 08/10/89 
4030 2 01/01/72 08/10/89 
4031 2 01/01/79 08/10/89 
4032 2 01/01/85 08/10/89 
4033 2 01/01/84 08/10/89 
4034 2 01/01/88 08/10/89 
4035 1 01/01/82 08/10/89 
4037 1 01/01/64 08/16/89 
4039 2 01/01/85 08/16/89 
4044 1 08/11/89 08/11/89 
4045 2 09/17/76 08/23/89 
4046 1 01/01/80 08/23/89 
4047 1 01/01/67 08/23/89 
4048 1 01/01/67 08/23/89 
4049 1 01/01/77 08/23/89 
4050 1 01/01/66 08/23/89 
4051 1 01/01/76 08/23/89 
4052 1 01/01/81 08/25/89 
4053 2 01/01/54 08/25/89 
4054 2 01/01/69 08/25/89 
4057 1 01/01/84 08/25/89 
4061 1 01/01/84 09/01/89 
4062 1 01/01/70 09/01/89 
4064 2 01/01/83 09/01/89 
4065 1 01/01/73 08/30/89 
4066 1 01/01/67 08/06/89 
4067 1 01/01/79 09/01/89 
4071 1 01/01/69 09/15/89 
4072 1 01/01/59 09/15/89 
4073 1 01/01/67 09/15/89 
4074 1 01/01/69 09/15/89 
4075 1 06/02/87 09/14/89 
4077 1 01/01/64 09/26/89 
4078 1 01/01/66 09/26/89 
4079 1 01/01/73 09/26/89 
4080 2 01/01/71 09/26/89 
4081 1 01 01 71 09 26 89 
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4085 2 01/01/82 09/26/89 
4091 1 01/01/85 10/12/89 
4092 2 01/01/74 10/12/89 
4093 1 01/01/49 10/12/89 
4094 1 01/01/49 10/12/89 
4095 2 01/01/71 10/11/89 
4102 2 01/01/74 10/03/89 
4103 2 01/01/49 10/10/89 
4106 2 01/01/64 10/18/89 
4107 1 10/11/89 10/11/89 
4109 2 01/01/78 10/24/89 
4110 2 01/01/64 10/23/89 
4111 2 01/01/59 10/23/89 
4112 1 01/01/67 10/23/89 
4113 2 01/01/64 10/25/89 
4114 2 01/01/68 10/25/89 
4115 2 01/01/64 10/25/89 
4118 1 01/01/80 10/31/89 
4119 2 01/01/69 10/31/89 
4120 2 01/01/66 10/31/89 
4121 2 01/01/83 10/31/89 
4124 1 01/01/69 10/31/89 
4125 1 01/01/68 11/01/89 
4128 2 01/01/75 11/09/89 
4129 2 01/01/71 11/06/89 
4130 1 01/01/67 11/02/89 
4133 1 01/01/85 11/16/89 
4136 2 01/01/65 11/16/89 
4137 2 01/01/67 11/16/89 
4138 2 01/01/75 11/16/89 
4139 1 01/01/69 11/16/89 
4140 2 01/01/70 11/17/89 
4141 2 01/01/79 11/17 /89 
4142 2 01/01/65 11/16/89 
4143 1 01/01/69 11/16/89 
4144 2 01/01/74 11/17/89 
4146 1 01/01/87 11/22/89 
4147 1 01/01/85 11/22/89 
4148 1 01/01/84 11/22/89 
4149 2 06/14/69 11/22/89 
4150 1 01/01/75 11/17/89 
4151 1 01/01/82 11/29/89 
4152 1 01/01/77 11/29/89 
4153 2 01/01/66 11/29/89 
4154 1 01/01/75 11/29/89 
4158 2 01/01/61 11/30/89 
4159 2 01/01/65 11/30/89 
4160 2 01/01/83 11/30/89 
4162 1 01/01/61 12/04/89 
4163 2 01/01/59 12/04/89 
4164 2 01/01/74 12/04/89 
4166 1 01 01 63 12 08 89 
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4172 2 01/01/67 12/08/89 
4173 2 01/01/69 12/08/89 
4174 1 01/01/73 12/08/89 
4177 2 01/01/49 12/08/89 
4178 2 01/01/49 12/08/89 
4179 2 01/01/55 12/08/89 
4180 1 01/01/67 12/08/89 
4181 1 01/01/65 12/08/89 
4182 2 01/01/74 12/08/89 
4183 1 01/01/49 12/08/89 
4184 1 01/01/87 12/08/89 
4185 1 01/01/86 12/08/89 
4186 1 01/01/86 12/08/89 
4187 1 01/01/80 12/08/89 
4188 2 01/01/86 12/08/89 
4189 2 01/01/79 12/08/89 
4190 2 01/01/87 12/08/89 
4191 2 01/01/67 12/08/89 
4192 2 01/01/73 12/08/89 
4193 2 01/01/80 12/08/89 
4195 1* 01/01/49 12/15/89 
4196 2 01/01/64 12/15/89 
4197 2 01/01/87 12/15/89 
4198 1 01/01/65 12/15/89 
4201 2 01/01/77 12/15/89 
4202 2 09/01/89 12/15/89 
4203 2 01/01/82 12/15/89 
4204 1 07/01/89 12/15/89 
4205 2 01/01/74 12/15/89 
4206 1 10/01/89 12/15/89 
4207 2 01/01/64 12/15/89 
4208 1 06/01/89 12/15/89 
4209 1 01/01/73 12/15/89 
4210 2 01/01/77 12/15/89 
4211 1 01/01/69 12/15/89 
4212 1 01/01/71 12/15/89 
4213 2 01/01/84 12/15/89 
4214 2 01/01/89 12/15/89 
4215 2 01/01/85 12/15/89 
4216 2 01/01/85 12/15/89 
4217 1 01/01/82 12/15/89 
4219 1 01/01/86 12/15/89 
4220 1 01/01/84 12/15/89 
4221 2 01/01/60 12/19/89 
4222 1 01/01/72 12/19/89 
4223 1 01/01/78 12/19/89 
4224 1 01/01/78 12/19/89 
4225 1 01/01/73 12/19/89 
4226 2 01/16/87 12/19/89 
4227 1 01/01/80 12/19/89 
4228 2 01/01/72 12/19/89 
4229 2 1 77 12 19 89 
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4233 2 01/01/84 12/21/89 
4234 2 01/01/75 12/21/89 
4263 2 07/24/88 01/22/90 
4264 2 07/23/88 01/22/90 
7003 1 01/01/85 10/21/88 
7027 2 04/01/75 08/09/88 
7028 2* 01/01/66 08/09/88 
APPENDIX II 
APPENDIX II 
CASE POPULATION DATA 
Key: Sex 1; male (gelding) 
Sex 2; female Genny) 
*; Dead donkey (See Appendix IV) 
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128 1* 01/01/52 24/07/74 14/07/85 
167 1 01/01/72 10/09/74 12/01/76 
248 2 01/01/66 01/01/75 19/04/83 344 2 01/01/62 18/03/76 15/07/86 
422 1* 01/01/72 21/04/77 01/10/84 
425 2 01/01/65 21/04/77 30/05/85 
429 2 01/01/75 08/05/77 01/11/83 
457 1* 01/01/47 02/09/77 12/04/78 514 2 01/05/78 03/05/78 09/07/85 543 2 01/07/78 18/07/78 23/01/87 556 1 01/01/77 08/09/78 07/06/83 560 2 01/01/70 14/09/78 15/10/87 
676 1* 01/01/49 17/07/79 16/05/84 
730 2 01/01/80 24/01/80 17/01/84 
757 2 01/01/77 11/03/77 24/03/82 
760 2 01/01/78 11/03/80 11/09/85 
835 2 01/01/76 29/04/80 14/07/85 
863 2 01/01/60 12/10/80 06/08/88 
868 1 01/01/79 29/10/80 05/08/83 
876 2 01/03/80 06/11/80 14/12/88 
886 2 01/01/78 18/11/80 23/07/83 
902 2 01/01/72 01/12/80 01/10/81 
978 1 01/01/67 10/04/81 30/07/85 
991 2* 01/01/50 24/04/81 30/07/85 
1070 1 01/04/79 27/08/81 09/02/84 
1096 2 01/01/63 13/10/81 25/07/86 
1120 1 01/09/80 04/11/81 05/06/86 
1134 2* 01/01/65 30/11/81 06/06/83 
1166 1* 01/01/67 21/08/82 15/10/84 
1217 1 01/01/75 24/03/82 01/05/86 
1228 1 01/01/81 02/04/82 01/08/86 
1236 1 01/06/80 16/04/82 10/05/83 
1237 1 01/11/80 16/04/82 31/07/86 
1296 2* 01/01/80 07/07/82 06/06/84 
1301 1 01/03/81 07/07/82 12/07/85 
1336 1 01/07/81 02/09/82 06/04/84 
1338 2* 01/01/80 03/09/82 07/03/85 
1354 1 01/01/76 12/10/82 13/01/88 
1370 2 01/01/70 10/11/82 03/07/85 
1493 2 01/01/81 12/04/83 16/07/86 
1519 1 01/01/75 10/05/83 30/07/86 
1657 1 01/01/80 21/10/83 10/07/87 
1708 2 01/01/79 09/12/83 19/10/84 
1727 1 01/01/81 13/01/84 15/07/86 
1734 1 01/01/82 27/01/84 28/02/85 
1750 1* 01/01/80 10/02/84 24/06/85 
1762 1 01/01/64 09/03/84 17/11/89 
1789 2 01/02/73 05/04/84 09/03/88 
1826 1 01/01/83 11/05/84 04/09/86 
1842 2 01/01/74 25/05/84 17/09/86 
1998 1 01/01/84 30/11/84 18/02/87 
2070 1 01/01/82 13/02/85 02/07/87 
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2148 1 01/01/83 04/04/85 13/11/86 
2154 2 01/11/78 10/04/85 14/02/89 
2245 1 01/01/84 12/06/85 14/06/89 
2344 1 01/01/79 23/09/85 13/04/86 
2400 2 01/01/76 24/10/85 05/02/87 
2428 2 18/10/81 18/10/85 04/09/86 
2435 2 01/01/82 14/11/85 22/04/87 
2439 2 01/01/80 14/11/85 08/11/89 
2515 1 01/06/79 13/01/86 21/11/88 
2627 1 01/01/77 09/04/86 12/09/88 
2712 2 01/01/82 25/06/86 30/10/89 
2735 1 01/01/85 18/07/86 01/06/87 
2817 1 01/01/79 01/10/86 06/06/88 
2932 1 01/01/77 21/01/87 19/01/90 
3008 2 01/01/81 14/04/87 14/08/89 
3037 1 01/01/69 08/05/87 13/12/88 
3051 1 01/01/84 22/05/87 29/09/89 
3075 2 01/01/85 08/06/87 25/08/88 
3346 1 01/01/86 29/03/88 02/03/89 
3408 1 01/01/86 23/03/88 14/02/89 
3470 1 01/01/87 27/05/88 03/11/89 
3696 1 01/01/87 01/12/88 20/09/89 
3700 1 01/01/87 01/12/88 02/02/90 
3914 1 01/01/70 24/05/89 07/03/90 
3966 1 01/01/85 23/06/89 16/05/90 
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APPENDIX III 
PRE-ENTRY POPULATION DATA 
Key: Sex 1; male (gelding) 
Sex 2; female (jenny) 
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723 2 01/01/56 08/01/80 
992 1 01/01/78 24/04/81 
1084 1 01/01/75 22/09/81 
1277 1 01/01/78 11/06/82 
1310 2 01/01/66 22/07/82 
1415 2 01/01/72 21/12/82 
1911 2 01/01/72 15/09/84 
2000 1 01/01/54 30/11/84 
2204 1 01/01/70 12/06/85 
2212 1 01/01/80 14/05/85 
2353 2 01/01/83 27/09/85 
2369 1 01/01/72 09/10/85 
2406 1 01/01/70 29/10/85 
2522 2 01/01/84 17/01/86 
2529 1 01/01/74 23/01/86 
2535 2 01/01/82 03/01/86 
2562 2 01/01/61 21/02/86 
2687 1 01/01/82 27/05/86 
2732 1 01/01/82 18/07/86 
3151 1 01/01/81 22/07/87 
3157 1 01/01/80 20/01/82 
3230 1 01/01/77 16/10/87 
3259 2 01/01/85 25/10/87 
3384 1 01/01/85 04/03/88 
3399 1 01/01/84 15/03/88 
3459 1 01/01/82 18/05/88 
3579 2 01/01/77 18/08/88 
3585 1 01/01/68 25/08/88 
3590 1 01/01/84 31/08/88 
3626 2 01/01/63 29/09/88 
3675 1 01/10/82 09/11/88 
3858 1 01/01/49 06/04/89 
3906 1 01/01/85 15/05/89 
3913 1 01/01/86 19/05/89 
3915 1 01/01/83 02/06/89 
3930 2 01/01/83 07/06/89 
4123 2 01/01/59 31/10/89 
4126 1 01/01/82 07/11/89 
4218 1 01/01/87 15/12/89 
4365 1 01/01/60 08/04/90 
4408 1 01/01/86 21/05/90 
4417 1 01/01/87 25/05/90 
4442 1 01/01/85 08/06/90 
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DEAD POPULATION DATA 
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1 01/01/63 15 
3 01/01/69 5 
6 01/01/63 11 
8 01/01/60 27 
9 01/01/53 33 
10 01/01/53 34 
11 01/01/69 6 
15 01/01/69 20 
16 01/01/66 23 
18 01/01/68 8 
22 05/01/72 4 
25 01/01/63 23 
28 01/01/70 7 
34 01/01/70 20 
35 01/01/70 17 
39 01/01/63 14 
42 01/01/47 31 
43 01/01/40 35 
44 01/01/59 19 
47 01/01/38 40 
48 01/01/71 15 
50 01/01/73 16 
52 01/01/58 17 
53 01/01/63 18 
58 02/01/74 1 
60 01/01/62 16 
63 01/01/67 11 
64 01/01/60 21 
65 01/01/59 25 
66 04/01/73 1 
67 01/01/66 20 
69 01/01/53 25 
73 01/01/69 12 
74 01/01/71 20 
78 01/01/65 20 
83 01/01/64 25 
84 01/01/66 23 
85 01/01/70 11 
89 01/01/70 9 
90 01/01/60 23 
93 01/01/70 8 
94 01/01/65 13 
95 01/01/54 31 
96 01/01/73 16 
97 01/01/70 5 
99 01/01/67 9 
100 01/01/69 7 
101 01/01/44 35 
102 01/01/54 27 
103 01/01/60 18 
105 01/01/58 19 
106 QYQYZ~ 7 
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113 01/01/70 8 
114 01/01/70 8 
120 01/01/68 9 
121 01/01/40 48 
122 01/01/66 17 
134 01/01/65 13 
136 01/01/57 31 
138 01/01/60 23 
144 01/01/60 23 
145 01/01/69 6 
148 01/01/64 14 
152 01/01/69 7 
153 01/01/54 31 
155 01/01/68 16 
156 01/01/49 34 
157 01/01/40 36 
161 01/01/69 7 
162 01/01/54 29 
163 01/01/44 35 
169 01/01/60 16 
171 01/01/67 21 
174 01/01/68 8 
177 01/01/60 22 
178 01/01/67 16 
181 01/01/71 6 
183 01/01/25 54 
186 11/01/74 1 
187 01/01/64 24 
188 01/01/62 17 
189 01/01/70 6 
190 01/01/60 22 
193 01/01/54 25 
194 01/01/55 27 
195 01/01/64 16 
196 01/01/64 23 
198 01/01/67 9 
202 01/01/70 7 
204 01/01/68 8 
205 01/01/72 18 
207 01/01/71 19 
208 01/01/70 13 
209 01/01/55 27 
210 01/01/70 13 
211 01/01/73 10 
212 01/01/70 9 
217 01/01/74 17 
223 01/01/72 14 
226 01/01/70 12 
228 05/01/63 25 
229 01/01/50 28 
230 01/01/68 9 
232 01/01/63 20 
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242 01/01/63 14 
246 01/01/69 13 
250 01/01/75 15 
251 01/01/65 18 
255 01/01/70 18 
260 01/01/70 6 
262 01/01/68 16 
272 01/01/70 10 
276 01/01/45 37 
277 01/01/55 28 
279 01/01/65 12 
281 01/01/55 28 
282 01/01/45 40 
283 07/01/75 8 
286 01/01/55 25 
287 01/01/74 11 
288 01/01/69 8 
290 01/01/60 30 
297 01/01/71 12 
298 01/01/55 26 
299 01/01/45 35 
302 01/01/63 20 
304 01/01/70 6 
306 01/01/59 17 
307 01/01/61 18 
311 01/01/66 13 
312 01/01/57 25 
314 01/01/70 20 
320 01/01/70 14 
329 01/01/73 6 
335 01/01/60 22 
343 01/01/50 27 
345 01/01/70 13 
350 01/01/70 13 
351 01/01/66 22 
368 01/01/60 29 
369 01/01/74 12 
376 01/01/56 30 
377 01/01/73 6 
378 01/01/69 16 
381 01/01/69 14 
382 01/01/56 26 
383 01/01/70 7 
386 01/01/56 24 
387 01/01/46 37 
388 01/01/66 20 
389 01/01/72 15 
393 01/01/57 24 
397 01/01/65 14 
401 01/01/70 8 
407 02/01/77 1 
411 01/01/72 11 
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435 01/01/65 17 
438 01/01/48 36 
439 01/01/62 28 
441 01/01/59 19 
443 01/01/63 20 
444 04/01/75 8 
446 07/01/77 13 
447 01/01/67 22 
449 01/01/50 38 
451 01/01/71 8 
454 01/01/42 43 
455 01/01/59 26 
456 01/01/47 57 
458 01/01/52 31 
459 01/01/55 35 
460 01/01/57 29 
461 01/01/67 21 
465 01/01/75 6 
477 01/01/63 24 
478 01/01/73 11 
483 01/01/47 33 
492 01/01/66 13 
493 01/01/58 21 
494 01/01/53 31 
497 01/01/68 21 
498 01/01/76 3 
502 01/01/64 23 
505 01/01/72 12 
507 01/01/62 21 
512 01/01/65 15 
517 01/01/52 37 
518 01/01/47 42 
519 01/01/43 42 
520 01/01/43 36 
522 01/01/48 36 
524 01/01/51 37 
527 01/01/48 34 
532 01/01/63 21 
534 01/01/73 6 
538 01/01/58 23 
539 01/01/58 21 
546 01/01/68 19 
547 01/01/48 41 
548 01/01/72 11 
552 01/01/62 23 
553 01/01/72 9 
555 01/01/73 6 
562 01/01/55 26 
572 01/01/63 16 
573 01/01/71 8 
577 01/01/62 23 
585 01/01/65 22 
- - --
-
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598 01/01/73 17 
602 01/01/66 17 
604 01/01/58 31 
606 01/01/70 20 
608 01/01/77 4 
609 01/01/69 17 
610 01/01/56 33 
613 01/01/59 21 
615 01/01/62 19 
617 01/01/49 34 
624 01/01/69 13 
625 01/01/69 13 
626 03/01/79 10 
627 01/01/62 21 
631 01/01/29 51 
632 . 01/01/69 16 
635 01/01/44 36 
639 01/01/71 13 
644 01/01/49 37 
645 01/01/73 11 
651 05/01/79 3 
654 01/01/39 45 
659 01/01/65 24 
664 01/01/61 24 
670 01/01/70 10 
673 01/01/59 22 
675 01/01/49 37 
682 01/01/63 20 
685 01/01/72 9 
688 01/01/49 32 
689 01/01/61 29 
690 05/01/76 13 
693 01/01/68 13 
704 01/01/74 15 
705 01/01/59 25 
707 01/01/39 42 
708 01/01/63 26 
711 01/01/64 22 
712 01/01/69 12 
718 01/01/65 16 
720 01/01/49 41 
732 01/01/77 4 
737 01/01/69 20 
742 01/01/72 14 
743 01/01/58 27 
745 01/01/63 23 
750 01/01/45 36 
753 01/01/50 34 
755 01/01/66 19 
758 01/01/62 23 
765 01/01/50 38 
767 01/01/55 32 
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794 01/01/73 10 
798 01/01/72 18 
808 01/01/71 11 
813 01/01/65 22 
814 01/01/76 5 
818 01/01/70 13 
822 01/01/73 8 
823 01/01/55 30 
827 01/01/60 25 
833 01/01/70 15 
834 09/01/80 4 
836 01/01/70 20 
844 01/01/55 35 
847 01/01/55 35 
850 01/01/56 31 
852 01/01/62 28 
857 01/01/73 12 
871 01/01/60 23 
882 01/01/68 16 
894 01/01/74 10 
895 01/01/58 30 
906 01/01/63 22 
907 01/01/50 32 
909 01/01/74 15 
920 01/01/65 18 
931 01/01/72 11 
933 01/01/71 19 
938 01/01/79 10 
943 01/01/77 12 
955 01/01/60 27 
956 01/01/73 17 
960 01/01/41 44 
968 01/01/65 25 
970 01/01/73 14 
971 01/01/71 11 
972 01/01/73 9 
982 01/01/50 35 
985 01/01/64 24 
986 01/01/56 27 
1000 01/01/70 20 
1001 01/01/70 20 
1007 01/01/61 29 
1008 01/01/59 30 
1009 01/01/56 28 
1015 01/01/71 12 
1019 05/01/81 2 
1020 01/01/60 24 
1021 01/01/60 22 
1023 01/01/71 19 
1036 08/01/79 11 
1045 01/01/72 12 
1048 01/01/74 16 
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1065 01/01/74 16 
1068 01/01/47 42 
1069 01/01/75 13 
1076 01/01/66 24 
1077 01/01/72 13 
1078 01/01/75 10 
1079 01/01/72 11 
1082 01/01/56 30 
1083 01/01/60 26 
1088 01/01/69 14 
1089 01/01/56 30 
1090 01/01/56 29 
1106 01/01/51 35 
1111 01/01/69 16 
1124 01/01/62 28 
1126 01/01/70 18 
1127 01/01/73 10 
1129 06/01/75 14 
1135 01/01/65 25 
1136 01/01/71 13 
1141 01/01/50 33 
1142 01/01/61 26 
1145 01/01/71 18 
1148 01/01/57 31 
1151 01/01/72 15 
1161 01/01/81 9 
1162 01/01/78 12 
1178 01/01/65 25 
1181 01/01/57 31 
1182 01/01/55 35 
1185 01/01/66 19 
1191 01/01/75 12 
1196 01/01/73 17 
1198 01/01/70 16 
1202 01/01/67 20 
1206 10/01/80 6 
1218 01/01/60 28 
1232 04/01/82 4 
1234 01/01/67 20 
1240 01/01/48 38 
1243 01/01/76 10 
1251 01/01/53 31 
1260 01/01/65 19 
1270 01/01/57 29 
1272 01/01/75 14 
1287 09/01/74 14 
1290 01/01/57 32 
1295 01/01/79 6 
1297 05/01/82 7 
1299 01/01/40 43 
1299 01/01/40 43 
1308 06/01/72 18 
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1346 01/01/69 17 
1353 01/01/68 16 
1360 01/01/70 16 
1385 01/01/72 16 
1391 01/01/70 20 
1397 01/01/69 20 
1398 01/01/68 16 
1399 01/01/69 16 
1400 01/01/42 46 
1401 01/01/68 20 
1414 01/01/69 15 
1422 01/01/63 24 
1433 01/01/75 13 
1436 01/01/45 39 
1441 01/01/63 27 
1442 01/01/74 16 
1447 01/01/68 20 
1448 01/01/63 24 
1454 01/01/71 13 
1461 01/01/63 22 
1467 01/01/70 17 
1471 01/01/53 36 
1475 01/01/79 11 
1480 06/30/82 5 
1483 01/01/53 36 
1501 01/01/67 22 
1504 01/01/63 27 
1507 01/01/73 17 
1511 01/01/73 15 
1514 01/01/58 32 
1520 01/01/71 16 
1529 01/01/63 22 
1536 01/01/48 38 
1539 01/01/43 42 
1541 01/01/60 27 
1546 01/01/63 22 
1547 01/01/73 11 
1555 01/01/66 23 
1564 01/01/63 27 
1568 01/01/79 6 
1574 01/01/58 27 
1591 01/01/68 18 
1616 01/01/69 15 
1622 01/01/79 11 
1659 01/01/78 7 
1660 01/01/70 20 
1665 01/01/53 37 
1668 01/01/63 22 
1671 01/01/70 19 
1680 01/01/43 42 
1691 01/01/70 19 
1694 01/01/71 15 
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1758 01/01/54 36 
1768 01/01/71 17 
1776 01/01/68 22 
1784 01/01/71 17 
1806 07/01/71 16 
1810 01/01/50 39 
1818 01/01/78 7 
1822 01/01/39 47 
1835 01/01/79 6 
1836 01/01/79 6 
1851 01/01/49 37 
1872 01/01/77 8 
1873 01/01/70 19 
1891 01/01/70 20 
1915 01/01/64 24 
1922 01/01/80 9 
1927 01/01/50 37 
1928 01/01/64 24 
1938 01/01/69 20 
1945 01/01/60 27 
1966 01/01/59 29 
1967 01/01/60 26 
1979 01/01/68 21 
1981 01/01/70 16 
1982 01/01/70 19 
1985 01/01/71 15 
1987 01/01/64 22 
1993 01/01/67 23 
1995 01/01/70 16 
2003 01/01/74 14 
2005 01/01/69 18 
2010 01/01/61 26 
2011 01/01/65 23 
2017 01/01/70 16 
2025 01/01/70 17 
2027 01/01/64 22 
2031 01/01/81 7 
2043 01/01/60 29 
2044 01/01/82 4 
2050 01/01/81 5 
2054 05/01/72 17 
2055 06/01/69 18 
2059 01/01/57 30 
2061 01/01/67 23 
2063 01/01/60 28 
2067 01/01/70 20 
2086 01/01/65 25 
2093 01/01/62 26 
2115 01/01/70 16 
2126 01/01/75 11 
2156 01/01/72 15 
2174 01/01/65 23 
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2205 01/01/70 20 
2232 01/01/73 14 
2252 01/01/76 10 
2252 01/01/76 10 
2284 01/01/67 23 
2303 01/01/67 20 
2306 01/01/65 23 
2307 01/01/70 18 
2311 01/01/69 20 
2315 01/01/64 23 
2330 01/01/82 7 
2336 . 09/01/65 23 
2337 09/01/60 29 
2342 01/01/65 21 
2352 01/01/45 41 
2354 01/01/55 33 
2358 01/01/74 15 
2362 01/01/55 33 
2368 01/01/50 36 
2386 01/01/74 12 
2392 01/01/77 9 
2442 01/01/73 15 
2444 01/01/73 14 
2445 01/01/62 28 
2453 01/01/60 30 
2467 01/01/69 19 
2483 01/01/60 29 
2532 01/01/46 42 
2547 01/01/66 22 
2556 01/01/68 21 
2565 01/01/58 30 
2593 01/01/58 31 
2636 01/01/69 20 
2640 01/01/60 29 
2671 01/01/46 42 
2672 01/01/66 23 
2695 01/01/71 17 
2721 01/01/46 42 
2722 01/01/46 43 
2731 01/01/60 28 
2761 01/01/49 38 
2786 01/01/61 28 
2825 01/01/62 28 
2838 10/01/66 24 
2841 01/01/82 7 
2845 01/01/61 27 
2868 01/01/51 37 
2871 01/01/61 26 
2884 01/01/61 29 
2888 01/01/70 20 
2892 01/01/71 17 
2893 01/01/56 31 
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2916 01/01/61 26 
2921 01/01/61 27 
2922 01/01/61 27 
2923 01/01/59 29 
2924 01/01/47 41 
2925 01/01/51 37 
2938 01/01/60 29 
2944 01/01/52 36 
2962 01/01/47 41 
2963 01/01/47 43 
2970 01/01/52 38 
3064 01/01/50 40 
3071 01/01/76 14 
3080 01/01/67 22 
3083 01/01/52 37 
3085 01/01/67 22 
3091 01/01/67 21 
3093 01/01/51 37 
3097 01/01/62 27 
3107 01/01/80 8 
3111 01/01/70 18 
3113 01/01/85 3 
3157 01/01/60 30 
3241 01/01/57 31 
3257 01/01/65 24 
3269 01/01/77 13 
3270 01/01/62 27 
3278 01/01/47 43 
3285 01/01/52 37 
3322 01/01/53 36 
3369 01/01/53 37 
3373 01/01/48 41 
3454 01/01/48 42 
3480 01/01/56 33 
3492 01/01/58 31 
3505 01/01/76 13 
3519 01/01/76 13 
3542 01/01/63 26 
3581 01/01/61 28 
3624 01/01/48 41 
3634 01/01/63 26 
3638 01/01/80 10 
3639 01/01/48 42 
3645 01/01/48 41 
3649 01/01/82 8 
3663 01/01/63 26 
3689 01/01/76 13 
3690 01/01/62 27 
3693 01/01/48 42 
3867 03/01/89 1 
4195 01/01/49 41 
7028 91!91!~6 24 
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676 01/01/49 36 
991 01/01/50 37 
1134 01/01/65 21 
1166 01/01/67 20 
1296 01/01/80 9 
1338 01/01/80 8 
1750 01/01/80 7 
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LIST OF SUPPLIERS 
APPENDIX V 
Amersham International pIc, 
UK Sales Office, 
Lincoln Place, 
Green End, 
Aylesbury, 
Buckinghamshire, 
HP202TP. 
BDH Chemicals, 
Poole, 
Dorset, 
BH151TD. 
Beckman Instruments UK Ltd., 
Sands Industrial Estate, 
High Wycombe, 
Buckinghamshire, 
HP124JL. 
Biorad Laboratories, 
Biorad House, 
Maylands Avenue, 
Hemel Hempstead, 
HP2TID. 
Boehringer Mannheim Corporation, 
Bell Lane, 
Lewes, 
East Sussex, 
BN71LG. 
GibcoBRL, 
Life Technologies Ltd., 
PO Box 35, 
Renfrew Road, 
Paisley, 
PA3 4EF. 
ILS Ltd., 
14-15, Newbury Street 
London, 
EC1A 7HU. 
Perkin Elmer Ltd., 
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Pharmacia, Ltd., 
Pharmacia LKG Biotechnology Division, 
Midsummer Boulevard, 
Central Milton Keynes, 
Buckinghamshire, 
MK93HP. 
Scotlab Ltd., 
Kirkshaws Road, 
Coatbridge, 
Strathclyde, 
MLS SAD. 
Smithkline Beecham Ltd., 
Walton Oaks, 
Dorking Road, 
Tadworth, 
Surrey, 
KT207NT. 
Stratagene Ltd., 
Cambridge Inovation Centre, 
Unit 140, 
Cambridge Science Park 
Cambridge, 
C134GF. 
Sigma Chemical Company 
Fancy Road, 
Poole, 
Dorset, 
BH177NH. 
United States Biochemical Corporation, 
PO Box 22400, 
Cleveland 
Ohio 44122, 
USA. 
Whatman LabSales Ltd., 
St. Leonard's Road, 
20/20, Maidstone 
Kent, 
ME160LS. 
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